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Abstract  
Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are common disorders 
associated with placental implantation abnormalities in early pregnancy.  Both conditions 
are heterogeneous, having complex and multiple aetiologies. PE complicates 5-8 % of 
pregnancies globally, and is characterised by new onset hypertension and elevated urine 
protein concentration. PE is a major cause of maternal and fetal morbidity and mortality. 
IUGR may co-occur with PE or separately, and affects babies born at or below the bottom 
decile for weight. Monitoring for these conditions has a tremendous cost burden for 
healthcare providers, and as yet we have no robust clinical predictors to identify those 
women who need extra monitoring. Mass spectrometry and Fourier transform infrared 
spectroscopy were used to analyse proteins within urine samples from pregnant women. 
Proteomic and bioinformatics analyses of urine samples have demonstrated that 
proteins, subjected to ultrafiltration and subsequent proteolysis and peptide labelling, are 
readily detected in urine samples, with differential detection of proteins showing 
disparate levels in women whose pregnancies are complicated by IUGR and PE.  
Quantitative changes in urinary protein expression are investigated in order to identify 
proteins showing differential expression in early pregnancy (15 weeks gestation) in the 
urine of patients who go on to develop pregnancy complications. A number of candidate 
proteins showing altered expression levels have been identified for future follow-up 
analysis.  This project suggests new methods of clinical diagnostics for these conditions, 
which could aid improved targeting of intensive monitoring in prenatal care. 
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Chapter 1  
 
1. General Introduction  
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1.1. Introduction  
The most common disorders associated with placental implantation abnormality in early 
pregnancy are pre-eclampsia (PE) and intrauterine growth restriction (IUGR). Both PE and 
IUGR are multifactorial conditions. PE is a multi-system disorder of pregnancy 
characterised by new onset of hypertension and elevated urine protein concentration 
(Law et al., 2015). Other types of hypertensive disorders of pregnancy, such as gestational 
hypertension and chronic hypertension can occur during pregnancy; the impact of these 
is rarely as acute or life-threatening. By contrast, PE represents a major cause of maternal 
and fetal morbidity and mortality (Duley, 2009). PE improves immediately after delivery, 
but currently no specific therapeutic treatment is available for PE. Prophylactic 
administration of low dose aspirin has however been demonstrated to be of clinical use, if 
administered to high-risk patients during their first-to-second trimester (6-16) weeks of 
pregnancy; this strategy reduces overall risk of PE by approximately 50 %, and achieves 
~80% reduction in severe PE incidence (Bujold et al., 2014). However, prediction of 
individual risk remains elusive.   
Various studies (Blankley et al., 2013; Buhimschi et al., 2008) have investigated proteomic 
biomarkers in preeclampsia. Due to the complexity of the proteome, various separation 
strategies have been employed prior to MS. Various biological samples have been used to 
study biomarkers in preeclampsia, such as serum (Auer et al., 2010), placental tissue 
(Wang et al., 2013), and amniotic fluid (Oh et al., 2012). No clinical test has, however, 
been developed to accurately predict preeclampsia risk for nulliparous women with high 
risk (Conde-Agudelo et al., 2004).   
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Urine and blood are two major relevant sources of material for proteomic studies. The 
choice of analyte is dependent on a variety of factors. For example, urine samples are 
considerably easier to obtain in a larger quantity than blood; collection of urine is a 
non-invasive technique, however the reproducibility of urine sampling may be lower than 
that of blood (Carty et al., 2011). Many studies (Schaub et al., 2004; Theodorescu et al., 
2006) have shown that proteins in biologic fluids other than urine could degrade quickly 
when handled inappropriately, whereas urinary proteins have been shown to remain 
stable long enough to perform reliable proteome analysis. The urinary proteome did not 
undergo significant alterations when urine was stored at 4° C for 3 days or at room 
temperature for 6 h (Theodorescu et al., 2006). Urinary proteins are typically resistant to 
hydrolysis, especially if stored in low temperature (-80° C) for years, without significant 
observed proteome alterations (Theodorescu et al., 2006; Schaub et al., 2004). This 
increased stability is in stark contrast to the blood proteome; further, the collection of 
blood for serum or plasma analysis is relatively invasive. Serum or plasma has an extreme 
dynamic range of proteins that may affect data quality and comparability, and 
necessitates pre analytical treatment such as immune-affinity depletion, which are highly 
costly (Kolch et al., 2005; Fliser et al., 2007). Developing a non-invasive, clinically-
acceptable and robust urine test which enables risk prediction for pregnant women at a 
sufficiently early gestational stage to enable intervention is therefore a desirable goal. 
Standard operating protocols (SOP) are therefore necessary for collection, storage, 
processing, and urine sampling (Fliser et al., 2007). 
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1.2. Preeclampsia 
Preeclampsia (PE) affects around 5-8% of pregnancies globally, and is the most significant 
hypertensive disorder of pregnancy, impacting both maternal and neonatal health (Van 
Lerberghe et al., 2005).  The World Health Organisation has reported an annual death toll 
of > 50,000 women globally due to preeclampsia; the condition is also a major cause of 
preterm birth (Van Lerberghe et al., 2005).  Diagnosis of PE is characterised by new onset 
hypertension (≥140/90 mmHg) and proteinuria (≥300 mg in 24 hr urine) (Aggarwal et al., 
2005, Van Lerberghe et al., 2005).  Symptoms of PE range from mild to severe, and 
include headache, abdomen pain, renal and liver failure (Jeyabalan, 2013).  Unfortunately, 
the diagnosis of PE is frequently only made in late pregnancy, with clinical signs mainly 
manifesting during the third trimester (Law et al., 2015).  The progress of PE from mild to 
severe can be rapid and unpredictable, with serious, potentially fatal consequences (Law 
et al., 2015). Eclampsia and HELLP syndrome are often associated with this condition; 
both are potentially life-threating complications.  HELLP syndrome is characterised by 
haemolysis, elevated liver enzymes, and low platelet counts; eclampsia features grand 
mal-like seizures (Law et.al. 2015).  A number of risk factors for PE have been identified, 
including ethnicity and family history (Caughey et al., 2005).  Other risk factors are also 
associated with PE such as obesity, diabetes, pre-existing hypertension, renal disease and 
autoimmune disease (Jeyabalan, 2013).  However, there remain no diagnostic tests for 
women with their first time pregnancy (Myers et al., 2013).  
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1.2.1. Preeclampsia and its complications 
PE is a major cause of preterm birth, in utero growth restriction (IUGR), and neonatal 
death.  Intrauterine growth restriction (IUGR) is a condition of poor fetal growth, which is 
commonly recognized as a weight below the 10th percentile for the gestational age (small 
for gestational age, SGA) (Battaglia and Lubchenco, 1967).  IUGR is usually diagnosed 
during a routine prenatal exam in the second half of pregnancy.  Diverse causes are often 
associated with low birth weight, with some cases of IUGR being etiologically linked to 
preeclampsia based on defects in implantation or placentation (Villar et al., 2006).  
Association has been found with other factors such as, maternal malnutrition, maternal 
smoking, gestational hypertension, or congenital malformations (Villar et al., 2001, Camm 
et al., 2010, Langley‐Evans, 2009).  Nevertheless many IUGR cases remain unexplained 
(Villar et al., 2001).  Preterm birth is defined as the delivery of a live infant before 37 
weeks gestation (Law et al., 2015).  Preterm delivery is associated with elevated risk of 
lifelong adverse consequences, including cerebral palsy, neurological disorders, language 
and learning disabilities (Irgens et al., 2001).  Furthermore, incomplete organ 
development of the premature infants can lead to poor organ development in future; for 
example, if born growth restricted, the child will have an increased propensity for 
hypertension, heart disorders, and diabetes in adulthood (Irgens et al., 2001; Davis et al., 
2012). The mortality rate for fetuses in pregnancies complicated by PE is 3 to 10-fold 
higher than uncomplicated pregnancies (Van Lerberghe et al., 2005).  PE may be 
responsible for 12–25 % of babies with IUGR, and around 15–20 % of all preterm births 
(Duley, 2009, Goldenberg and Rouse, 1998).   
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1.2.2. Mechanisms underlying preeclampsia and known risk factors 
The exact mechanism of preeclampsia remains unknown, but a commonly held 
hypothesis describes two distinct phases in the development of the condition (Carty, 
2012).  The first, initiation, is caused by disruption to normal placentation; this is followed 
by a generalised inflammatory response, resulting in endothelial dysfunction, proteinuria, 
and multi-organ damage (Sankaralingam et al., 2006).  Oxidative stress, caused by 
placental hypoxia, leads to release of trophoblast debris and soluble factors such as the 
angiogenic markers soluble endoglin (sENG) and fms-like tyrosine kinase 1 (sFlt-1) into 
maternal circulation (see Figure 1.1) (Carty et al., 2011; Marusic et al., 2013).   
 
Figure 1.1: Schematic diagram of putative preeclampsia mechanism.   
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Disruption in placentation (implantation) leads to inflammatory response, endothelial 
dysfunction, growth restriction, proteinuria; placental hypoxia, results in oxidative stress, causing 
release of trophoblast debris and soluble factors such as the angiogenic markers soluble endoglin 
(sENG) and fms-like tyrosine kinase 1 (sFlt-1) into maternal circulation. These changes induce cell 
damage and other complications within body organs. This figure was edited from (Parikh and 
Karumanchi, 2008). 
 
1.3. Proteomics 
In 1995, the term ‘proteome’ was described by Marc Wilkins as, “… all proteins expressed 
by a genome or tissue”. This definition was later extended to include the component of 
time, as protein expression varies dynamically dependent upon cellular circumstances 
(Blackstock and Weir, 1999). The umbrella term “-omics” encompasses the disciplines 
used to discover the molecular basis, relationships, and activities of the different 
molecular entities which comprise the biochemistry of cells and organisms. There are four 
principal sub-domains within -omics: genomics, transcriptomics, proteomics and 
metabolomics, with “interact-omics” being used variably to ascribe functional 
relationships either between or within sub-domains. Genomics refers to genetic 
information, typically DNA sequences stored as database entries. The genome of an 
organism is essentially a static entity (Plebani, 2005). Transcriptomics refers to the 
production of gene products (transcription), i.e. the generation of messenger RNA. Many 
studies have confirmed that gene expression alone cannot provide full information about 
the behaviour of a cell or system. For instance, Lawrie and co-workers demonstrate little 
to no correlation between mRNA and protein levels (Lawrie et al., 2001). A later study by 
Ghazalpour and colleagues describes the relationship between transcript (RNA) and 
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protein levels in mouse, with relatively little concordance being observed between RNA 
levels and the corresponding protein levels in response to DNA perturbations (Ghazalpour 
et al., 2011). Metabolomics refers to the global study of small molecule levels as readouts 
for cellular metabolism (Barh et al., 2011). Figure 1.2 illustrates general fields of study in 
‘-omics’. 
 
Figure 1.2: Schematic image describing the major ‘-omics’ sub-disciplines   
Major ‘-omics’ terms include genomics, transcriptomics, proteomics and metabolomics. Whilst 
there is a broad relationship between these domains, there is also a lack of direct correlation 
between levels of analyte. 
 
Higher organisms such as humans have multiple organs, each comprised of many cells.  
Each cell has various proteins, which play a vital role in physiological functions.  The levels 
of protein show dynamic response to cellular stress via changes in expression, post-
translational modification and/or protein degradation (Plebani, 2005).  Post-translational 
modifications such as phosphorylation, glycosylation acetylation, sulphation and 
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methylation, and non-enzymatic chemical damage such as, glycation, oxidation and 
nitration increase protein heterogeneity and influence stability (Plebani, 2005).  Proteins 
showing altered levels or changes in their modification status may therefore be 
considered as biomarkers for disease conditions.  As such, proteomics has attracted 
significant interest in the wider field of clinical research.  Discovery and validation of 
putative clinical protein biomarkers, remains challenging, with some biomarkers being 
seldom observed or poorly validated (Plebani, 2005). 
 
1.3.1.  Application of proteomics methodologies to the study of 
preeclampsia  
A number of studies have used proteomic methods to identify potential biomarkers which 
predict preeclampsia. Various patient-derived materials (urine, serum, placenta, amniotic 
cervical-vaginal fluid) have been investigated.  These studies have highlighted a number 
of candidate biomarkers that could discriminate complicated pregnancies from 
uncomplicated.  The following section introduces the use of methodologies by 
presentation of different studies to detect potential biomarkers, specifically focussing on 
urine sampling.   
 
1.3.2. Urinary studies of preeclampsia 
A urinary proteomics study by Chen et al., (2011) used iTRAQ labelling coupled with 2D 
LC-MS/MS to investigate complicated hypertensive pregnancies (Chen et al., 2011).  
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Seventy-one women were enrolled in this study; 30 women in the exploratory arm and 41 
women in a validation set which was used to validate potential biomarkers.  Three groups 
of women were described in the exploratory set: preeclampsia (n=10), gestational 
hypertension (n=10) and normal pregnancy (n=10).  362 Non-redundant proteins were 
identified in total, of which, 113 were expressed differentially between complicated 
hypertension and normal pregnancy.  31/113 proteins showed statistically significant 
difference between the three study groups.  Gene ontology analysis of the differentially 
expressed proteins identified that many of these markers had significant roles in 
metabolic pathogenesis processes related to preeclampsia such as blood coagulation, cell 
adhesion, cytoskeleton remodelling, and immune response.  Hierarchical clustering 
demonstrated differential proteins in preeclampsia and gestational hypertension cases 
compared to normal pregnancy.  Among these, keratin [type I cytoskeletal 19, and keratin 
4], α-actinin-4, afamin, α-2-macroglobulin, serum albumin (ALB), isoform 1 of α-1-
antitrypsin precursor (SERPINA1), vimentin and tubulin β-2C chain were clustered 
together. AGT (angiotensinogen), SERPINA1 and ALB showed significant expression 
differences in both preeclampsia and gestational hypertension compared to 
normotensive pregnancies.  SERPINA1 and ALB were down-regulated in gestational 
hypertension, but up-regulated in preeclampsia compared to normal pregnancy.  These 
results are in agreement with other studies (Buhimschi et al., 2008).  Receiver Operating 
Characteristic (ROC) and ELISA were used to validate urinary AGT down regulated in 
preeclampsia (Chen et al., 2011). 
In 2005, Buhimschi et al., used immunoassay to study urinary protein biomarkers such as 
soluble fms-like tyrosine kinase 1 (sFlt-1), vascular endothelial growth factor (VEGF), and 
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placental growth factor (PlGF) (Buhimschi et al., 2005).  68 Women were enrolled in this 
study and classified into four groups: healthy non-pregnant women (n=14), healthy 
pregnant control (n=16) at gestational age range (3-39) weeks, mild preeclampsia (n=21) 
at gestational age range (24-40) weeks, severe preeclampsia (n = 17) at gestational age 
range (16-40) weeks.  In women with severe preeclampsia, the level of antiangiogenic 
factor sFlt-1 was increased, but PlGF level showed decreases at the time of clinical 
manifestation.  Urinary output of VEGF was raised significantly in severe preeclampsia 
compared with non-pregnant women, but did not show any alteration among other 
pregnant groups.  Moreover, the log [sFlt-1/PlGF] ratio showed 88.2% sensitivity and 
100% specificity in differentiating women with severe preeclampsia from normotensive 
controls. Authors suggested that severe PE is associated with the increased urinary 
excretion of antiangiogenic factor sFlt-1 and decreased of PIGF output at the time of 
clinical manifestation based on sFlt/PIGF ratio may be providing a non-invasive 
hypertension women screening measurement for severity of the disease (Buhimschi et 
al., 2005).   
In 2008, Buhimschi, et al., used tandem mass spectrometry surface enhanced laser 
desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) analysis to 
study urinary biomarkers in preeclampsia (Buhimschi et al., 2008).  Urine samples were 
collected from 284 women, classified according to having high and low risk related 
condition, and severity of preeclampsia: control pregnant women (n=18) at gestational 
age at 25 week of range (7-41) weeks, pregnant women with chronic hypertension 
(n=26), gestational age 33 (24-40) weeks, mild PE (n=29), gestational age 36 (24-40) 
weeks, severe PE (n=31), gestational age 36 (24-40) weeks, superimposed PE (n=28) 
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gestational age 34 (16-39) weeks, pregnancy-associated conditions unrelated to PE (n=64) 
at gestational age 28 of range (21-34) weeks and non-pregnant proteinuric women 
(n=10). The study was divided into three phases, exploratory; challenge, and translation. 
59 Samples were used in the exploratory phase, where proteomic profiles were 
determined in severe preeclampsia that mandated delivery. Here 13 putative biomarker 
peaks (denoted P1-P13) were found.  In the challenge phase, samples taken from 225 
women were used for validation screening for both high and low risk related conditions, 
including preeclampsia. Here, 169 women had preeclampsia, with 86 having mandated 
deliveries for preeclampsia, of which 73 % occurred preterm, and in 50% of cases before 
34 weeks of gestational age.  Urinary [protein/creatinine and sFlt-1/PlGF] ratio 
measurement was used as an indicative marker in 19 women with severe preeclampsia.  
Peptide fragments of human SERPINA1 (SERine Protease INhibitor A1) were found to 
correspond to putative biomarkers: P1, P2, P3, P5, and P7; and albumin using MS/MS. The 
last phase (translational), identification of biomarker by tandem mass spectrometry and 
validation experiments in urine, serum, and placenta were employed to identify, quantify, 
and localize the biomarkers or related proteins (Buhimschi et al., 2008). 
Another study by Lee et al., (2001), using SELDI-TOF-MS to analyse urinary protein profile 
to distinguish between the severity of preeclampsia cases, compared with uncomplicated 
pregnancy (Lee et al., 2011).  Urine samples from 26 women, categorised as having severe 
preeclampsia (n=11), mild preeclampsia (n = 7), or as normotensive (controls, n=8) were 
compared.  A scoring system was constructed, designated as Preeclampsia Proteomic 
Score of Urine (PPSU) was used to differentiate severe preeclampsia from mild 
preeclampsia and uncomplicated pregnancy controls.  They identified four distinctive 
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protein-related peaks (m/z ratio: 4155, 6044, 6663, and 7971), all of these were down-
regulated in the severe preeclampsia.  PPSU<2 had shown 90.9% sensitivity and 93.3% 
specificity (Lee et al., 2011). 
Proteomic analyses using ionisation methods based on laser desorption/ionization (LDI) 
has shown limited reproducibility, specificity and selectivity (Tiss et al., 2007, Stimson et 
al., 1997).  Ultimately this led to a loss of faith by many in the clinical community for these 
sorts of discovery-based methods.  
In 2011, Carty and co-workers used CE coupled with TOF-MS to identify proteomic 
biomarkers in urine samples obtained from two independent cohort studies, SCreening 
fOr Pregnancy Endpoints (SCOPE) and Proteomics in Preeclampsia (PIP) (Carty et al., 
2011).  Candidate biomarkers were identified via LC-MS/MS.  Outcomes showed a panel 
of 284 pregnancy-specific proteomic biomarkers when compared with non-pregnant 
controls.  A reported model of 50 biomarkers from cases obtained at late stage (week 28) 
showed an association with PE development.  The biomarkers of interest found included 
fibrinogen alpha chain, collagen alpha chain, and uromodulin fragments.  The authors of 
this study suggested that the biomarkers provided a good confidence to predict 
preeclampsia at later gestational stage (week 28), but not reliably enough at earlier 
stages (weeks 12–16 and 20). The observation of different results in two cohort studies is 
perhaps unsurprising.  The two studies (SCOPE vs PIP) had different subject gestational 
ages for sampling (20 vs. 28 weeks) and different study populations; for SCOPE the 
control subjects were healthy nulliparous women, whilst PIP recruited a mixed-parity 
general obstetric population (Carty et al., 2011). 
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In 2015, Hart et al., used iTRAQ method coupled with LC.MS/MS to identified proteomic 
biomarkers in urine samples in nulliparous women with PE (Hart et al., 2015).  This work 
was a proof-of-concept study as a potential application for the PE prediction.  Samples 
obtained through the SCOPE consortium were collected at 15 and 20 weeks gestational 
age. Master pools were compared from uncomplicated pregnancies (control) to 
preeclampsia cases. The samples were subjected to ultracentrifugation to separate 
samples over 10 kDa molecular weight cut-off membranes.  Bradford assay was 
performed before iTRAQ labelling and LC-MS/MS analysis. Around 400 proteins were 
observed at a 1 % false discovery rate (FDR) cut-off, of which 150 proteins had a sufficient 
reporter ion signal for high-confidence quantification.  Some of these proteins had 
changes in expression in women who subsequently developed preeclampsia such as, 
periplakin 1, growth and differentiation factor 15 and ICOS ligand 1.  The authors here 
concluded that iTRAQ labelling with LC-MS/MS analysis presented a method for low-to-
medium throughput for identification and quantification of proteins (Hart et al., 2015). 
The present project was therefore developed based on this previous proof-of-concept 
study by (Hart et al., 2015) in larger cohort of women complicated with PE and IUGR using 
both 15 and 20 weeks gestation samples, paired with normotensive controls at each 
gestational time point; again, the samples were obtained through SCOPE consortium. 
Methodology development is used for identification / quantification of detected 
proteomic biomarkers. Figure 1.3 illustrates general steps for sampling process of the 
project. 
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Figure 1. 3:  Schematic workflow summarising sample process of project 
Urine samples (240 in total) were collected from pregnant women, either uncomplicated or 
affected by either PE (n=30) or IUGR (n=30). Samples were obtained at 15 and 20 weeks gestation, 
and paired with their control at each gestational time point. All sample collection was via the 
SCOPE consortium (University College Cork). Sample preparation, data collection and 
bioinformatic analysis constitute the steps undertaken in this project.  This figure was edited from 
(Hart et al., 2015). 
 
1.4. Aims and project objectives  
Throughout this study our aims are to identify novel proteomic biomarkers that can 
predict in early pregnancy those who will subsequently develop late pregnancy 
complications such as PE or / and in utero growth restriction (IUGR). The hypothesis of 
this study is that a difference in protein presentation will be observed between control 
urine and that collected from women found to present clinical signs PE and IUGR. 
Diagnostic biomarkers could aid the development of clinical tests better predicting 
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maternal / fetal risk of preeclampsia. Such tests could potentially target increased 
monitoring frequency to at-risk first time pregnancies, and if accurate reduce rate of 
deaths from preeclampsia, and increase survival rate and life chances for (premature 
and/or small) babies. Such a test would help decrease the complex fiscal, social and 
emotional burden of these pregnancy related complications upon individuals and society.  
The aims of the series of experiments contained in this thesis are highlighted as below: 
Chapter 2: Proteomic analysis for pregnancy complications using iTRAQ labelling 
coupled with MS techniques  
The aims of this chapter are to investigate proteomic biomarkers at urine to predict PE 
and IUGR disorders earlier.  Initial aim is to establish a Standard Operating Protocol (SOP) 
based on protein molecular weight cut-off membranes > 10 kDa at urine sample for 
proteomic analysis.  Mass spectrometry-based quantitative proteomics (typically iTRAQ) 
strategies are used to identify robust biomarkers in PE and IUGR.  These experiments 
aimed to generate MS / MS conditions that provide high-quality product ion spectra, 
enabling high-throughput sample analysis and unsupervised searching of sequences 
databases to ascribe product ion data to protein identity.  This strategy enabled 
identification of peptides / proteins showing reporter ion abundance changes to 
investigate dysregulated urinary proteins for pregnant women with PE and IUGR at 15 
and 20 weeks gestational age respectively.  
Chapter 3: FTIR analysis of urine – optimisation method using animal model 
FTIR spectroscopy was used to study spectral profile on rat urine samples.  The main aim 
of this chapter is to establish a procedure for use with urine samples, using an animal 
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model for optimisation experiments. The use of locally available animal-derived materials 
allowed us to preserve the valuable and limited volume human samples.  Rat urine 
samples were available locally and with no significant impact on the animals involved as 
this is their waste.  The chapter aim is to investigate volume sensitivity vs spectrum 
detection using whole urine sample of rat using FTIR spectroscopic analysis. Moreover, 
methodology development and optimisation are presented for FTIR spectroscopy used to 
identify the spectral profile of urine samples. The processes evaluated included 
separation of urine into protein fractions with specific molecular weights.  Optimised 
workflow was used for clinical urine samples collected from the international SCOPE 
biobank of both PE and IUGR. 
Chapter 4: Study of spectral profile for pregnancy complications using FTIR spectroscopy 
This chapter aims to identify spectral profile of both PE and IUGR using FTIR technique. 
Optimised workflow that was established in Chapter 3 was used for sample preparation 
protocol of clinical sample.  Sample was collected from the international SCOPE biobank 
of both PE and IUGR.  This enabled the investigation of sample spectral profiling for both 
PE and IUGR during 15 and 20 week of gestation, and compared with control respectively 
using FTIR. 
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Chapter 2 
 
2. Proteomic analysis for pregnancy 
complications using iTRAQ labelling 
coupled with mass spectrometry 
techniques  
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2.1. Introduction isobaric labelling method (iTRAQ) 
Mass spectrometry-based quantitative proteomics strategies can be classified in two 
major categories: firstly, label-free methods, based on integral MS signal of each 
(protein/peptide); and alternatively those approaches using stable isotope labelling, 
which introduce a mass difference between two proteomes or produce an internal 
standard for relative quantification information (Ong and Mann, 2006).  Isobaric labelling 
methods (iTRAQ and TMT) use a common approach, labelling labile functional groups 
upon protein/peptide molecules, with identification and quantification being performed 
using various types of tandem mass spectrometer. iTRAQ and TMT employ identical 
target functional groups upon tryptic peptides, attacking the primary amines of 
peptide/protein. Both tags employ an N-hydroxysuccinimide (NHS-) activated group; this 
moiety reacts with N-terminal amine groups (primary amine) and with ε-amine groups of 
lysine residues to covalently attach the tags to the peptides. (Figure 2.1) illustrates the 
chemical structure of the 4-plex iTRAQ variant isobaric mass tagging reagent. The NHS- 
activated group renders most biological samples susceptible to these labelling 
approaches. Labelling will not occur at modified peptide N-termini, such as N-terminal 
cyclised glutamic acid (pyro-glutamic acid), or N-terminal acetylated peptides (Rauniyar 
and Yates III, 2014). The earliest experiments employed MALDI-TOF-TOF or quadrupole 
time-of-flight (Q-TOF) instruments (Alvarez et al., 1997, Thompson et al., 2003). Time-of-
flight (TOF) mass spectrometry is particularly suited to iTRAQ/TMT methods, due to the 
ability of TOF mass analysers to detect low m/z fragment ions (the region where reporter 
ions are observed) (Fuller and Morris, 2012). 
20 
 
 
Figure 2. 1: Generalised structure of N-hydroxysuccinimide (NHS-) iTRAQ tag and its 
derivatisation activity. 
This compound consists of an isobaric tag (reporter ion and balancer group), and NHS- tag group 
that reacts with free N-terminal amines and ε-amine of lysine residues of the peptides, allowing 
easy peptide identification (based on product ions resulting from backbone cleavage) and relative 
quantification (based upon reporter ion intensity). 
 
2.2. Proteome analysis by mass spectrometry  
Several proteomic methods can be used successfully for analysis of biomarkers 
(Gevaert et al., 2003; Bergman and Bergquist, 2014).  Mass spectrometry (MS) is a 
method commonly used to analyse proteins (Han et al., 2008).  Mass spectrometry is a 
primary methodology providing an effective means to chemical characterisation, with a 
number of desirable characteristics, such as unbiased methods, rapid, high sensitivity and 
high throughput (de Hoffmann, 1996; Dass and Brodbelt, 2001).  Quantitative proteomics 
strategies highlight variations between experiment and control samples (Ong and Mann, 
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2006).  Proteomic analyses can be broadly divided into either by ‘top down’ approaches, 
where the intact protein is the target, or ‘bottom up’ approaches where digested proteins 
are investigated.  The latter is often used to characterise proteins (either isolated or as 
mixtures), which are subjected to site-specific proteolysis using enzymes (typically 
trypsin) (Wingert et al., 2015). 
 
2.3. Basics of mass spectrometry  
Mass spectrometry (MS) plays a vital role in proteomic studies. Mass spectrometers 
typically consist of three essential components:  ionisation source, mass analyser and 
detector.  Figure 2.2 illustrates a generalised schematic of a mass spectrometer, 
describing the main components and their basic functions. 
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Figure 2. 2:  Schematic diagram of the basic components of a mass spectrometer and 
their roles in MS analysis  
Mass spectrometers generally consist of three major components: ion source, mass analyser and 
detector. Molecules are volatilised and induced into an ionised state within the ion source, 
allowing analysis according to m/z ratio (detected as ion signals). Acquired data are interrogated 
using computerised algorithms.  Edited from (Yates, 2000). 
 
 Ionisation  2.3.1.
In order to perform analysis of the molecular content of samples according to 
mass/charge (m/z), molecules must firstly undergo conversion into the gas-phase and 
ionisation. To be able to detect ions, they must remain intact into the mass analyser, 
therefore for large, in-volatile and fragile biological molecules such as proteins and 
peptides, low energy transfer or ‘soft’ ionisation techniques must be used (de Hoffmann, 
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1996).  Two principal types of ionisation source are commonly used for this purpose, 
namely electrospray ionisation (ESI) (Nguyen and Schug, 2008) and Matrix Assisted Laser 
Desorption/Ionization (MALDI) (Korte et al., 2015).  ESI is the main technique which is 
used in this project. 
 
 Electrospray ionisation (ESI) 2.3.1.1.
ESI is a method which enables the generation of intact molecular ions from liquid phase 
samples by application of electrical potential. In the late 1980s, Professor John Fenn’s 
group developed electrospray ionisation (ESI) (Fenn et al., 1989).  This technique enables 
the generation of gas-phase ions via the application of an electrical charge to solution-
phase sample (typically in an acid-containing organic solvent) (Gaskell, 1997). The organic 
solvent is volatile and thus readily evaporates by heating, increasing charge density in the 
resultant electrospray droplets, which causes electrostatic repulsion and thus plume 
expansion (Gaskell, 1997). There are a number of aspects of ESI which are attractive for 
characterization of biological samples; the technique has high sensitivity (femto- to 
attomolar, depending upon the mass analyser), it is readily coupled to high pressure 
liquid phase (HPLC), and further is amenable to miniaturization for further reductions in 
sample consumption and thus increased sensitivity.  Peptide ions generated from tryptic 
hydrolysates typically bear multiple charges (Nguyen and Schug, 2008); this property, 
together with low internal energy of precursors, means that products of collisional 
dissociation occupy lower energy pathways, and can be readily assigned to sequence 
databases (Yates, 2000).  ESI is not without disadvantages; it is poorly tolerant of 
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inorganic salts, whilst the multiplicity of charge states for larger analytes with more 
chargeable sites can reduce sensitivity for intact proteins and larger polypeptides (Abian 
et al., 1999).   
 
 Instrumentation used in biological mass spectrometry  2.3.2.
There are several types of mass analyser commonly employed in biological mass 
spectrometry, including Time-of-flight (TOF), the quadrupole and the various types of ion 
trapping mass analysers (quadrupole, Fourier Transform Ion Cyclotron Resonance and 
orbitraps) (Wiley and McLaren, 1955, Hu et al., 2005, Han et al., 2008, Walther and Mann, 
2010).  These analysers are frequently combined into hybrid mass analysers, allowing 
optimum mass analysis results. ESI and MALDI are typically implemented on similar 
platforms, although there are some pairings which are particularly apposite.  The 
continuous nature of ESI and finite nature of the typical mass range of ions thus 
generated (due to multiple charging) means that tandem quadrupoles and the various 
types of ion traps are commonly paired with ESI, whilst the addition of a semi-
discontinuous quadrupole mass filter renders quadrupole time-of-flight (Q-q-TOF) mass 
analysers highly effective (Bateman and Hoyes, 2000). 
 
 Time-of-Flight 2.3.2.1.
Time-of-flight mass spectrometer (TOF-MS) is a widely-used mass analyser type, which 
was developed in the 1950s (Balcerzak, 2003). Time-of-flight analysers work on a simple 
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basic principle: a set distance exists between ionisation source and ion detector.  Ions are 
initially accelerated from the ionisation region towards the detector via application of 
typically electrical (field).  This initial ion extraction is followed by transition of the ion 
population through a field-free region, where ions of differing mass-to-charge ratio (m/z) 
are separated and detected at differing ‘time-of-flight’ (Wiley and McLaren, 1955). 
Molecular ions of differing m/z differ in their kinetic energy (Ek). These differing kinetic 
energies translate to differing velocities (v) in a field-free ‘drift’ region with the following 
relationship:  
EK= m v
2/ 2         Equation 1.1 
where m is mass of an ion and v is the velocity of the ion following acceleration 
(Balcerzak, 2003).Therefore, an ion with low mass will be transmitted faster than one 
with higher molecular mass.  The detector is calibrated using signals of known m/z to 
enable conversion of time of flight to mass-to-charge (m/z) ratio for unknown signals. A 
schematic of this process is illustrated in Figure 2.3 (Dass and Brodbelt, 2001). 
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Figure 2. 3: Diagram of Time Of Flight (TOF) analyser. 
Ions are subjected to mass analysis according to their time of flight, with a reference mixture 
being used to calibrate the relationship between time of flight and m/z ratio. 
 
 Quadrupole analysers  2.3.2.2.
Quadrupole analyser devices typically consist of four parallel rods. These rods are in two 
pairs, with two opposite rods of positive polarity and two of negative polarity (see Figure 
2.4).  These rods use an oscillating electrical field to influence ions’ trajectories according 
to their m/z ratio (Dawson, 2013).  As the oscillating current changes, ions of varying m/z 
can be transmitted towards the detector; ions with unstable trajectories will be ejected or 
collide with rods (Figure 2.4).  Quadrupole analysers can be employed to transmit and/or 
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select ions of differing m/z ratio; they have consequently been utilised in various types of 
tandem and hybrid mass analysers (Dawson, 2013). 
Quadrupole mass analysers are well-suited to receive ions from sources which produce a 
constant beam, such as those created by an ESI ionisation source (Wingert et al., 2015). 
Quadrupole mass analysers are capable of high mass accuracy, with unit mass resolution. 
Accordingly, quadrupoles are frequently used as ion selectors for hybrid analysers such as 
Q-TOF instruments.  Since TOF analysers can measure multiple ions simultaneously, such 
analysers require an ion guide that transports all ions together at the same time over the 
entire mass range of the analyser (Vaz et al., 2015, de Hoffmann, 1996). 
 
Figure 2. 4: Diagram of quadrupole mass analyser 
Ions are generated in within the source region and accelerated in the z direction after applying 
voltage and radio frequencies to rods.  Ions within a specific m/z range maintain a stable 
oscillatory trajectory and are thus transmitted through the quadrupole to reach the detector (red 
line) after applying a particular RF/DC. However, the oscillations of ions with other m/z ratio 
become unstable causing them either to be lost via transmission outside the mass analyser (blue 
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line) or collision with rods (green line).  This figure was adapted from (www.Shimadzu. com, 
2015). 
 
Conventional tandem quadrupole instruments consist of three quadrupole regions; the 
first (Q1) can be used as a mass-selective filter or in broad pass mode.  Q1 is followed by 
an rf-only quadrupole, typically used as a collision cell, with Q3 either being used to 
transmit and analyse product ions (product ion scanning), or to selectively transmit 
specific products (termed reaction monitoring); the latter process has an extremely high 
duty cycle and can be both very selective and of high sensitivity (Figure 2.5) (McLuckey, 
1992). 
 
Figure 2. 5:  Diagram of reaction monitoring using a triple quadrupole analyser 
Initial analytical quadrupole (Q1) is used here as a mass selective filter, with the ‘red’ ions being 
selected for collisional activation in the radio frequency-only quadrupole collision cell (q2). The 
third quadrupole region (Q3) could be used to scan out the products (product ion scan), or as is 
shown here, operated as a filter to provide high-confidence quantification information for a 
specific product ion population generated from the selected precursor (red triangles); this is 
termed reaction monitoring. 
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 Hybrid orbitrap mass spectrometers  2.3.2.3.
Orbitraps are a unique class of resonance mass spectrometers which have become 
extremely popular due to their high resolving power and mass accuracy, combined with 
simple maintenance and lack of requirement for cryogenic cooling. These properties 
stand in direct contrast to the superconducting magnet instruments which have similar if 
not higher resolving power but significant ongoing maintenance requirements.  The 
orbitrap instruments are electrostatic ion traps, with a central electrode surrounded by 
an outer electrode. Ions ‘orbit’ as oscillating packets or rings around the central electrode 
with different axial oscillatory frequencies depending upon the m/z of the ions (Watson 
and Sparkman, 2007). The ions are detected as an image current by the outer electrode 
according to the frequency of the oscillations (Watson and Sparkman, 2007). Orbitraps 
require electrodynamic ‘squeezing’ of ion packets to enable their coherent entry into the 
electrostatic field, and are therefore in practice always operated as hybrid instruments 
with various arrangements of quadrupole and linear ion trap acting as ion 
storage/filtering devices ahead of ‘squeezing’ in a curved linear ion trap (“C-trap”) 
(Watson and Sparkman, 2007). 
The Fusion mass spectrometer is one such hybrid instrument, in this case a “tribrid” 
consisting of a quadrupole mass filter, dual (low/high) pressure linear ion trap (LT), and 
Orbitrap mass analyser (Williamson et al., 2016) . This hybrid instrument allows spatio- 
temporal separation of ion isolation, fragmentation, and detection.  This configuration 
increases the efficiency of the orbitrap duty cycle to enable high-throughput, sensitive 
peptide identification (Williamson et al., 2016).  In particular, these instruments enable 
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sensitive and high-resolution of the low mass region for iTRAQ/TMT-labelled quantitative 
proteome analyses of biological samples (Wen et al., 2013, McAlister et al., 2014).   
 
2.4. Application of mass spectrometry in PE and IUGR studies  
Mass spectrometry-based quantitative proteomics strategies can be classified in two 
major categories: firstly, label-free methods, based on integral MS signal of each 
(protein/peptide) (Bergman and Bergquist, 2014, Blankley et al., 2013); and alternatively 
those approaches using stable isotope labelling, such as isobaric tagging strategies 
(Rauniyar and Yates III, 2014).  Isobaric labelling-based quantification, (e.g. iTRAQ) is a 
means to providing relative quantitative information, providing a set of reporter ions 
whose intensity profiles correlate with differences between two or more proteomes (Ong 
and Mann, 2006, Lehnert et al., 2012, Rauniyar and Yates III, 2014). 
Previously a number of studies (Auer et al., 2010, Blankley et al., 2013, Wen et al., 2013) 
have been performed to study proteomic biomarkers for both PE and IUGR conditions; 
these studies used MS coupling with labelling technique (iTRAQ) or label free bases 
analysis.  In 2010, Auer et al., used iTRAQ labelling coupled with MALDI-TOF-MS to 
identified proteomic biomarkers in blood plasma from pregnant women obtained at or 
near term (Auer et al., 2010).  Women were categorised into four groups: preeclampsia 
(PE, n=7), isolated Intra-Uterine Growth Restriction (IUGR, n=7), PE and IUGR (n=7), and 
normal pregnancies (control. n=6).  Before labelling with iTRAQ, the samples were 
immuno-depleted of major plasma proteins (albumin, IgG, antitrypsin, IgA, transferrin 
and haptoglobin) using multiple affinity removal spin MARS-6 cartridges.  In order to 
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identify proteins which are changed in placental diseases, the first set samples were 
pooled with iTRAQ labelling from patients diagnosed with isolated PE, isolated IUGR, PE 
with IUGR and controls (normal pregnancies).  In the second step, they used four pools 
categorised into two control groups.  First group (6 patients from the first set and 
4 others from a second independent set) and a second group included two IUGR groups 
(7 from the first series and 6 others from a second independent series).  They selected 
two candidate proteins from the analysed pools to validate them on individual samples by 
Western blot.  166 proteins in total were identified from the first iTRAQ experiment, with 
31/128 identified proteins showing expression changes in IUGR (14 up and 17 down-
regulated); 54 proteins out of 130 identified were different in the serum of isolated PE, 
(28 up and 26 down-regulated). Finally, in (PE + IUGR) cases 28/134 proteins were 
significantly dysregulated (13 up and 15 down-regulated). Nine proteins were identified 
that showed altered expression in all pathologies investigated, for the majority of cases 
compared to controls; these proteins showed differential patterns of dysregulation for 
different conditions.  For instance, fibronectin (FN1) was specifically increased in the 
cases of PE and PE+IUGR, but reduced in isolated IUGR.  The authors concluded that the 
differences in the terms at which samples were collected (on average 5 weeks difference 
between control samples and pathological cases) may have led to many of the differences 
observed in these putative biomarkers, and further suggested that a larger cohort size is 
needed in order to gain results with increased precision (Auer et al., 2010)  
In 2013, Wen et al., used LC-MS/MS LTQ-orbitrap to analyse serum peptidome profiles in 
a case control study in preeclampsia (Wen et al., 2013).  Sixty-two pregnant women were 
investigated; (n=31) had PE and (n=31) were healthy pregnant women (controls).  All 
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subjects within the study were categorised into two groups.  2/3 of the cohort were used 
as a training set (n=21 preeclampsia case and n=21 control), whilst the remaining 1/3 
were used as test set (n=10 case group, n=10 healthy group).  They were able to identify 
612 peptides in total.  Two algorithms, significance analysis of microarrays (SAM) and 
predictive analysis of microarrays (PAM), were used for analysis.  SAM identified 52 
differential profiling peptides, of which 14 protein precursors were highly significant in 
cases compared to control.  They also found nineteen peptide panels derived from 
6 different protein precursors: (13 from fibrinogen alpha (FGA), 1 from alpha-1-antitrypsin 
(A1AT), 1 from apolipoprotein L1 (APO-L1), 1 from inter-alpha-trypsin inhibitor heavy 
chain H4 (ITIH4), 2 from kininogen-1 (KNG1), and 1 from thymosin beta-4 (TMSB4).  All 
nineteen peptides had a minimal false discovery rate significant (q < 0.05) value.  
According to trained PAM prediction analysis, all PE (n =21), were predicted correctly, 
whereas 3 of 21 (14.3 %) control samples were false positive.  For the training set, 
sensitivity was 85.7 % and specificity was 100 %; these results showed around 92.9 % 
accuracy in the overall prediction.  Test set results gave an overall prediction accuracy of 
90 % (sensitivity was 80 % and specificity was 100 %).  Pathway analysis (Ingenuity 
Pathway Analysis) was used to analyse 14 parental proteins of the 52-peptide markers, 
which may play vital roles in the pathophysiology of PE.  The limitation of this study was 
that proteomic profiling data were obtained from a commercial vendor with little specific 
information on the clinical characteristics; the analysis can therefore only be of 
confirmative diagnostic rather than predictive value; the sample set lacked samples from 
other hypertensive disorders of pregnant women to define if the panel differentiates 
between these women and PE.  The authors of this study also suggested using 
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multiplexed peptide detection coupled with multiple reaction monitoring (MRM) for 
confirmation of putative differential markers.  
The international Screening fOr Pregnancy Endpoints (SCOPE) study enrolled 3182 
pregnant women, of whom 5.6 % had preeclampsia (Blankley et al., 2013).  This study 
used iTRAQ tags coupled with a combination of MS tools (LC-MS or with MALDI-TOF-TOF) 
to study serum biomarkers in preeclampsia.  A pool of samples (n=12) were taken at 
15 weeks from women who developed PE later, early onset PE (EO-PE, delivery 34 weeks) 
and two control pools (uncomplicated pregnancies, n=12 each).  A plasma sample was 
immuno-depleted before iTRAQ labelling using either the SepproIgY 14 -SuperMix Liquid 
Chromatography Column system or the Multiple Affinity Removal LC Column - Human 14 
(MARS 14).  This study performed in three experimental steps.  From exploratory phase of 
iTRAQ experiments of first cohort, 502 proteins were identified (319 proteins in the IgY 
14-SuperMix-Q-STAR data set, 331 in the IgY 14-SuperMix-5800 data set, and 189 in the 
MARS 14 –5800 data set), 133 proteins were modified in abundance in each one of the 
iTRAQ data sets, which are represent a discovery data.  SRM method was used for 
verification of candidate proteins that were detected in the discovery data set such as, 
platelet basic protein (PBP, CXCL7), and pregnancy-specific beta-1-glycoprotein 9 (PSG9).  
PSG9 is a member of a large multigene family, which expressed in a pregnancy specific 
manner.  In second cohort, 108 enrolled women had PE; n=16 (EP-PE), n= 42 late onset 
(LO-PE), and 42 control), eight technical replicates of pooled samples (after immune-
depletion, proteins fractionation and digestion). LC-SRM analysis was performed on an 
uHPLC using QqQ-LC/MS platform with electrospray source.  Six isoforms of PSG specific 
peptides (PSG9) were observed to show statistically significant differences between EO-
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PE and controls. These changes were then verified with ROC analysis and ELISA based 
quantification (Blankley et al., 2013). 
Many studies have previously investigated metabolic profiles in PE and IUGR.  No studies 
so far identified robust biomarkers to predict PE and IUGR disorders earlier.  At the time 
of writing, no screening test was currently in use with predictive capacity to accurately 
identify women whose first time gestations will develop late pregnancy diseases.  Urine 
sample is an ideal bodily fluid for antenatal testing due to the non-invasive nature of 
obtaining samples; indeed women under routine prenatal care are required to provide 
urine samples for testing, making this a highly-acceptable methodology.  Moreover, urine 
proteins have more stability and low dynamic range compared to blood proteome. 
 
2.5. Chapter aims 
1.  To establish Standard Operating Protocol (SOP) based on urinary protein 
separation over nominal molecular weight cut-off (NMWCO) membranes >10 kDa. 
This informed the experimental design and sample preparation for 8-plex iTRAQ 
labelling coupling for the LC-MS technique for proteomic analysis. 
2. To undertake proteomic analysis for PE and control at both 15 and 20 weeks 
gestational age respectively using LC-MS analysis. 
3. To perform proteomic analysis for IUGR and control at each 15 and 20 week of 
pregnancy respectively using LC-MS analysis  
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4. To determine dysregulated protein quantitatively that showing significant 
alteration in protein expression in PE and IUGR during 15 and 20 weeks 
respectively. 
 
2.6. Materials and methods 
2.6.1 Chemicals 
All chemicals were used as received from the supplier. Table 2.1 presents a full list of all 
standard chemicals used within the work presented in this chapter.  
Table 2. 1: Chemicals and suppliers  
Item Supplier 
Acetonitrile  VWR Chemicals (Lutterworth, UK), 
Bovine Serum Albumin (BSA) Waters-UK 
Bovine Serum Albumin digestion Standard 
(BSA) 
(Waters-UK) 
Bradford Reagent  Sigma-Aldrich (Poole, UK) 
Enolase digestion standard MassPREP (Waters-UK) 
HPLC-grade water VWR Chemicals (Lutterworth, UK) 
Isopropanol Sciex, USA 
Methyl methane-thiosulfonate (MMTS) in 
isopropanol 
Sciex, USA 
SDS Sciex, USA 
Sequencing Grade Modified Trypsin:  Promega-UK 
Trie thylammonium bicarbonate (TEAB) Sigma-Aldrich, UK 
Trifluoroacetic acid Fisher Scientific (Loughborough, UK)   
Tris-(2-carboxyethyl)-phosphine (TCEP). Sciex, USA 
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2.6.2. Sample acquisition and preparation 
2.6.2.1. Acquisition of human urine samples  
Urine samples were obtained from The international SCreening fOr Pregnancy Endpoints, 
(SCOPE) biobank, held at University College Cork.  These samples were collected 
prospectively at 15 and 20 week gestation from women whose pregnancies were 
eventually complicated by IUGR (n=30) or with PE (n=30). Samples from pregnancy 
complications were compared to uncomplicated pregnancies, matched for ethnicity and 
BMI (n=30 in each case).  The acquisition and transport of the urine sample from 
University College Cork (UCC) were performed under a Material Transfer Agreement 
(MTA) (see Appendix 1).  UCC undertook ethical review governing the recruitment of 
patients, sample and metadata collection and storage (see Appendix 2), and provided 
detailed assurance of their informed written consent procedures.  All donor information 
is held by SCOPE in Cork; we have no direct access to this data; all patients are given 
unique references and the identifying data are held securely and accessible only by UCC. 
Evidence of consenting procedures was requested at the time of procurement and ethical 
review (see Appendix 2) arranged prior to use through Keele University’s Research Ethics 
Committee in accordance with HTA-41. 
2.6.2.2. Transportation of human tissue and storage  
A total of 240 cryo-tube urine samples (450 µL per tube) were shipped from Cork to Keele 
University (Huxley Building).  120 samples totally collected from each preeclampsia and 
IUGR respectively, 120 samples from normal pregnant (control).  The samples (n=30) are 
matched accordance to each case-control for both PE and IUGR respectively.  These 
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samples were collected at two period’s gestational age, 15 and 20 weeks respectively.  
Shipping was undertaken by Marken, an authorised dry ice shipping company in 
accordance with the signed Material Transfer Agreement (MTA) (see Appendix 1).  
Cryobox temperatures were recorded and monitored during the shipment.  The 
consignment was transported in accordance with IATA / UN 1845 standards for approved 
shipping containers, with double packaging to avoid leaks and the services of a registered 
delivery agency requiring a signature on receipt of the consignment.  This group does not 
deal in primary patient information and thus had no access / did not store any patient 
identifiable information, thus loss of confidentiality was not a risk in this situation.  Upon 
receipt, all samples were directly stored at -80◦ C, subject to routine temperature 
monitoring by University staff.  Samples were clearly labelled with unique identifiers. 
 
2.6.3. Samples preparation process 
Urine samples were prepared to examine proteomic biomarkers according to protocol 
below: 
2.6.3.1. Centrifugation, ultrafiltration and protein purification 
Urine samples were selected from -80o C freezer, thawed and cleared from pelleted 
urinary tract cells (i.e. uroepithelial cells) using centrifuge (Eppendorf, Germany) at 3220 g 
for 10 min, 4o C.  The remaining acellular supernatant material of each sample was 
subjected to isolation of proteins using >10kDa proteins ultrafiltration tubes 
Polyethersulfone (PES) MWCO 10000, 2 mL. (Sartorius AG,).  Ultrafiltration centrifuge 
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devices were washed 3 X with HPLC grade water to remove PES membrane interference 
materials.  Buffer exchange was performed on the retentate fraction of urine, spinning (3 
X) with 0.5M triethylammonium bicarbonate (TEAB) (Sigma-Aldrich, UK) at 3220 g, 4° C to 
clear proteins from undesirable ionic materials and salts using 3220 g, 4° C (Eppendorf, 
Germany).  Assay on protein fraction in 96-well plate using well-plate reader vs. a 
standard curve generated using BSA of known concentration was carried out on final 
concentrated pool retentate in each cohort. 
2.6.3.2. Verification of protein concentration 
Spectrophotometry (BioTek, E L 800, USA) was used to verify protein concentration of 
> 10 kDa retentate in each pool cohort samples.  The amount of protein was determined 
using a microtiter plate format Bradford assay, standardised against bovine serum 
albumin. The assay was carried out as per manufacturer’s protocol, monitoring 
spectrometric absorbance at 595 nm.  60 µg of protein was used in each labelling 
experiment.  Protein concentration was measured using standard concentration curve 
(Bradford assay) at the particular wavelength to calculate their concentrations using Beer-
Lambert law, Equation 2.1:  
A =  L c                                                                                                                 - Equation 2.1 
A = absorbance,  = molar extinction coefficient, c = concentration and L = light 
pathlength, the concentration can be calculated by given Equation 2.2: 
c= A / L                                                                                                                - Equation 2.2 
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2.6.3.3. Tryptic digest and iTRAQ labelling 
Tryptic digestion was carried out on proteins >10 kDa at amount 60 µg. (Sigma-Aldrich, 
UK), Proteins were subjected to reduction using tris-(2-carboxyethyl)-phosphine (TCEP) 
(AB Sciex, UK), at a final concentration of 50 mM.  Reduction proceeded at 60o C for 60 
min.  Alkylation of free cysteines was performed using methyl methanethiosulfonate (AB 
Sciex, UK) (final concentration 200 mM) at room temperature, 10 min.  Protein was then 
digested overnight at 37° C using 10 µg of Promega modified trypsin (Waters, UK).  A 
known amount at final concentration (~1 pmole) of peptides mixture derivative from 
yeast enolase was spiked into urine samples, these served as a convenient internal 
standard for quantification. 
iTRAQ labelling (8-plex) was then performed as per manufacturer’s protocol.  Labelling 
reagent (Sciex, USA) was dissolved in 100 µl of a mixture solution (0.5 M TEAB and 
ethanol).  Reagent and digest were then mixed and incubated at room temperature for 2 
hr.  Table 2.2 shows descriptive method for samples labelling with iTRAQ reagents 
(8-plex) in each group in this study.  Samples were dried down using vacuum 
centrifugation and dissolved in 60 µL of buffer A (5 % acetonitrile, 0.1 % formic acid) for 
LC-MS/MS. 
Table 2.2: Labelling reagents with all samples of each PE and IUGR samples.  iTRAQ® 
Reagent – 8plex - Buffer Kit materials (Sciex, USA), S: Case, Ctl: Control . 
Condition PE IUGR 
Gestational 
age 
15 week (n=60) 20 week(n=60) 15 week(n=60) 20 week(n=60) 
Subjects (no.) S (30) Ctl (30) S (30) Ctl (30) S (30) Ctl (30) S (30) Ctl (30) 
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2.6.3.4. Strong cation exchange clean up  
Excess iTRAQ reagent was removed from the sample by performing SCX based SPE using 
Empore Cation (3 M) disks in a pipette tip. The disk was prepared by successive washes of 
acetone, methanol, water, 5% (v/v) ammonium hydroxide and water. The sample was 
bound to the disk and washed with 1 % (v / v) trifluroacetic acid. The sample was eluted 
using 5 % ammonium hydroxide, dried and re-suspended in 3 % (v / v) methanol, 97% 
(v / v) HPLC water, 0.1 % (v / v) TFA. This clean-up step was carried out at Liverpool 
University. 
 
2.6.3.5. Mass spectrometry set up 
Experiment 1: 
LC-MS was performed on a hybrid quadrupole-time-of-flight mass spectrometer Q-TOF 
Premier (Waters), coupled to nanoflow HPLC (Dionex Ultimate 3000, ThermoFisher 
Corporation, Hemel Hempstead).  Tandem mass spectrometry was performed to identify 
tryptic peptides.  Peptide mass spectra were obtained using nanoflow electrospray 
ionisation MS (nESI-MS) with tandem MS using MassLynx version 4.1.  Approximately 1 ug 
of sample was analysed.  Separation was performed over 120 min (90 min gradient) using 
a gradient from 5-90 % of acetonitrile [buffer A (5 % acetonitrile, 0.1 % formic acid and 
Labelling 
reagents 
113 114 115 116 117 118 119 121 
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buffer B (95 % acetonitrile, 0.1 % formic acid)] on a C 18 column (75 µm x 150 mm, 
poresize 200 Å, 5um particle size, Dionex/ThermoFisher, San Jose, CA).  Automated 
switching between MS (survey mode) and MS / MS (product ion mode) was used to 
generate sequence tag-specific product ion spectra.  MS / MS was performed on the 
“top 3” multiply-charged (z ≥ 2) precursors observed per survey scan.  To prevent 
repeated MS / MS being performed upon the same precursors, dynamic exclusion was 
selected, with a repeat duration of 3 min.  Sample analysing in duplicate injections with 
iTRAQ experimental set up was used.  This experiment enabled verification of high 
labelling efficiency. 
Following labelling efficiency verification, samples were transferred to Liverpool 
University to be analysed on the orbitrap Fusion mass spectrometer (Thermo Scientific).   
Experiment 2: 
The data-dependent iTRAQ analysis was performed using an Ultimate 3000 RSLCTM nano 
system (Thermo Scientific) coupled to a Fusion mass spectrometer (Thermo Scientific). 
The sample (4 μL corresponding to 400 ng of protein for human sample was loaded onto 
the trapping column (Thermo Scientific, PepMap 100, C 18, 75 μm X 20 mm), using partial 
loop injection, for 7 minutes at a flow rate of 9 μL/min with 0.1% (v / v) TFA. The sample 
was resolved on the analytical column (Easy-Spray C 18 75 μm x 500 mm 2 μm column) 
using a gradient of 96.2% A (0.1% formic acid) 3.8% B (79.9 % ACN, 20 % water, 0.1% 
formic acid) to 50% A 50% B over 90 min at a flow rate of 300 nL/min.  The MS acquisition 
program followed the multi-notch MS 3 method described in (McAlister et al., 2014).  The 
program consisted of a 60,000 resolution full-scan MS scan (AGC set to 4e5 ions with a 
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maximum fill time of 50 ms) with MS / MS using quadrupole ion selection with a 0.7 m/z 
ratio window, HCD fragmentation with a normalized collision energy of 35 and LTQ 
analysis using the rapid scan setting and a maximum fill time of 50 msec.  The 10 most 
intense MS 2 peaks were simultaneously selected for MS 3 analysis using SPS isolation, 
HCD fragmentation at collision energy 65 and analysis in the Orbitrap using a nominal 
resolution of 50,000 over a mass range of 100-500 m/z. The machine was set to perform 
as many MS/MS scans as possible, maintaining a cycle time of 3 sec.  To avoid repeated 
selection of peptides for MS/MS the program used a 60 sec dynamic exclusion window. 
 
2.6.3.6. Data processing  
Raw product ion spectral data from experiment 1 (see Section 2.6 3.5.) were extracted as 
text formatted .mgf files using Mascot Distiller (Matrix Science, London), altering the 
default parameters to include isotopic peak extraction over the reporter ion region (m / z 
ratio 112-122).  Mgf files were subjected to database searching using Mascot (Matrix 
Science).  SwissProt protein sequence database was used for these searches, with the 
following parameters: trypsin as enzyme, precursor ion tolerance 100 ppm, product ion 
tolerance 0.6 Da, fixed modification methylthio cysteine, variable modification: 
methionine oxidation, and at peptide N-termini and lysine side-chains with iTRAQ 8-plex. 
Data were analysed using Mascot (Matrix Science) to determine labelling efficiency. These 
data were excluded from the following results section due to low data density in 
comparison to the orbitrap Fusion dataset, and duplication therewith.   
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Data were processed from experiment 2 (section 2.6 3.5) using Proteome Discoverer V2.2 
(Thermo Scientific) in combination with Mascot V2.6 (Matrix Science) search engine for 
protein identification.  Peptide identification was performed against the reviewed entries 
from the Uniprot Human reference proteome (20328 entries) using a precursor mass 
tolerance of 10 ppm, a product mass tolerance of 0.6 Da, fixed methylthio cysteine 
modification and variable iTRAQ (8-plex) modification of lysine and the N-terminus. 
Peptide and protein identifies were accepted using 0.01 FDR for strict filtering and 0.05 % 
for relaxed filtering. Unique peptides were only accepted for quantification if all reporter 
channels were present, with an average S/N > 5.  Sample normalisation was performed 
based on the spiked enolase standard.  Resultant data were exported to Microsoft Excel. 
 
2.6.3.7. Statistical analysis  
The analysis of the data was carried out within Excel (Microsoft, version 10) and 
GraphPad (Prism 8), to plot relevant tables and graphs  Online Venn diagrams (Venny 2.1) 
(Oliveros, 2007) were used for data comparison.  Data were analysed using descriptive 
statistics of box and whisker plot using GraphPad (Prism 8).  Non-parametric statistical 
analysis was performed using GraphPad (Prism 8), using one sample Wilcoxon test, and 
two samples analysis using Mann-Whitney test. 
 
2.7. Methods outline workflow  
The major method in this chapter is summarised using outline workflow in Figure 2.6.  
44 
 
 
Figure 2. 6:  Schematic chart flow illustrating typical proteomic method. 
 
2.8. Results 
2.8.1 Proteomic analysis for PE at 15 and 20 weeks gestational age  
Proteome analysis of the iTRAQ-labelled urine tryptic peptides generated a dataset of 
protein identification and quantification data.  988 peptides in total were identified from 
315 proteins as being differentially expressed.  Proteins which are detected as 
differentially expressed are filtered using the following criteria: ≥ 2 peptides; Confidence 
Interval (CI) 99 %, FDR < 0.01.  173 / 826 (proteins / peptides) remained following this 
filtering with all 8 label channels being present.  Peptides with significant changes for 
samples taken from women who went on to develop PE at a FDR < 0.01 and confidence 
interval 99 % are presented for samples collected at 15 and 20 weeks gestational age as 
Tables S 1 and S 2 respectively (see appendix 3).  Identified proteins are also quantified, 
Sample 
acquisition    
• 240  samples: PE (n=30), IUGR (n=30) paired  with their normal pregnants (n= 30) at both 
15 and 20 weeks gestational age respectively via SCOPE centre (UCC), Republic of Ireland 
Filtration 
/tryptic 
digestion  
•Isolate >10kDa protein from acellular supernatant material using ultracentrifugal filtration 
•Reduction/ Alkylation/ Tryptic digestion of proteins 
Labelling 
protocol 
•Peptides labelled using iTRAQ  reagent (8 plex) for each group 
Data 
process 
•LC-MS (Q-TOF/ Orbitrap fusion ) 
Data 
analysis 
•Database searching, statistical analysis of differential proteins 
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with differential expression being determined using log 2 fold change of abundance ratio 
(cases: control) at 15 and 20 weeks gestation for PE cases respectively compared with 
uncomplicated pregnancies, shown in Figure 2.7 and 2.8 respectively.  All quantitation 
data underwent normalisation using a known amount of internal standard, adjusting the 
log 2 fold change ratio for internal standard to zero (Figure 2.7, 2.8, and 2.9). 
At PE at 15 weeks gestational age, 173 proteins were identified as showing significant 
changes in expression (P < 0.01) (Figure 2.7).  These data are showed a median at (-0.576) 
with (3.5-(-4.08)) max. and min. values of dysregulated proteins using one sample 
Wilcoxon test (see Figure 2.7). For PE at 20 week of gestation, outcome showed highly 
statistically significant differences quantitatively (P < 0.01) at 95 % confidence interval of 
173 proteins using log 2 fold change of abundance ratio (case/ control) using one sample 
Wilcoxon test.  The data have a median ratio of (0.089), max. and min. values at (2.91-(-
1.639)) (Figure 2.8).  A Mann-Whitney test comparing log 2 fold changes ratio (case/ 
control) observed between 15 and 20 week gestation pregnancies for PE showed a 
significant difference (P < 0.01) at 95 % confidence interval for 173 proteins (Figure 2.9).   
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Figure 2. 7: Differentially expressed protein changes quantitatively for PE at 15 weeks’ 
gestation 
Plot displays log 2 fold change of abundance ratio of (case: control) for PE at 15 week gestational 
age.  Data were analysed showed proteins differentially expressed changes quantitatively vs 
internal standard of enolase at zero value (dotted line).  173 Proteins are analysed are showed 
highly significant changes (P <0.01) at confidence interval 95 % using one sample Wilcoxon test.  
Data were expressed as interquartile range of upper and lower quartiles (box), median (line inside 
box), lines at top and bottom represent the highest and lowest values (whiskers), confidence 
intervals (95 %),  ** represents highly significant value (P < 0.01), black balls represent outliers 
points that showed highest and lowest ratio compared with internal standard.  
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Figure 2. 8: Differentially expressed protein changes for PE cases at 20 weeks’ gestation 
Plot displays log 2 fold change of abundance ratio of (case: control) for PE at 20 weeks’ gestation.  
Differentially expressed are expressed as fold change in comparison to enolase tryptic digest 
internal standard (dotted line).  173 observed proteins showed highly significant changes (P <0.01) 
at confidence interval 95 % using one sample Wilcoxon test.  Data were expressed as interquartile 
range of upper and lower quartiles (box), median (line inside box), lines at top and bottom 
represent the highest and lowest values (whiskers), confidence intervals (95 %),  ** represents 
highly significant value (P < 0.01), black balls represent outlier points with highest and lowest 
ratios compared with internal standard.  
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Figure 2. 9: Differentially expressed protein changes for PE cases at 15 and 20 weeks of 
pregnancy 
Plot shows comparison analysis of log 2 fold change of abundance ratio of (case: control) for PE at 
both 15 week (blue box) and 20 week (red box) gestational age respectively.  Data are analysed 
show proteins expression differences quantitatively between 15 and 20 weeks of gestational age 
of PE.  Significant differences between groups are observed (P <0.01), confidence interval 95 % for 
the 173 proteins analysed using a non-parametric Mann-Whitney test of unpaired two samples 
groups.  Data are expressed as interquartile range of upper and lower quartiles (box), median (line 
inside box), lines at top and bottom represent max and min values (whiskers).  ** represents 
significant changes (P < 0.01), dotted line represents internal standard value of enolase. 
 
The following section describes outlier/dysregulated proteins (highest / lowest) identified 
as significant in previous analysis at 15 and 20 weeks’ gestation respectively  
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2.8.1.1. Highly dysregulated proteins for PE at 15 and 20 weeks  
Differentially expressed proteins were identified as outliers (Figure 2.7 and 2.8) at 15 and 
20 weeks gestation respectively for PE in comparison to uncomplicated pregnancy.  16/ 
42 (proteins/ peptides) were identified as outliers in previous analyses (Figures 2.7) as 
highly dysregulated proteins at 15 weeks’ gestation for PE compared with uncomplicated 
pregnancy.  50 % (n = 8) of these proteins are upregulated and downregulated 
respectively compared with uncomplicated pregnancy (Table 2.3).  At 20 weeks’ 
gestation, 15 / 96 (proteins/ peptides) were dysregulated in pregnancies complicated by 
PE vs. uncomplicated pregnancies.  Of these, 7 proteins were upregulated and 8 proteins 
were downregulated compared with uncomplicated pregnancy Table 2.4.  Three of the 
candidate dysregulated proteins showed identical profiles at 15 and 20 weeks gestation. 
These proteins are fibrinogen beta chain, haptoglobin and carboxypeptidase, and are 
highlighted in Table 2.3 and 2.4, and the comparison in Figure 2.10. 
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Table 2.3: Dysregulated proteins dataset of PE at 15 week gestational age compared with control  
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
Protein name # 
Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of PE at 
15 W 
Abundances 
of reporter 
ion of 
control at 
15W 
Abundance 
ratio 
(Case/ 
Control) of 
PE at 15 W 
Log 2 fold 
change 
ratio 
Up/ 
Down  
1 High P01023 Alpha-2-macroglobulin 
OS=Homo sapiens OX=9606 
GN=A2M PE=1 SV=3 
2 163.2 234.4 20.7 11.33 3.502 Up 
2 High P02675 Fibrinogen beta chain 
OS=Homo sapiens 
OX=9606 GN=FGB PE=1 
SV=2 
2 55.9 159.4 16.9 9.415 3.235 Up 
3 High Q6GTX8 Leukocyte-associated 
immunoglobulin-like 
receptor 1 OS=Homo 
sapiens OX=9606 GN=LAIR1 
PE=1 SV=1 
2 31.4 143.4 15.6 9.223 3.205 Up 
4 High Q8IYS5 Osteoclast-associated 
immunoglobulin-like 
receptor OS=Homo sapiens 
OX=9606 GN=OSCAR PE=1 
SV=3 
2 30.5 42.4 5.4 7.89 2.980 Up 
5 High P00738 Haptoglobin OS=Homo 
sapiens OX=9606 GN=HP 
PE=1 SV=1 
4 45.2 219.5 38 5.78 2.531 Up 
6 High P02788 Lactotransferrin OS=Homo 
sapiens OX=9606 GN=LTF 
PE=1 SV=6 
3 78.1 273.3 50.6 5.404 2.434 Up 
7 High P06733 Alpha-enolase OS=Homo 
sapiens OX=9606 GN=ENO1 
PE=1 SV=2 
4 47.1 98.4 18.4 5.351 2.420 Up 
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8 High P13796 Plastin-2 OS=Homo sapiens 
OX=9606 GN=LCP1 PE=1 
SV=6 
4 70.2 177.4 37.8 4.692 2.230 Up 
9 High Q06830 Peroxiredoxin-1 OS=Homo 
sapiens OX=9606 
GN=PRDX1 PE=1 SV=1 
2 22.1 19 69.2 0.274 -1.868  Down 
10 High P10253 Lysosomal alpha-
glucosidase OS=Homo 
sapiens OX=9606 GN=GAA 
PE=1 SV=4 
4 105.3 14.5 60.5 0.24 -2.059  Down 
11 High Q9Y646 Carboxypeptidase Q 
OS=Homo sapiens 
OX=9606 GN=CPQ PE=1 
SV=1 
2 51.9 16.4 79 0.208 -2.265  Down 
12 High Q9P121 Neurotrimin OS=Homo 
sapiens OX=9606 GN=NTM 
PE=1 SV=1 
2 37.9 13.5 72.9 0.184 -2.442  Down 
13 High P07195 L-lactate dehydrogenase B 
chain OS=Homo sapiens 
OX=9606 GN=LDHB PE=1 
SV=2 
2 36.6 13 79.8 0.163 -2.617  Down 
14 High Q8WZ75 Roundabout homolog 4 
OS=Homo sapiens OX=9606 
GN=ROBO4 PE=1 SV=1 
2 107.4 7.8 71.6 0.109 -3.198  Down 
15 High Q9HCU0 Endosialin OS=Homo 
sapiens OX=9606 
GN=CD248 PE=1 SV=1 
2 80.8 3.3 38 0.086 -3.540  Down 
16 High Q07075 Glutamyl aminopeptidase 
OS=Homo sapiens OX=9606 
GN=ENPEP PE=1 SV=3 
3 109.2 1.7 28.2 0.059 -4.083  Down 
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Data identified at confidence interval 99 %, FDR (False Discovery Rate) < 0.01, Peptides no.≥ 2; Outlier of data that quantified at confidence interval 95 
%. P < 0.05, highlighted data is showed identical in protein profile at both 15 and 20 weeks of PE. 
 
 
Table 2.4: Dysregulated proteins dataset of PE at 20 week gestational age compared with control 
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
Protein name # Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of PE at 20 
W 
Abundances 
of reporter 
ion of 
control at 
20W 
Abundance 
ratio 
(case/ 
control) of 
PE at 20 W 
Log 2 
fold 
change 
ratio 
Up/ 
Down 
1 High P02675 Fibrinogen beta chain 
OS=Homo sapiens 
OX=9606 GN=FGB PE=1 
SV=2 
2 55.9 167.3 22.2 7.526 2.912 Up 
2 High P00738 Haptoglobin OS=Homo 
sapiens OX=9606 GN=HP 
PE=1 SV=1 
4 45.2 183.4 48 3.823 1.935 Up 
3 High P02787 Serotransferrin OS=Homo 
sapiens OX=9606 GN=TF 
PE=1 SV=3 
12 77 179.2 61.4 2.919 1.545 Up 
4 High P01861 Immunoglobulin heavy 
constant gamma 4 
OS=Homo sapiens 
OX=9606 GN=IGHG4 PE=1 
SV=1 
3 35.9 201.1 75.1 2.677 1.421 Up 
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5 High P01877 Immunoglobulin heavy 
constant alpha 2 OS=Homo 
sapiens OX=9606 
GN=IGHA2 PE=1 SV=4 
3 36.6 203 78.6 2.582 1.368 Up 
6 High P00450 Ceruloplasmin OS=Homo 
sapiens OX=9606 GN=CP 
PE=1 SV=1 
13 122.1 227.8 88.8 2.564 1.358 Up 
7 High P01859 Immunoglobulin heavy 
constant gamma 2 
OS=Homo sapiens 
OX=9606 GN=IGHG2 PE=1 
SV=2 
4 35.9 179.4 71.7 2.502 1.323 Up 
8 High P04264 Keratin, type II cytoskeletal 
1 OS=Homo sapiens 
OX=9606 GN=KRT1 PE=1 
SV=6 
17 66 56 95.3 0.588 -0.766 Down 
9 High P19013 Keratin, type II cytoskeletal 
4 OS=Homo sapiens 
OX=9606 GN=KRT4 PE=1 
SV=4 
12 57.3 59.2 108.7 0.545 -0.876 Down 
10 High Q9Y646 Carboxypeptidase Q 
OS=Homo sapiens 
OX=9606 GN=CPQ PE=1 
SV=1 
2 51.9 84.6 162.8 0.52 -0.943 Down 
11 High P07911 Uromodulin OS=Homo 
sapiens OX=9606 
GN=UMOD PE=1 SV=1 
7 69.7 94.1 186.4 0.505 -0.986 Down 
12 High P05062 Fructose-bisphosphate 
aldolase B OS=Homo 
sapiens OX=9606 
GN=ALDOB PE=1 SV=2 
2 39.4 57.7 116.4 0.496 -1.012 Down 
13 High P09211 Glutathione S-transferase P 2 23.3 54 124.9 0.433 -1.208 Down 
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OS=Homo sapiens 
OX=9606 GN=GSTP1 PE=1 
SV=2 
14 High P07355 Annexin A2 OS=Homo 
sapiens OX=9606 
GN=ANXA2 PE=1 SV=2 
8 38.6 78.5 184 0.427 -1.228 Down 
15 High P63104 14-3-3 protein zeta/delta 
OS=Homo sapiens 
OX=9606 GN=YWHAZ PE=1 
SV=1 
5 27.7 37.6 116.9 0.321 -1.639 Down 
Data identified at confidence interval 99 %, FDR (False Discovery Rate) < 0.01, Peptides no. ≥ 2 ; Outlier of data that quantified at confidence interval 
95 %. P < 0.05, highlighted data is showed identical in protein profile at both 15 and 20 weeks of PE. 
 .
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Figure 2. 10: Dysregulated proteins comparison between 15 and 20 weeks gestational 
age of PE  
Venn diagram plot showing dysregulated proteins comparison between 15 and 20 week 
gestational age of PE.  Outlier protein accession numbers were compared for each 
gestation.  Data are presented as proteins numbers and % of differential protein profile at 
15 and 20 weeks of PE. 
 
2.8.2. Proteomic analysis for IUGR at 15 and 20 weeks gestational age 
The full dataset of proteins identified as showing significant changes with a FDR < 0.01 
and confidence interval 99 % related to IUGR at both 15 and 20 weeks gestational age 
respectively are shown in Table S 3 and S 4 (see Appendix 3).  Total of 988 peptides from 
315 proteins were identified.  Proteins detected as differentially expressed were filtered 
using the following criteria: Peptide number ≥ 2; Confidence Interval (CI) 99 %, FDR < 
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0.01.  173/826 (proteins / peptides) following data filtering showed significant changes 
(FDR < 0.01 at confidence interval 99 %) in all 8 label channels at both 15 and 20 weeks 
gestational age of IUGR; these changes are shown in Table S 3 and S 4 (see Appendix 3).   
Differentially expressed candidate proteins were also quantified using log 2 fold change in 
abundance ratio (cases: control) at 15 and 20 weeks gestation for pregnancies 
subsequently complicated by IUGR respectively against uncomplicated controls. The 
comparisons at 15 and 20 weeks’ gestation are shown in Figure 2.12 and 2.13 
respectively.  Quantitatively, all data are subjected to normalisation using an internal 
standard (yeast enolase), whose log 2 fold change ratio was adjusted to zero (Figures 2.11, 
2.12, and 2.13).   
At 15 week gestational age, no statistically significant protein alterations quantitatively 
observed using one sample Wilcoxon test (Figure 2.11).  For 20 week of gestation of IUGR, 
results showed highly statistically significant differences quantitatively (P < 0.01) at 95 % 
confidence interval using log 2 fold change of abundance ratio (case/ control) using one 
sample Wilcoxon test.  A median log 2 fold change in ratio of (-0.353) was observed, with 
max. and min. values (1.549-(-2.44)) (Figure 2.12).  Comparison ratios of log 2 fold change 
(case/ control) between 15 and 20 weeks gestation pregnancies complicated by IUGR was 
showed a significant differences (P < 0.01) using a Mann-Whitney test at 95 % confidence 
interval is presented in Figure 2.13. .   
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Figure 2. 11: Differentially expressed protein changes quantitatively for IUGR at 15 
week of gestation 
Plot displays log 2 fold change of abundance ratio of (case: control) for IUGR at 15 week 
gestational age.  Data were analysed showed differentially expressed proteins changes 
quantitatively vs internal standard of enolase at zero value (dotted line).  No statistically 
significant change is observed for 173 proteins using one sample Wilcoxon test.  Data were 
expressed as interquartile range of upper and lower quartiles (box), median (line inside box), lines 
at top and bottom represent the highest and lowest values (whiskers), confidence intervals (95 
%), black balls represent outliers points that were showed highest and lowest ratio compared 
with internal standard.at 95 % confidence interval.  
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Figure 2. 12: Differentially expressed protein changes quantitatively for IUGR at 20 
week of gestational age 
Plot displays log 2 fold change of abundance ratio of (case: control) for IUGR at 20 week’ gestation.  
Data were analysed showed proteins differentially expressed changes quantitatively vs enolase 
internal standard at zero value (dotted line).  173 proteins are analysed, showed highly significant 
changes (P <0.01) at confidence interval 95 % using one sample Wilcoxon test.  Data are 
expressed as interquartile range of upper and lower quartiles (box), median (line inside box), lines 
at top and bottom represent the highest and lowest values (whiskers), confidence intervals (95 
%),  ** represents significant observed differences (P < 0.01), black balls represent outliers points 
that showed highest and lowest ratio compared with internal standard value.  
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Figure 2. 13: Differentially expressed protein changes quantitatively for IUGR cases at 
15 and 20 weeks’ gestation 
Plot shows comparison analysis of log 2 fold change of abundance ratio of (case: control) for IUGR 
at 15 week (blue box) and 20 week (red box) gestational age respectively.  Proteins showing 
significant changes in expression between 15 and 20 weeks (P <0.01) are observed at confidence 
interval 95 %. 173 proteins at each gestational week were analysed using non-parametric analysis 
(Mann-Whitney test of unpaired two samples groups).  Data are expressed as interquartile range 
of upper and lower quartiles (box), median (line inside box), lines at top and bottom are 
represented max and min values (whiskers).  ** is represented extremely significant changes (P < 
0.01), dotted line represents internal standard value of enolase. 
 
The following section describes outliers/ dysregulated protein (highest / lowest) 
quantitatively of IUGR that determined at above section at 15 and 20 weeks of 
pregnancies respectively.  
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2.8.2.1 Highly dysregulated proteins for IUGR at 15 and 20 weeks  
Differentially expressed proteins were identified as outlier observations in previous 
quantitative analysis (Figure 2.11 and 2.12), which showed highly dysregulated (up / 
down) proteins compared with uncomplicated pregnancies at 15 and 20 weeks of IUGR 
respectively.  At 15 weeks gestation, outlier data were identified 16/ 74 
(proteins/peptides) as being highly dysregulated for IUGR compared with uncomplicated 
pregnancies.  Of which 50 % (n = 8) proteins are upregulated and downregulated 
respectively are showed in Table 2.5.  For 20 weeks gestation, 16 / 60 (proteins/peptides) 
were showed dysregulation for IUGR-complicated pregnancies, of which 8 proteins are 
upregulated and 8 proteins are downregulated compared with uncomplicated 
pregnancies are showed in Table 2.6.  Seven dysregulated proteins showing outlier 
behaviour had similar profiles at both 15 and 20 weeks gestation in IUGR-complicated 
pregnancies. These are zinc-alpha-2-glycoprotein, leucine-rich alpha-2-glycoprotein, 
alpha-1-acid glycoprotein 1, alpha-1-acid glycoprotein 2, histone H4, CD44 antigen and 
lysosome-associated membrane glycoprotein 2; these proteins are highlighted in Tables 
2.5 and 2.6, and illustrated in Figure 2.14. 
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Table 2.5: Dysregulated proteins dataset of IUGR at 15 week gestational age compared with control  
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
Protein name # 
Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of IUGR 
at 15 W 
Abundances 
of reporter 
ion of control 
at 15 W 
Abundance 
ratio (case/ 
control) of 
IUGR at 
15W 
Log 2 
fold 
change 
ratio 
UP/ 
Down 
1 High P25311 Zinc-alpha-2-glycoprotein 
OS=Homo sapiens OX=9606 
GN=AZGP1 PE=1 SV=2 
13 34.2 271.3 41.6 6.528 2.707 UP 
2 High P02750 Leucine-rich alpha-2-
glycoprotein OS=Homo 
sapiens OX=9606 GN=LRG1 
PE=1 SV=2 
5 38.2 195.9 56.7 3.458 1.790 UP 
3 High P02763 Alpha-1-acid glycoprotein 1 
OS=Homo sapiens OX=9606 
GN=ORM1 PE=1 SV=1 
3 23.5 236.2 68.6 3.442 1.783 UP 
4 High P19652 Alpha-1-acid glycoprotein 2 
OS=Homo sapiens OX=9606 
GN=ORM2 PE=1 SV=2 
2 23.6 193.5 78.5 2.464 1.301 UP 
5 High P02765 Alpha-2-HS-glycoprotein 
OS=Homo sapiens OX=9606 
GN=AHSG PE=1 SV=1 
3 39.3 142.1 62.9 2.26 1.176 UP 
6 High P04217 Alpha-1B-glycoprotein 
OS=Homo sapiens OX=9606 
GN=A1BG PE=1 SV=4 
3 54.2 146.8 69.5 2.112 1.079 UP 
7 High P01009 Alpha-1-antitrypsin 
OS=Homo sapiens OX=9606 
GN=SERPINA1 PE=1 SV=3 
14 46.7 181.5 91.8 1.978 0.984 UP 
8 High P62805 Histone H4 OS=Homo 
sapiens OX=9606 
GN=HIST1H4A PE=1 SV=2 
3 11.4 149 79.4 1.876 0.908 UP 
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9 High P07911 Uromodulin OS=Homo 
sapiens OX=9606 GN=UMOD 
PE=1 SV=1 
7 69.7 82.1 148.7 0.552 -0.857 Down 
10 High P16070 CD44 antigen OS=Homo 
sapiens OX=9606 GN=CD44 
PE=1 SV=3 
3 81.5 78.6 146.8 0.535 -0.902 Down 
11 High P01877 Immunoglobulin heavy 
constant alpha 2 OS=Homo 
sapiens OX=9606 GN=IGHA2 
PE=1 SV=4 
3 36.6 82.3 155.3 0.53 -0.916 Down 
12 High P08637 Low affinity immunoglobulin 
gamma Fc region receptor 
III-A OS=Homo sapiens 
OX=9606 GN=FCGR3A PE=1 
SV=2 
2 29.1 110.9 232.1 0.478 -1.065 Down 
13 High P13473 Lysosome-associated 
membrane glycoprotein 2 
OS=Homo sapiens OX=9606 
GN=LAMP2 PE=1 SV=2 
2 44.9 98.8 210.1 0.47 -1.089 Down 
14 High P31944 Caspase-14 OS=Homo 
sapiens OX=9606 
GN=CASP14 PE=1 SV=2 
2 27.7 85 189.9 0.448 -1.158 Down 
15 High P13796 Plastin-2 OS=Homo sapiens 
OX=9606 GN=LCP1 PE=1 
SV=6 
4 70.2 52.4 161.2 0.325 -1.621 Down 
16 High P35908 Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
OX=9606 GN=KRT2 PE=1 
SV=2 
5 65.4 89.2 277.4 0.321 -1.639 Down 
Data identified at confidence interval 99 %, FDR (False Discovery Rate) < 0.01, Peptides no.≥ 2; Outlier of data that quantified at confidence interval 95 
%. P < 0.05, highlighted data is showed identical in protein profile at both 15 and 20 weeks of IUGR. 
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Table 2.6: Dysregulated proteins dataset of IUGR at 20 week gestational age compared with control. 
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
Protein name # 
Unique 
Peptides  
MW 
[kDa] 
Abundances 
of reporter 
ion of IUGR 
at 20 W 
Abundances 
of reporter 
ion of 
control at 
20 W 
Abundance 
ratio (case/ 
control) of 
IUGR at 
20W 
Log 2 
fold 
change 
ratio  
Up/ 
Down  
1 High P25311 Zinc-alpha-2-glycoprotein 
OS=Homo sapiens 
OX=9606 GN=AZGP1 PE=1 
SV=2 
13 34.2 171.4 58.6 2.927 1.549 Up 
2 High P02675 Fibrinogen beta chain 
OS=Homo sapiens 
OX=9606 GN=FGB PE=1 
SV=2 
2 55.9 133.2 50.5 2.638 1.399 Up 
3 High P02750 Leucine-rich alpha-2-
glycoprotein OS=Homo 
sapiens OX=9606 
GN=LRG1 PE=1 SV=2 
5 38.2 173.2 70.8 2.445 1.290 Up 
4 High P02763 Alpha-1-acid glycoprotein 
1 OS=Homo sapiens 
OX=9606 GN=ORM1 PE=1 
SV=1 
3 23.5 131.4 62.7 2.097 1.068 Up 
5 High P19652 Alpha-1-acid glycoprotein 
2 OS=Homo sapiens 
OX=9606 GN=ORM2 PE=1 
SV=2 
2 23.6 127.6 67.3 1.895 0.922 Up 
6 High P16070 CD44 antigen OS=Homo 
sapiens OX=9606 
GN=CD44 PE=1 SV=3 
3 81.5 104.1 60.3 1.727 0.788 Up 
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7 High Q9Y5Y7 Lymphatic vessel 
endothelial hyaluronic acid 
receptor 1 OS=Homo 
sapiens OX=9606 
GN=LYVE1 PE=1 SV=2 
2 35.2 110.5 69.2 1.598 0.676 Up 
8 High Q01459 Di-N-acetylchitobiase 
OS=Homo sapiens 
OX=9606 GN=CTBS PE=1 
SV=1 
2 43.7 149.5 96.3 1.552 0.634 Up 
9 High P34059 N-acetylgalactosamine-6-
sulfatase OS=Homo sapiens 
OX=9606 GN=GALNS PE=1 
SV=1 
2 58 62.4 175.3 0.356 -1.490 Down 
10 High P60174 Triosephosphate isomerase 
OS=Homo sapiens 
OX=9606 GN=TPI1 PE=1 
SV=3 
2 30.8 39.3 118 0.333 -1.586 Down 
11 High P62736 Actin, aortic smooth 
muscle OS=Homo sapiens 
OX=9606 GN=ACTA2 PE=1 
SV=1 
5 42 65.4 198.7 0.329 -1.604 Down 
12 High P11021 Endoplasmic reticulum 
chaperone BiP OS=Homo 
sapiens OX=9606 
GN=HSPA5 PE=1 SV=2 
5 72.3 59.4 182.3 0.326 -1.617 Down 
13 High P62805 Histone H4 OS=Homo 
sapiens OX=9606 
GN=HIST1H4A PE=1 SV=2 
3 11.4 42.8 134.2 0.319 -1.648 Down 
14 High P08779 Keratin, type I cytoskeletal 
16 OS=Homo sapiens 
OX=9606 GN=KRT16 PE=1 
SV=4 
6 51.2 44.8 157.9 0.284 -1.816 Down 
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15 High P13473 Lysosome-associated 
membrane glycoprotein 2 
OS=Homo sapiens 
OX=9606 GN=LAMP2 PE=1 
SV=2 
2 44.9 50.5 218 0.232 -2.108 Down 
16 High P02788 Lactotransferrin OS=Homo 
sapiens OX=9606 GN=LTF 
PE=1 SV=6 
3 78.1 28.7 156.2 0.184 -2.442 Down 
Data identified at confidence interval 99 %, FDR (False Discovery Rate) < 0.01, Peptides no.≥ 2; Outlier of data that quantified at confidence interval 95 
%. P < 0.05, highlighted data is showed identical in protein profile at both 15 and 20 weeks of IUGR. 
 
 
66 
 
 
Figure 2. 14: Dysregulated proteins comparison between 15 and 20 weeks gestational 
age of IUGR  
Venn diagram plot shows dysregulated proteins comparison associates with differences / matches 
of protein profile between 15 and 20 week gestational age of IUGR.  Outlier data are associate 
with accession number of protein profile correspond with log 2 fold change of abundance ratio of 
(case/ control) was used for this analysis.  Data are presented as proteins numbers and % of 
protein profile at both 15 and 20 weeks of IUGR.  
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2.9. Discussion  
The term “biomarker” is defined by the medical subject heading term: “measurable and 
quantifiable biological parameters, (e.g., specific enzyme concentration, specific hormone 
concentration, specific gene phenotype distribution in a population, presence of biological 
substances) which serve as indices for health- and physiology-related assessments, such as 
disease risk, psychiatric disorders, environmental exposure and its effects, disease 
diagnosis, metabolic processes, substance abuse, pregnancy, etc.” (Bergman and 
Bergquist, 2014).  Desirable characteristics for a biomarker include that it should be 
specifically and quantitatively correlated with the state or disorder in question; it can be 
studied with particular and sensitive approaches, which provide reproducible outcomes 
(Bergman and Bergquist, 2014).  In addition, the biomarker should be chemically stable 
during examination and storage, and should not be susceptible to alteration from outside 
sources (Bergman and Bergquist, 2014).  Ideally, a biomarker is also available by non-
invasive estimation, and in an individual the levels of biomarker should be somewhat 
constant (Rossi et al., 2006). 
Various biomarkers have been demonstrated during pregnancy complicated with 
preeclampsia.  For instance, vascular endothelial growth factor (VEGF), placental growth 
factor (PIGF), and their antagonists such as fms-like tyrosine kinase 1 (sFlt-1) and endoglin 
(sEng) are common biomarkers which are significantly associated with preeclampsia (Grill 
et al., 2009, Carty, 2012, Kar, 2014, Unal et al., 2007).  These biomarkers (VEGF and PIGF) 
have been shown significantly decreased in serum from the end of first trimester 
gestational age throughout pregnancy in women at high risk of condition.  Buhimschi and 
colleagues used immunoassay method to study proteomic biomarkers in preeclampsia 
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(Buhimschi et al., 2005).  In this study, 68 women were enrolled prospectively 
categorised: non-pregnant reproductive age (NP-CTR n = 14), uncomplicated pregnant 
control (P-CTR n = 16), pregnant hypertensive and proteinuric women who did not meet 
criteria for severe preeclampsia (pHTN n = 21), and women with severe preeclampsia (sPE 
n = 17).  The urinary output of antiangiogenic factor sFlt-1 was found to be increased, 
while output of placental growth factor PlGF decreased at the time of clinical 
manifestation in severe preeclampsia. Authors suggested these results provide a fast non-
invasive screening of hypertensive women based on a sFlt / PlGF ratio.  They concluded 
that the sFlt / PlGF ratio could be used as marker for severity of preeclampsia; this 
measure shows improved specificity and selectivity compared to random urinary protein 
measurements (Buhimschi et al., 2005). 
In the present study, outcome identified 988 peptides from 315 proteins totally in all 8-
plex labelling samples at 99 confidence interval, FDR < 0.01, of which 173 proteins have a 
sufficient reporter ion signal for quantification related to PE and IUGR at each week 
respectively (see supplementary Tables S1-S4 in appendix 3).  Proteins with < 2 peptides 
are excluded from identification / quantification analyses, due to the low confidence 
associated with these “one-hit wonders”; others have suggested that these data should 
be excluded from ratiometric determinations (Evans et al., 2012).   
Identified proteins showing differential expression, associated with log 2 fold change of 
abundance ratio (cases: control) are reported for 15 and 20 weeks of PE and IUGR 
respectively compared with uncomplicated pregnancies, (Figure 2.7 - 2.9 for PE, Figure 
2.11 - 2.13 for IUGR).  All data were normalised using enolase as an internal standard. 
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According to PE, dysregulated proteins (n=173) that shown highly significant differences 
(P < 0.01) in protein profile at 95 % confidence interval using one sample Wilcoxon test 
Figure 2.7 and 2.8 at 15 and 20 weeks of PE respectively.  Additionally, quantitative data 
in Figure 2.9 are showed highly significant differences (P < 0.01) between 15 and 20 
weeks of PE related to log 2 fold change abundance ratio (case / control) at 95 % 
confidence interval using Mann-Whitney test.  Similar study of urinary proteomic analysis 
using iTRAQ labelling worked by (Chen et al., 2011), they identified 113 proteins. These 
proteins were expressed differentially between complicated hypertension (PE and 
hypertension pregnancies) and normal pregnancy.  Of which 31/113 proteins revealed 
statistically significant difference between these study groups. 
Outlier data in these analyses are represented as highly dysregulated proteins (up / 
down) compared with control for PE (Table 2.3 and 2.4).  16 proteins were identified as 
outliers suggesting highly dysregulated proteins compared with uncomplicated 
pregnancies using one sample Wilcoxon test (Figure 2.7), of which 50 % (n = 8) proteins 
are upregulated and downregulated respectively for PE during 15 week of pregnancy 
(Table 2.3).  For 20 week of PE, 7 proteins were upregulated, and 8 downregulated 
proteins were identified (Table 2.4).  However, in present study, the putative proteomic 
biomarkers (n=28) showed a highly dysregulated protein profile compared with the 
corresponding proteins in a control group of uncomplicated pregnancies for PE at both 15 
and 20 weeks; those identified in previous studiesare illustrated in Table 2.7.  3 Proteins 
identified with similar profiles at both 15 and 20 weeks of PE (fibrinogen beta chain, 
haptoglobin and carboxypeptidase) are highlighted in Table 2.3 and 2.4 and shown in 
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Figure 2.10.  Similar identifications were observed in previous studies are highlighted in 
Table 2.7 below. 
Table 2.7: Proteomic biomarkers for PE 
Protein name  Sample source References 
Alpha-2-macroglobulin  Serum / plasma, urine  (Auer et al, 2010), 
(Blumenstein et al., 2009), 
(Chen et al., 2011), (Carty et 
al., 2011), (D'Silva et al., 
2018), (Little et al., 2010) 
Fibrinogen beta chain  Serum, urine (Auer et al, 2010), (Chen et al., 
2011) 
Leukocyte-associated 
immunoglobulin-like 
receptor 1  
Blood / bone marrow (Van der Vuurst de Vries et al., 
1999) 
Osteoclast-associated 
immunoglobulin-like 
receptor  
Uterine cells (Weiner et al., 2010) 
Haptoglobin  Serum, urine, amniotic 
fluid 
(Auer et al, 2010), (Chen et al., 
2011), (D'Silva et al., 2018), 
(Tsangaris et al., 2006) 
Lactotransferrin  Serum  (Auer et al, 2010) 
Alpha-enolase  Urine (Chen et al., 2011) 
Plastin-2  Serum (Nagalla et al., 2010) 
Peroxiredoxin-1 Urine (Chen et al., 2011) 
Lysosomal alpha-
glucosidase  
Serum / urine (Jackson et al., 1996) 
Carboxypeptidase Q  urine (Carty et al., 2011) 
Neurotrimin  Uterine cells (Weiner et al., 2010) 
L-lactate 
dehydrogenase B chain  
Urine (Carty et al., 2011) 
Roundabout homolog 4  Urine, serum (Chen et al., 2011), (Nagalla et 
al., 2010), (Myers et al., 2013) 
Endosialin Blood (Enquobahrie et al., 2011) 
Glutamyl 
aminopeptidase  
Serum (Mizutani et al., 1987)  
Serotransferrin  Urine, amniotic fluid  (Chen et al., 2011), (Tsangaris 
et al., 2006) 
Immunoglobulin heavy 
constant gamma 4  
Blood, cells/ DNA (Ellison and Hood, 1982), 
(Hofker et al., 1989) 
Immunoglobulin heavy 
constant alpha 2 
Cells / DNA  (Hofker et al., 1989) 
Ceruloplasmin  Serum, urine (Auer et al, 2010), (Chen et al., 
2011) 
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Immunoglobulin heavy 
constant gamma 2 
Cells /DNA (Hofker et al., 1989) 
Keratin, type II 
cytoskeletal 1 
Serum, urine (Auer et al, 2010), (Chen et al., 
2011) 
Keratin, type II 
cytoskeletal 4 
Serum, urine (Auer et al, 2010), (Chen et al., 
2011), (Carty et al., 2011) 
Uromodulin  Urine (Carty et al., 2011) 
Fructose-bisphosphate 
aldolase B  
Blood (Cox, 1994) 
Glutathione S-
transferase P 
Serum (Nagalla et al., 2010) 
Annexin A2 Placental cells (Xin et al., 2012) 
14-3-3 protein zeta / 
delta  
Serum (Nagalla et al., 2010) 
 
Among proteomic biomarkers that are shown as highly dysregulated in their profile 
associated with complicated pregnancies such as PE compared with uncomplicated 
pregnancies (Table 2.7), for instance, alpha-2-macroglobulin, haptoglobin and 
roundabout were identified.  According to alpha-2-macroglobulin, log 2 fold change 
abundances ratio (case: control) has shown upregulated at value (3.5) at 15 week of PE 
compared with uncomplicated pregnancies (control).  Alpha-2-macroglobulin has 
antiplasmin activity and possibly the increasing in this levels protein in preeclampsia 
explain its important role in the intravascular coagulation of this condition (Horne et al., 
1970). Similar findings were reported in serum-based studies of proteomic biomarkers of 
PE (Auer et al, 2010, Blumenstein et al., 2009, D'Silva et al., 2018).  Studies of proteomic 
biomarkers for PE also agreed with findings of other groups using urine sample (Chen et 
al., 2011, Carty et al., 2011). 
Another biomarker shown as high dysregulated in protein expression in this study is 
haptoglobin, log 2 fold change abundances ratio (case: control) showed upregulation 
(2.53-fold) in PE cases compared with uncomplicated pregnancies (control) at 15 weeks’ 
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gestation.  Haptoglobin is an alpha-2 sialoglycoprotein that is found in plasma, and is 
considered to have antioxidative properties (Tseng et al., 2004).  The major physiological 
role of haptoglobin is to capture, and combine with the free plasma hemoglobin that 
results from hemolysis (Langlois and Delanghe, 1996), thereby preventing the release of 
heme iron which can accumulate in the kidney and cause oxidative damage (Tolosano et 
al., 2002)  The finding is reported previously by (Sammour et al., 2010).  Previous studies 
have reported similar result using different types of samples e.g. urine and / or serum to 
study proteomic biomarkers in PE (Auer et al, 2010, Blumenstein et al., 2009, Chen et al., 
2011, Carty et al., 2011, D'Silva et al., 2018, Little et al., 2010) (see Table 2.7).   
Roundabout (ROBO4) showed downregulation (-3.19-fold) in protein expression for PE 
subjects at 15 weeks gestational age compared with non-complicated pregnancies (Table 
2.3).  Roundabout (ROBO4), is also known as axon guidance receptor, homolog 4 
(Drosophila); the protein is reported to be a receptor for SLIT proteins, at least for SLIT2, 
and seems to be involved in angiogenesis and vascular patterning (Huminiecki et al., 
2002).  This protein has previously been found in developing placental and embryonic 
tissues (Park et al., 2003), and has been shown to inhibit endothelial cell migration (Park 
et al., 2003).  As such downregulation in specific protein expression could be an indication 
of poor vascular development in the growing fetoplacental unit, and hence a direct 
readout for the impaired fetal development observed in later pregnancy.  Similar finding 
has been previously identified in urine (Chen et al., 2011) and in serum / blood studies of 
preeclampsia (Nagalla et al., 2010, Myers et al., 2013) (see Table 2.7).  
Similar analysis was performed using urine sample of IUGR condition during 15 and 20 
weeks gestational age.  According to IUGR at 15 weeks’ gestation, no statistically 
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significant quantitative differences were detected for the 173 proteins observed, 16 
differentially expressed proteins were identified as outliers.  Eight proteins are (up/ 
down) respectively compared with uncomplicated pregnancies were identified at 
confidence interval 95 % using one sample Wilcoxon test (see Figure 2.11).  For 20 week 
of gestation of IUGR, results showed highly statistically significant differences 
quantitatively (P < 0.01) at 95 % confidence interval of log 2 fold change of abundance 
ratio (case/ control) using one sample Wilcoxon test within median (-0.353) within max. 
and min. values at (1.549-(-2.44)) of 173 proteins (Figure 2.12).  Additionally, quantitative 
data were observed in Figure 2.13 had showed highly significant differences (P < 0.01) 
between 15 and 20 weeks of IUGR at 95 % confidence interval associates with log 2 fold 
change of abundance ratio (case/control) using Mann-Whitney test.  Similar study worked 
by (Auer et al., 2010) using iTRAQ labelling coupled with MS analysis to identify proteomic 
biomarkers in IUGR using serum sample. Outcome revealed 166 proteins totally were 
identified, of which 31/128 identified proteins/ peptides showing expression changes in 
IUGR (14 up and 17 down-regulated) (Auer et al., 2010). 
Outlier data analysis identified a total of 74 peptides from 16 proteins as candidate 
dysregulated proteins.  50 % (n = 8) of these proteins are each upregulated and 
downregulated respectively at 15 weeks’ gestation for IUGR subjects compared with 
uncomplicated pregnancies, shown in Table 2.5.  At 20 weeks’ gestation for IUGR cases, 
16 / 60 (protein/peptides) were observed as highly dysregulated, again, 8 proteins are 
upregulated and 8 proteins are downregulated compared with uncomplicated 
pregnancies, shown in Table 2.6.  Previous studies corroborate these findings (Table 2.8) 
in various different sample types such as urine (Chen et al., 2011)(Carty et al., 2011), 
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serum (Auer et al, 2010), plasma (Blumenstein et al., 2009), amniotic fluid (Tsangaris et 
al., 2006) and placental cells (Mandò et al., 2016, Xin et al., 2012), to identify different 
proteomic biomarkers. 
Table 2. 8: Proteomic biomarkers for IUGR 
Protein name  Sample source References 
Zinc-alpha-2-glycoprotein  Serum, urine (Auer et al., 2010); 
(Blumenstein et al., 2009); 
(Chen et al., 2011); (Carty 
et al., 2011) 
Leucine-rich alpha-2-
glycoprotein 
Amniotic fluid, 
serum, 
(Tsangaris et al., 2006), 
(Kay et al., 2009) 
Alpha-1-acid glycoprotein 1 Serum (Auer et al., 2010) 
Alpha-1-acid glycoprotein 2 Amniotic fluid  (Tsangaris et al., 2006) 
Alpha-2-HS-glycoprotein Serum (Auer et al., 2010) 
Alpha-1B-glycoprotein Serum (D'Silva et al., 2018) 
Alpha-1-antitrypsin Urine (Chen et al., 2011) 
Histone H4 Urine (Chen et al., 2011) 
Uromodulin Urine (Chen et al., 2011) 
CD44 antigen Placental cells (Mandò et al., 2016); 
(Banerji et al., 1999) 
Immunoglobulin heavy 
constant alpha 2 
Cells (Hofker et al., 1989) 
Low affinity immunoglobulin 
gamma Fc region receptor 
III-A 
Cells (Hofker et al., 1989) 
Lysosome-associated 
membrane glycoprotein 2 
Cells (Gough and Fambrough, 
1997) 
Caspase-14 Cytotrophoblastic 
cells 
(White et al., 2007) 
Plastin-2 Serum (Nagalla et al., 2010) 
Keratin, type II cytoskeletal 2 
epidermal 
Urine (Chen et al., 2011) 
Fibrinogen beta chain Urine (Chen et al., 2011) 
Alpha-1-acid glycoprotein 1 Serum (Auer et al., 2010), 
(Tsangaris et al., 2006) 
N-acetylgalactosamine-6-
sulfatase 
Placental cells (Nakashima et al., 1994) 
Triosephosphate isomerase Plasma (Little et al., 2010) 
Actin, aortic smooth muscle Serum (Nagalla et al., 2010) 
Endoplasmic reticulum 
chaperone BiP 
Placental cells (Burton et al., 2009) 
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Keratin, type I cytoskeletal 
16 
Serum, urine (Auer et al., 2010), (Chen et 
al., 2011) 
Lactotransferrin Milk (Weiner et al., 2010) 
 
However, 7 dysregulated proteins detected here as outlier observations have shown 
identical profiles at both 15 and 20 weeks of IUGR: zinc-alpha-2-glycoprotein, leucine-rich 
alpha-2-glycoprotein, alpha-1-acid glycoprotein 1, alpha-1-acid glycoprotein 2, histone 
H4, CD44 antigen and lysosome-associated membrane glycoprotein 2. These proteins are 
highlighted in Table 2.5 and 2.6, and shown in Figure 2.14.  Similar findings were observed 
in various previous studies, highlighted in Table 2.8 above  
Among proteomic biomarkers which have shown dysregulation in their profile associated 
with pregnancies complicated by IUGR shown in Table 2.8, for example, Zinc-alpha-2-
glycoprotein, log 2 fold change value has upregulated at (2.707) in Table 2.5.  Zinc-alpha-2-
glycoprotein, has various important functions in the human body, including fertilization 
(Ohkubo et al., 1990) and lipid mobilization (Morse et al., 2017).  Zinc-alpha-2-
glycoprotein stimulates lipid degradation in adipocytes and causes the extensive fat 
losses associated with some advanced cancers (Hirai et al., 1998, Zhang et al., 2018); and 
could bind with polyunsaturated fatty acids.  Therefore, the upregulation in that protein’s 
expression explains the impaired fetal growth observed in later pregnancy. Similar 
outcomes were identified by previous studies using serum or urine samples to study 
proteomic biomarkers in complicated pregnancies such as IUGR and/or PE (Auer et al., 
2010, Blumenstein et al., 2009, Chen et al., 2011, Carty et al., 2011). 
Leucine-rich alpha-2-glycoprotein-1 (Lrg1), another biomarker in IUGR has showed (1.79) 
upregulated (Table 2.5). Leucine-rich alpha-2-glycoprotein-1 (Lrg1) is an emerging 
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biomarker for angiogenesis (Lio et al., 2018).  Angiogenesis a process of new blood vessel 
formation that participates to the development and progression of several diseases, such 
as cancers, proliferative diabetic retinopathy and chronic wound healing (Carmeliet, 
2005).  Vascular endothelial growth factors (VEGFs) and their receptors play a crucial role 
in angiogenesis (Carmeliet et al., 1996).  This protein has recently been found up-
regulated in ocular tissues in both human patients with proliferative diabetic retinopathy 
and rodent models of pathological angiogenesis (Zhang et al., 2018).  Similar finding was 
detected using serum sample to identify protein leucine‐rich alpha-2‐glycoprotein as a 
putative biomarker of recombinant human growth hormone (rhGH) abuse which worked 
by (Kay et al., 2009).  Another study has also identified similar protein using amniotic fluid 
to predict abnormal fetuses biomarkers has been worked by (Tsangaris et al., 2006)  
The presence of urothelial markers as differentially expressed proteins is an indication 
that the amount of epithelial shedding from different individual during micturition 
(urination) is playing a role in the biological variation observed; therefore, this influence 
needs to be excluded before further exploitation of these putative biomarkers is possible.  
2.10. Conclusions 
All in all, the passage of fetoplacental markers of hypoxia and vascular dysfunction into 
urine via the maternal blood in a manner enabling quantitative detection of their 
variation is a strong indicator that this strategy has merit for determination of potential 
markers for malfunction of the fetoplacental unit. This study identified 28 proteomic 
biomarkers have shown highly dysregulated (up / down) for PE, and 24 biomarkers for 
IUGR compared with uncomplicated pregnancies as shown in Table 2.7 and 2.8 
respectively.  The limitations of this study are that we have not performed independent 
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quantitative validation of these markers in a separate cohort of women who have the 
same conditions, nor have putative markers found in pooled samples been investigated in 
(preferably independent) individuals.  Confirmation of these markers on an independent 
set of individual patient samples, using targeted mass spectrometric assay and/or 
biochemical assay methods such as ELISA is vital before these markers can be taken 
forward for clinical translation.  
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Chapter 3 
 
3. Fourier transform infrared analysis of 
urine – optimisation method using 
animal model  
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3.1 Introduction Infrared Spectroscopy  
Infrared (IR) radiation is a component of the electromagnetic spectrum.  The IR spectral 
region covers a wide range of frequencies, typically segmented into three ranges, the 
near (NIR), mid (MID) and far (FIR) infrared ranges.  This region of the electromagnetic 
spectrum interacts strongly with biological macromolecules. This property is exploited in 
infrared spectroscopy, where a beam of IR radiation typically interacts with a sample of 
interest and the incident spectra are detected by comparison with a background 
reference ‘sample’ (Griffiths and De Haseth, 2007).  Energy within the IR range is 
absorbed by covalent bonds within molecules, inducing an excited quantum state and 
consequent bond vibration.  The strength of vibrational bonds between atoms differs 
such that the excitation energy can be used as a distinguishing feature, i.e. each bond 
type absorbs at a different energy, which is read from an infrared spectra as a function of 
wavenumber (1/; being related to the energy of the bond via Equations 3.1 and 3.2). 
Different spectra are observed for molecular species, with the maximum absorbance for a 
species varying with the bonds/atoms involved and the strength of any intermolecular 
interactions.  Hence the IR spectrum is a fingerprint of the chemical structure of a given 
sample (Griffiths and De Haseth, 2007). 
c=f          Equation 3.1 
Where c is the speed of light in a vacuum, f is the frequency of vibration (in Hz) and  is 
the wavelength of the vibration (in cm). 
E=hf          Equation 3.2 
Where E is the energy of the bond Joules (J) and h is Plank’s constant (6.626 X 10-34 J·s) 
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In a given molecule, the energy is partitioned into 3N (N being the number of atoms in the 
molecule) degrees of freedom; these describe three translational and three rotational 
motions in the molecule.  In order to absorb IR radiation, the vibrational displacement of 
the molecular atoms must cause a change in dipole moment; therefore, not all molecular 
vibrations absorb IR radiation.  For example, a carbon dioxide molecule allows four 
vibrational modes (Colthup, 2012).  The CO2 molecule is a linear molecule in shape, with 
consequently four vibrational modes, the symmetric stretching (st), the anti-symmetric or 
asymmetric (as) and two bending vibrational modes (Colthup, 2012).  During symmetric 
stretching, both oxygen atoms of the molecule are stretched/ compressed at the same 
time, causing no change in net dipole (Figure 3.1 A).  The symmetric stretch vibration of 
the molecule therefore does not absorb IR radiation, while both the anti-symmetric and 
bending vibrations of the CO2 molecule show strong absorbance maxima (Figure 3.1). 
 
Figure 3. 1: IR spectra of CO2 molecule and its vibrational modes  
Main panel:  IR spectrum of CO2 showing absorbance maxima associated with varying modes of 
vibration (inset). Carbon dioxide has four theoretically possible vibrational modes:  A: symmetric 
stretch (st), which lacks change in dipole and consequently spectral output, D: asymmetric stretch 
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(as), predicted at 2640 cm-1 and observed at 2345 cm-1, whereas both B, C: are bending modes, 
predicted at 546 cm-1 vibrational mode (Colthup, 2012).   
 
3.2 FTIR spectroscopy and Michelson interferometer 
Fourier transform infrared (FTIR) spectroscopy utilises an interferometer based on the 
Michelson interferometer (Figure. 3.2).  This device features a beam splitter, fixed mirror 
and a movable mirror, with adjustments in the path of the beam caused by the moveable 
mirror generating interference which is then recorded by the detector.  This movement 
enables FTIR simultaneous measurement of all infrared frequencies (Griffiths and De 
Haseth, 2007).  This speeds up the rate of analysis considerably in comparison to 
monochromatic approaches. 
 
Figure 3. 2: Schematic diagram of a Michelson interferometer  
An initial source beam (A) is split towards both fixed and moveable mirror by the beam splitter. 
Reflected beams are recombined using a one-sided mirror and the collimated beams detected.
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3.3 Spectroscopy and Beer-Lambert law relationship  
In spectroscopy wavenumber (ṽ) is used to describe frequency divided by the speed of 
light in vacuum (Fuwa and Valle, 1963).  Spectrophotometric analysis is typically used to 
quantitatively analyse a light absorbing analyte in solution according to the Beer-Lambert 
law.  This relationship principally states that absorbance is directly proportional to the 
concentration of analyte in the sample, (Fuwa and Valle, 1963) described by Equation .3.3  
A= εlc           Equation (3.3) 
A refers to an absorbance, ε is the molar absorptivity at that wavelength or known as 
(molar extinction coefficient), l is the distance the light travels through the sample (the 
path length), and c is the concentration of the analyte in solution.  
The light passed through a sample of interest has a fixed pathlength, l.  The detector 
measures the incident intensity of the light 𝐼, and compares it to that of initial source light 
𝐼0.  The ratio of [𝐼 / 𝐼0 ] is a measure of the fraction of light that passes through a given 
sample and is called the transmittance (T) (Figure 3.3) (Fuwa and Valle, 1963).  
Absorbance is related to transmittance at Equation. (3.4)  
A=-log [𝐼/𝐼0 ]         Equation (3.4) 
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Figure 3. 3: Incident light vs. transmitted  
Intensity of the transmitted light reduced due to sample absorption proportional to the specific 
absorbance coefficient ɛ and concentration of a given substance C.  For a constant given 
pathlength l, the absorbance of a compound will have the mathematical relationship as above 
(Fuwa and Valle, 1963).  
 
3.4 FTIR spectroscopy to study biological molecules 
Biological samples typically contain biomolecules including proteins, lipids, carbohydrates 
and nucleic acids.  These major macromolecule classes play critical roles in biological 
functions, such as, proliferation, differentiation and cell death (Movasaghi et al., 2008).  
The vibrational frequencies of the principal functional groups of these macromolecules 
are well defined.  As mentioned before, each biomolecule will give its own ‘fingerprint’ 
spectrum, based on its covalent bond makeup, and therefore each kind of biological 
sample will produce a signature spectrum (Movasaghi et al., 2008).  A representative 
spectrum of a generalised biological sample can be viewed below in Figure 3.4. 
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Figure 3. 4: Typical FTIR absorption spectrum of a biological sample  
Generalised FTIR spectrum of a biological sample including molecular assignment of the main 
absorption bands in the mid FTIR spectrum (reproduced from Movasaghi et al., 2008). 
 
3.4.1 Protein FTIR 
During protein synthesis, amino acid monomers within the growing polypeptide chain are 
linked via a condensation reaction termed peptide bond formation. Amino acid 
monomers are differentiated on the basis of their sidechain or R group composition 
(Figure 3.5) (Vasudevan et al., 2013).  Proteins can therefore be considered generally as 
polymers comprised of amino acids (bearing varying sidechains) linked by amide bonds. 
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Figure 3. 5: Typical structure of amide bond via amino acids linking  
Peptide bond is the name for an amide bond (red line) in a polypeptide. Protein characterises as a 
backbone of poly peptide chain via links of terminal base (amine) of one amino acid with acid 
termini of other amino acid, the condensation of these linkage will generate nascent protein 
molecules.   
 
A high intensity broad peak for both amide I and II at mid FTIR wavenumber have 
previously been observed (reviewed by Romeo et al., 2008).  Amide I absorption band 
corresponds to the polypeptide backbone of protein, which provides the most 
information on protein geometric structure (Romeo et al., 2008). Proteins have a number 
of levels of structure; primary structure, and 3 dimensional structures, both secondary 
and tertiary.  Amide I corresponds to linear polypeptide (primary structure); secondary 
structure describes folding of proteins into two main patterns, α-helices and β-sheets 
(Roach et al., 2005, Gauglitz and Vo-Dinh, 2014).  FTIR micro-spectroscopy is able to 
provide important information about secondary structure of proteins.  The stretching 
vibrations of the C=O bond within the amide I band and bending vibrations of the N-H 
bond with C-N stretching within amide II correspond to protein secondary structure 
components. Amide I is typically observed as a broad absorbance from 1700-1600 cm-1, 
with an intense maximum at 1650 cm-1, and derives primarily from C=O stretching.  
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Amide II is observed as an intense absorbance at ~1530 cm-1, and is associated with N-H 
and C-N bond bending vibrations (Movasaghi et al., 2008).  Amide III is observed around 
1300-1180 cm-1 and is associated with C–N stretching and N–H bending.  The amide A 
band (about 3500 cm-1) and amide B (about 3100 cm-1) originate from a Fermi resonance 
between the first overtone of amide II and the N-H stretching vibration (Movasaghi et al., 
2008).  Proteins are thus a good example of the complex overlapping that can occur 
within FTIR spectra when attempting to investigate biomolecules (Gauglitz and Vo-Dinh, 
2014). 
 
3.4.2 Lipid FTIR 
Lipids are another major component of biological samples, and can be grossly described 
as containing a long hydrophobic hydrocarbon chain, covalently attached to an acyl 
group.  The hydrocarbon component of lipids is primarily comprised of C-C and C-H 
bonds, absorption maxima for which appear at range 3000-2830 cm-1 in IR spectra.  All 
four major classes of biological macromolecule absorb in the region 3000-2830 cm-1.  This 
is at least partly attributable to the presence of C-C and C-H bonds, veritably the “building 
blocks” of organic molecules.  The overlapping contributions from the different 
macromolecule classes can be distinguished readily; lipid molecule acyl chain vibrations 
are of more significant intensity than the other three major macromolecular structures, 
due to the increased presence of C-C and C-H groups in lipids.  IR vibrations in the region 
of 3000-2830 cm-1 are therefore primarily attributable to lipid molecular structures when 
87 
 
examining biological samples within mid IR spectra (Figure 3.4) (Mannock et al., 2006, 
Dukor, 2002, Yonar et al., 2018). 
 
3.4.3 Carbohydrate and nucleic acid FTIR 
Carbohydrates (CHO) are a diverse group of macromolecules, ranging from monomers 
(monosaccharides, e.g. glucose) to complex branched polysaccharides which may have a 
molecular weight of several kilodaltons.  The primary structural components which 
characterise carbohydrates are alcohol and aldehyde functional groups.  These groups are 
associated with wide IR absorbance bands at ~3400-3380 cm-1 due to the OH stretching at 
2930-2900 cm-1 corresponding to CH2 groups undergoing C-H stretching.  Additional peaks 
appear at 1240-950 cm-1, arising from C-O, C-C stretching and C-OH bending modes 
vibration (Figure 3.4). 
Nucleic acids (DNA and RNA) represent a major class of biomolecules which include a 
sugar-phosphate backbone, which also contributes to the C-O absorbance observed in 
biological samples, observed around 1100-1005 cm-1 (Brandenburg and Seydel, 2002, 
Kačuráková and Mathlouthi, 1996).  The contribution of nucleic acids is however of 
(relatively) limited relevance to our analyses due to the absence of cells in the samples. 
 
3.5 FTIR spectroscopy studies of biofluids 
Fourier Transform Infrared (FTIR) spectroscopy can be used to study the composition of 
biologically-derived materials, such as biofluids and human tissue samples.  Biofluids such 
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as urine, whole blood, plasma and serum and saliva are a valuable biological sample type 
for clinical diagnostics due to their (variably) non-invasive collection, relative ease of 
handling and high biological information content.  Infrared spectroscopy can provide a 
rapid, robust and high throughput tool for biological sample analysis.   
Biofluid samples have previously been subjected to IR spectroscopy by various others 
(Harrigan et al., 2004, Hoşafçı et al., 2007).  A study published by Hosafci et al. subjected 
blood plasma, whole blood, and urine to FTIR analysis. 100 urine samples and 400 blood 
samples were subjected to ATR-FTIR spectroscopy and clinical reference assays.  Partial 
least-squares (PLS) regression calibration models were built for predicted sample 
components, namely albumin, total protein, glucose, urea, cholesterol, and triglycerides 
in whole blood and blood plasma; and urea, creatinine, inorganic phosphate and uric acid 
in urine.  Additional calibration models were established using FTIR spectra of artificial 
urine components containing, ammonia, sulphate, hydroxybutyric acid, and acetoacetate 
(Hoşafçı et al., 2007).  Authors observed good correlation with their reference standards. 
(Harrigan et al., 2004) used FTIR spectroscopy to investigate urinary metabonomic 
components in an investigation of drug toxicological effects.  Pre-dosing controls were 
compared with samples collected from rats subjected to treatment with a potential 
inflammatory agent, bacterial lipopolysaccharide (LPS) and the antacid ranitidine over a 
time course.  Hepatotoxicity of the ranitidine was observed using this non-invasive FTIR-
based metabonomics method (Harrigan et al., 2004).  
Centrifugal filtration devices, based retention of (predominantly) protein fractions using 
specific molecular weight cut-off filters are commonly used in bioanalysis workflows to 
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prepare biofluid samples prior to analysis.  Concentration and relative purification of 
protein represents an important improvement for the application of vibrational 
spectroscopic technique (Bonnier et al., 2014).  Bonnier and co-workers (2014) were used 
commercially available centrifugal filters to segregate protein of blood serum according to 
molecular weight fractionation prior to FTIR analysis.  Centrifugal concentration of the 
sample was shown to result in an improvement in both spectral intensity and quality.  
They suggested these devices are suited for application of vibrational spectroscopy to 
disease diagnostics purposes (Bonnier et al., 2014).  
In proteomic studies based on molecular weight fractions of samples of interest, other 
components have similar chemical moieties to peptides and proteins, such as urea and 
creatinine; interference from these components should be considered in order to avoid 
the spectral profile overlapping during analysis of the biomolecules of interest.  
Therefore, there is a need for appropriate method of sample collection and preparation 
prior to analysis in order to verify spectral profile of spectroscopic analysis.   
The aim of this chapter is to establish a protocol for use with urine samples, using an 
animal model for sampling and method optimisation experiments.  The use of locally-
available animal-derived materials allowed us to develop methods using a freely-available 
waste material, with no significant ethical or governance concerns involved in their 
collection or storage.  We aimed to develop a reproducible method, investigating the 
impact of sample volume upon analytical sensitivity, using whole urine sample of rat. 
Identification of the lower limit for routine operation using FTIR analysis; moreover, we 
sought to establish an appropriate methodology to identify FTIR spectral profiles for urine 
samples based on protein fractions with specific molecular weights. One of the major 
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factors in this study was the optimisation with a focus on the sample volume used for 
each repeat. For animal urine this would not be a problem but when moving onto human 
samples collected from a clinical trial it was essential to get the maximum data with 
reliable reproducibility. These are the factors highlighted in this optimisation chapter. 
 
3.6 Chapter aims  
1. To investigate threshold volumes for analysis of whole rat urine using FTIR 
spectroscopy.  
2. To determine the influence of sample preparation procedures on FTIR spectra 
(whole rat urine, >10 kDa ultrafiltration urine sample without buffer exchange and 
>10 kDa after buffer exchange). 
3. To establish a Standard Operating Protocol (SOP) based on use of 10 kDa nominal 
molecular weight cut-off membranes to segregate urine samples, compliant with 
methods used for proteomic analysis (Chapter 2). 
 
3.7 Materials and methods 
3.7.1 Urine sample collection  
All animals used in this study were kept in accordance with UK Home Office legislation 
“Animals Scientific Procedures Act 1986 United Kingdom”, with ad libitum access to food 
and water, at (19-23) °C and 40-70 % relative humidity, maintained on a 12 hr light-dark 
cycle.  Sprague Dawley rats were used for the study, being of the age 4-7 months at the 
time of collection.  Urine collection was carried out by trained personnel according to 
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routine husbandry practices, under the supervision of the named Animal Care and 
Welfare Office, with approval by the local ethics committee. All samples were collected 
over 14 hrs from animals kept in metabolism cages. 10 samples of 20 mL volume each 
were collected from each animal, representing one sample over this time period. 10 
samples from non-pregnant and 5 samples from pregnant rats at 17 day’s gestation were 
collected. 
3.7.2 Sample preparation  
20 mL from each urine sample was centrifuged to pellet urinary tract cells (i.e. 
uroepithelial cells) (Eppendorf, Germany) at 3220 g for 10 min, 4 °C.  The supernatant 
fraction of this step was aliquoted into 100 μL portions for storage at -80 °C.  Thawed 
samples were mixed by vortexing before analysis to ensure homogeneous distribution of 
solutes throughout the sample.  Aliquots were subjected to triplicate FTIR analysis each 
using different volumes of 1, 2, 5, and 10 μL respectively. 
3.7.3 Ultrafiltration method  
An ultrafiltration step was carried out on acellular supernatant material (20 mL) of rat 
urine to segregate samples on the basis of molecular size using ultrafiltration tubes 
polyethersulfone (PES) MWCO 10000, 20 mL, (Sartorius AG,).  Ultrafiltration centrifuge 
tubes were washed 3 X with HPLC grade water to remove storage components which can 
contribute to spectral interference before applying a urine sample.  Buffer exchange was 
performed on the >10 kDa retentate fraction, via the addition and spin-through of three 
cycles of 0.5 M triethylammonium bicarbonate (TEAB) (Sigma-Aldrich, UK) at 3220 g, 4 °C.  
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Concentrated retentates (~ 1mL) were collected, aliquoted and stored at -80 °C.  5 μL of 
sample at different conditions was spotted and dried for FTIR analysis.   
3.7.4 FTIR instrument set-up  
Urine samples were analysed using an FTIR spectrometer (ThermoFisher Scientific IS50).  
This spectrometer is fitted with a single bounce germanium ATR accessory.  Prepared 
urine samples as per each (section 3.7.2 and 3.7.3) respectively above were spotted upon 
germanium crystal piece and air dried prior analyses to reduce the water contribution in 
the data collection.  Spectra were collected at room temperature using Omnic software 
(version 2.0).  5-point adjacent averaging smoothing was used to improve (signal / noise) 
ratio with linear baseline offset spectral correction.  Each spectrum was collected with 
128 scans being averaged within Omnic, at a resolution of 4 cm-1.  Three separate spectra 
were recorded from each sample, with all samples being spotted in triplicate. Critical to 
the workflow was that a blank ATR background was collected between each sample.  
Peak height and area were measured and corrected with a linear baseline set between 
the upper and lower limits of the spectral region examined. Ultrafiltration-treated urine 
samples of pregnant (n = 4) and non-pregnant (n = 4) rat urine were subjected to FTIR 
analysis.  5 μL of each sample of rat urine was spotted on the ATR germanium crystal and 
air dried prior analyses to reduce the water contribution to FTIR spectra.  Spectra were 
collected at room temperature using Omnic.   
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3.7.5 Statistical analysis  
Data analysis was performed using Excel (version 10, Microsoft).  Data were expressed as 
a mean and inter-sample variation expressed as stander error.  Principal Component 
Analysis was used to interrogate differences between samples. 
3.7.6 Principal Component Analysis  
Principal Component Analysis (PCA) an unsupervised multivariate algorithm.  PCA is 
typically used to identify differences in multivariate data, such as spectral variation 
recorded from different biological samples.  In order to perform PCA, a dataset must be 
transformed to ensure all points are distributed using a common set of axes.  In the case 
of our FTIR data, this required mean centering of the original dataset matrix.  The 
transformed matrix has different spectral absorption mean intensities distributed around 
zero.  The centred mean matrix (X) which has the same original matrix dimensions I x J (I 
the number of samples and J the number of wavenumbers variable in the given dataset 
matrix; loadings (P) (square matrix that derivative from variables in the original data set 
which has the same number of rows and columns).  This transformation generates new 
variables within the new modelled matrices, termed principal components (PCs).  PCA is a 
dimensionality reduction method, which allows large numbers of variables (such as 
spectral wavenumbers and resultant intensities) to be transformed into a few principal 
components (that are calculated from the covariance of the analysed dataset).  PCA and 
other multivariate methods enable us to understand and identify the origin of differences 
in datasets in an unbiased and unsupervised manner. A number of principal components 
can be generated to explain the origin of variance between samples within a dataset.  PC1 
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is the component which describes the largest proportion of this variance, with higher 
ordinals describing lower variance components.  Figure 3.6 summarises the major 
experimental approach in this chapter. 
3.7.7 Summary workflow for methods 
The following workflow illustrates the major experimental approach in this chapter is 
summarised in Figure 3.6 below: 
 
Figure 3. 6: Summary workflow protocol optimisation and application 
 
3.8 Results  
FTIR spectra were collected at mid-IR region using whole urine samples (n=10).  Samples 
were subjected to analysis in triplicate analysis.  Spectra were limited the range 1800-
1500 cm-1, corresponding to amide I and amide II, as shown in Figure 3.7.  This region was 
selected due to its importance in protein spectroscopy, and all sensitivity/volume 
 PCA  for rat urine from pregnant (n=4) and non-pregnant (n=4) females 
FT-IR analysis of sample at different conditions using 5 μL retentate 
Ultrafiltration method using PES membranes >10 kDa NMWCO 
Purification / buffer exchange / retentate concentration    
FTIR analysis for lowest volume investigation at (1,2,5,10 ) μL 
Rat urine samples (n=10) were collected   
Centrifugation to collect whole urine supernatant  
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determination experiments are based on observations of this region (section 3.8.1).  
Qualitative analysis of FTIR spectra was carried out to investigate the impact of 
ultrafiltration with different conditions for selection of an optimised protocol (Figure 3.9).  
The FTIR spectral profile of pregnant and non-pregnant rat urine after ultrafiltration 
process was then investigated, using PCA to observe emergent differences (Figure 3.10, 
Section 3.8.2). 
 
Figure 3. 7: FTIR spectra at particular range 1800-1500 cm-1 of mid region using whole 
rat urine  
FTIR spectra over mid-IR region 4000-650 cm-1 for whole rat urine. 10 samples were each analysed 
in triplicate.  Highlighted area of interest (delimited by black lines, 1800-500 cm-1), corresponds to 
amide I and amide II region.  
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3.8.1. Volume sensitivity investigation of FTIR analysis using whole rat 
urine 
Identification of spectra is typically used for qualitative analysis of substances, and 
involves the identification of absorbance at specific wavenumbers in a spectrum. Figure 
3.7 illustrates typical FTIR spectra for of whole rat urine at mid-IR region.  Subsequent 
analyses focussed on the region 1800-1500cm-1, – cropping spectra over the desired 
wavenumbers Figure 3.8.  This region represents wavenumbers of amide I, II peaks in 
biological samples.  Spectra were collected with varying volumes of whole rat urine, from 
1, 2, 5, and 10 μL respectively.  Figure 3.8 presents the observed variation in the range 
1800-1500 cm-1 region in amides I, II band height and peak area for these different 
volumes.  This region was analysed to provide clarity of peak maxima signal / noise and to 
see if peak area was a better method to use, as an integrated area is likely to present a 
lower sample to sample (repeated measures) variance.  
 
97 
 
 
Figure 3. 8: Bar graphs of FTIR analysis at (1850-1500) cm-1 range  
A series of volumes of whole rat urine (1, 2, 5 and 10 μL) were measured, with spectral 
parameters being examined at amide I and II wavenumbers.  Peak area is bordered by the 
spectrum when the X-axis limits of the area under curve and the baseline.  Peak height was 
measured from the maxima at full absorbance, taking into account a linear baseline fitted to the 
extents of the wavenumber range intercepting the band; limits of peak (left and right) with peak 
max in each volume were identified.  All data are represented as mean and error bar. 
 
The methods optimised above demonstrated that sample volume of 5 μL robustly gave a 
good degree of reproducibility and high signal to noise. For this reason, all following 
processes used this volume as part of further sample preparation.  
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3.8.2. Influence of ultrafiltration preparation procedure on FTIR spectra 
using rat urine sample 
FTIR data were collected at mid-IR range 4000-600 cm-1 using 5 μL in triplicate analysis of 
the same sample.  Here, we wished to investigate the impact of sample preparation steps 
on spectral variability.  Table 3.1 provides a list of band assignments describing the major 
macromolecules in urine.  The results of this experiment show differences in spectral 
observations before using centrifugal filtration devices Figure 3.9 (A); and after using >10 
kDa NMWO membrane filters for centrifugal ultrafiltration without buffer exchange 
Figure 3.9 (B), and after a buffer exchange step during ultrafiltration Figure 3.9 (C).  Figure 
3.9 (A and B) show spectra for the components in the urine with similar chemical moieties 
to peptides and proteins, therefore the spectral profile overlap with biomolecules of 
interest could occur.  Following ultracentrifugation, spectra show observed improvement 
in characteristics related to protein identification. This can be attributed to removal of 
interference from small molecules and salts by buffer exchange Figure 3.9 (C). 
Table 3. 1: Major FTIR bands of macromolecules described in urine 
Bands cm-1 Functional groups Description 
3450-3070 N-H or H2O Broad peak of N-H bending vibration and 
water 
2990-2840 CH2 group  Asym. (2990-2950) cm
-1  ; sym. (2880-
2850) cm-1, stretching vibration  
2920-2850 CH3 group Stretching vibration of asym.(2985-2950) 
cm-1 ; sym. (2885-2865) cm-1 
1800-1750 C=O ester Stretching vibration of saturated (1750-
1730) cm-1, unsaturated (1730-1715) cm-
1 
1650 Amide I Stretching vibration of C=O hydrogen 
bonding , which range (1600-1700)cm-1 
1541 Amide II Coupling of (C-N ) stretching and (C-N-H 
bending) range (1585-1500)cm-1 
1463 C-N; N-C-N Wagging vibration; asym. stretching 
99 
 
vibration 
1155 NH2 Rocking vibration  
1055 NH2 Asym. bending vibration 
1000 C-N; N-C-N Stretching vibration (sym.; asym) 
788 C-O; NH2 Bending vibration; sym. stretching 
vibration 
Sym: Symmetric; Asym: Asymmetric. 
 
 
Figure 3. 9: Typical FTIR spectra comparison of sample preparation in different 
conditions  
FTIR spectra were taken at (4000-600) cm-1 region.  Spectrum (A): whole urine sample; spectrum 
(B): > 10 kDa NMWCO filtration alone (without buffer exchange); spectrum (C): urine sample 
following buffer exchange into TEAB; spectrum (D): triethyl ammonium bicarbonate (0.5 M) alone. 
 
Clear differences in spectral profile were observed related to amide I at 1700-1600 cm-1 
(corresponding to protein bands) under varying sample preparation conditions (Figure 3.9 
(A), (B), (C) and (D). The observed spectral profile using ultrafiltration device coupled with 
buffer exchange condition (Figure 3.9 C) gave the most pronounced improvement in 
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spectral profile compared with using ultrafiltration device alone (Figure 3.9 B) or when 
using whole rat urine sample (Figure 3.9 A) respectively.  Similar findings were observed 
for amide A and OH bands at 3650-3500 cm-1 and also C-H stretching band at 3000-2830 
cm-1 in IR (Fig 3.9 A-C).  TEAB buffer analysed in the absence of urine sample shows no 
peaks of significant intensity within this region Figure 3.9 (D). 
The results above indicated that ultrafiltration protocol improved the observed spectral 
profile for FTIR measurements of 5 μL urine.  This supported further analyses of spectra 
with PCA to investigate spectral profile of FTIR for pregnant and non-pregnant rat urine.  
The following analysis will focus on the mid-IR region, specifically the protein fingerprint 
region (1800-1000 cm-1), and the lipid region (3100-2700 cm-1).  
 
3.8.3. Mean differences of spectral profiles for pregnant and non-pregnant 
rat urine at mid-FTIR  
A difference in averaged spectral profile between pregnant (n=4) and non-pregnant (n=4) 
is presented in Figure 3.10.  Data were collected over the mid-IR range (4000-600 cm-1), 
with absorbance intensity being plotted vs wavenumber.  Mean spectral profiles for 
pregnant rat urine showed increased absorbance intensity compared with those for non-
pregnant rats (Figure 3.10).  These observed differences include peaks within the range 
3500-3100 cm-1 related to amide A, N-H and O-H stretching vibrations (Figure 3.10).  
Different intensities in spectral profile relating to protein fingerprint at range 1800-1000 
cm-1 is presented in Figure 3.10.  Amide I and amide II show sample-dependent 
differences within the range 1700-1450 cm-1 and at amide III (1235-1224 cm-1).  Peaks 
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within the C-H stretching bond (lipid region), over 3100-2700 cm-1 are also observed in 
Figure 3.10.  A small peak at 1730 cm-1, attributed to (C=O) stretching bond of ester; and 
bending vibration of (CH2) (1465 cm
-1) were also observed, as were “stretch band” signals 
at range 1100-1050 cm-1 related to both (C–O) and (C–O–C) of carbohydrates (Figure 
3.10). 
 
Figure 3. 10: Mean differences of FTIR spectra intensity for rat urine from pregnant and 
non-pregnant females 
Mean of FTIR spectra for each group of urine samples taken from pregnant (n=4) and non-
pregnant (n=4) female rats were analysed.  FTIR spectra were taken at (4000-600) cm-1 region.  
Wavenumber (cm-1) vs absorbance (a.u.) is used for this analysis.  Red=mean of pregnant rat 
(n=4), blue= mean of non-pregnant rat (n=4).  
 
3.8.4. Spectral profile of protein fingerprint region of urine from pregnant 
and non-pregnant rats  
Variation in observed spectral profiles for rat urine from pregnant and non –pregnant 
females is shown in Figure 3.11, a PCA plot of the protein fingerprint region.  For these 
102 
 
data, 77 % of variance was accounted for by PC1 vs. 14 % in PC2 (Figure 3.11 A) for 
pregnant and non-pregnant rat urine.  Data were analysed at a 95% confidence interval 
over the protein fingerprint region at (1800-1000 cm-1), with triplicate analysis being 
performed for each sample in each group.  Scores plot (Figure 3.11 A) presents the 
observation that some data points remain as outliers using a 95% confidence interval.  
PC1 and PC2 loading spectra were examined, and observed absorbance variation 
corresponds to amide I at range 1700-1500 cm-1, amide II at range 1500-1350 cm-1, and 
amide III at range ~1335-1220 cm-1 (Figure 3.11 B).  
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Figure 3. 11: PCA plot for fingerprint protein region of pregnant and non-pregnant rat 
urine 
PCA plot of PC1 and PC2 score distribution around a normalised scale (A) for urine from pregnant 
and non-pregnant rats.  Protein fingerprint region (1800-1000 cm-1) was examined in triplicate, 
with a confidence interval of 95 %.  Observed variation of absorbance intensities between PC1 
and PC2 loading spectra (B) were.  A: Scores of IR spectral waves, RC = Non pregnant rat, RP = 
Pregnant rat, B: Loading score of IR vibrational bands at 1800-1000 cm-1 region; PC1 (blue); PC2 
(red). 
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3.8.5. Spectral profile of lipid region for pregnant and non-pregnant rat 
urine  
PCA reveals that emergent differences in the spectral profile of urine samples from 
pregnant and non –pregnant rats are related to the lipid region (3100-2700 cm-1), as 
shown in Figure 3.12.  Within this region, 91 % of inter sample variance was accounted for 
in PC1, and 7 % in PC2 (Figure 3.12 A) within these triplicate analyses.  Examination of the 
loading plot showed differentially-observed C-H stretching bond peaks, associated with 
lipids (2980–2950 cm-1), and additionally (CH), 2880–2865 cm-1 and 2860–2840 cm-1 for 
(asymmetric and symmetric) vibrational bonds respectively of CH3 and CH2 (Figure 3.12 
B).   
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Figure 3. 12: PCA plot for lipid region of pregnant and non-pregnant rat urine  
PCA plot displays scores distribution of PC1 and PC2 around normalised scale (A) for pregnant and 
non-pregnant rat urine.  Lipid region data (3100-2700 cm-1) were investigated at a confidence 
interval of 95 %.  Different absorbance intensities between PC1 and PC2 loading spectra (B) were 
observed.  A: Scores of IR spectral waves, RC = Non pregnant rat, RP = Pregnant rat, B: Loading 
score of IR vibrational bands at 3100-2700 cm-1 region; PC1 (blue); PC2 (red). 
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3.9 Discussion  
This study was performed to derive an optimised protocol for FTIR analysis of (rat) urine 
as an animal model.  Due to the extensive requirements for ethical approval and sample 
handling and storage associated with sampling of human biofluids, the use of these 
materials for method optimisation is prohibitively difficult.  Human samples are therefore 
expensive and available in limited amounts, therefore rat urine was used as an alternative 
to human samples for method optimisation experiments, as the latter is available locally 
and with little-to no impact on the animals involved as this is their waste.  Protein 
typically represents a crucial component in bio-fluid samples (Alberts et al., 2002, Moore, 
2014), with a high intensity broad peak for amide I and amide II being observed at ~1800-
1500 cm-1 (Romeo et al., 2006).  Spectra of interest were cropped at amide I and amide II 
(Figures 3.7) to study parameters such as peak area, peak height, and peak max relation 
to different volume of sample.  Data presented in Figure 3.8 show the variation at range 
1800-1500 cm-1 region in amides I and amide II band relation to both height and peak 
area at different volumes. The results indicated that volumes as low as 5 μL generated 
reproducible data with high signal to noise (Figure 3.8).  
Use of ultrafiltration protocol improved spectral identification/ classification (Figure 3.9). 
This type of sample pre-fractionation was previously used by Bonnier, et al., giving good 
discrimination of blood sample (Bonnier et al., 2014).  For instance, spectral differences 
are clearly identified in the range 1700-1650 cm-1 with a distinct peak at ~1650 cm-1 
(amide I).  A band of amide II observed at 1650-1500 cm-1, amide III peak at ~1530-1220 
cm-1 was also observed (Lacombe et al., 2015). Similar findings corresponding to amide A 
and OH bands at 3650-3500 cm-1 and also C-H stretching band at 3000-2830 cm-1 were 
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reported for blood samples (Lacombe et al., 2015).  No distinct peaks were observed in 
the mid-IR region for TEAB buffer (Figure 3.9 (D)), thus encouraging the use of this buffer 
as part of a unified sample preparation method in line with our proteomics methods. 
Prior to urine application, PES centrifugal filters were washed well with HPLC grade water 
to remove any contaminants such as traces of storage (e.g. glycerine), which could give 
rise to spectral interference (Bonnier et al., 2014).  This data showed good indication that 
the spectral bands observed arise from urine samples rather than overlapping vibrations 
pertaining to buffer components or to PES storage materials (Bonnier et al., 2014). 
However, no attempt has been made to quantify the spectral characteristics 
corresponding to the constituent components in the urine; the optimisation experiments 
demonstrated development of Standard Operating Protocol (SOP) for further analysis of 
clinical samples.  
Very limited discrimination was seen between urine from pregnant and non- pregnant 
rats within the protein fingerprint (Figure 3.11 A) and lipid (Figure 3.12 A) regions, 
although the differences in mean spectral intensities were observed between urine from 
pregnant and non- pregnant rats (Figure 3.10).  This study was not without limitations; 
specifically, the repeated use of a single bounce germanium ATR accessory during FTIR 
spectra collection could cause technical variation. The limited cohort size for this study 
was a further limitation.  
3.10 Conclusions  
This work presents proof of concept, using a rat urine model for optimisation experiment 
design to measure volume sensitivity and built up a standard operating protocol for the 
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further study of human clinical urine samples.  The 5 μL loading volume showed 
appropriate sensitivity for the mid FTIR region.  Moreover, ultrafiltration protocol 
displayed robust and simple preparation method for protein and lipid identification by 
FTIR within a urine sample.  
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Chapter 4  
 
4. Study of spectral profile for 
pregnancy complications using Fourier 
transform infrared spectroscopy 
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4.1. Application of FTIR in biological studies  
FTIR micro-spectroscopy (FTIRMS) instruments are typically used to perform 
spectroscopic analysis, generating spectra of biological samples at high speed and 
sensitivity.  Biological samples are often of limited volume and heterogeneous in nature, 
thus micro-spectroscopic methods were developed to enable microscale FTIR 
measurements to be obtained.  Numerous studies have successfully employed FTIR to 
investigate molecular biomarkers (Cakmak et al., 2006, Manoharan et al., 1993, Lin et al., 
2007, Baker et al., 2014, Lacombe et al., 2015).  As mentioned in chapter 3 (section 3.4) a 
generalised biological sample is comprised of several classes of biomolecules; such as 
proteins, lipids, carbohydrates and nucleic acids.  The principal assignment of 
spectroscopic vibrations to biomolecules of clinical relevance has been previously 
described (Lacombe et al., 2015).  Table 4.1 demonstrates a list of band assignments of 
the major macromolecules in blood plasma reproduced from (Lacombe et al., 2015).  FTIR 
spectroscopy of biological molecules was discussed previously in detail in chapter 3 
(section 3.4).   
Table 4. 1: Assignment of main FTIR absorption bands of plasma 
Bands (cm−1) Major assignment for plasma content 
3300 ν (N–H) of proteins (amide A band) 
3055–3090 ν ( CH) of lipids and proteins 
2950–2960 ν as (CH3) of lipids and proteins 
2920–2930 ν as (CH2) of lipids and proteins 
2865–2880 ν s (CH3) of lipids and proteins 
2840–2860 ν s (CH2) of lipids and proteins 
1730–1760 ν (C O) of fatty acids 
1660 ν (C O) of proteins (amide I band) 
1550 δ (N–H) of proteins (amide II band) 
1400 ν (COO−) of amino acids 
1240 ν as (P O) of nucleic acids 
1170–1120 ν (C–O) and ν (C–O–C) of carbohydrates 
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 ν, stretching vibrations; δ, bending vibrations; s, symmetric; as, asymmetric.   
 
A previous study by (Mukherjee et al., 2014) used FTIR and NMR analysis of serum to 
investigate metabolic profiles in patient samples collected from women with early and 
late onset PE.  80 subjects were enrolled in this study, classified into 4 sub-groups 
according to gestational age at onset of symptoms: early onset PE (gestational age at 
onset <34 weeks, n=20), late onset PE (onset >34 weeks, n=20), and 20 subjects with 
uncomplicated pregnancy outcome at the same gestational age of these cases.  13 peaks 
showed significant variation in early onset PE (P < 0.001). These peaks had wavenumbers 
associated with carbohydrate, protein and lipid region.  Fisher’s linear discriminant 
analysis (FLDA) identified five vibrational bands of highly significant wave-numbers 
(maxima at 1078, 1088, 1122, 1169 and 1171 cm-1 respectively); these spectral numbers 
gave strong predictive capacity of outcome (≥ 80 % overall accuracy compared with 
control).  Hierarchical clustering was able to separate early from late onset PE, although 
PCA demonstrated that the main separation of the wavenumbers resulted from 
gestational stage.  The authors suggested that further validation of putative markers 
using orthogonal techniques such as liquid chromatography–mass spectrometry (LC–MS) 
in a larger population was required prior to clinical adoption (Mukherjee et al., 2014).   
Despite many studies exploring metabolic profiles in preeclampsia and IUGR, no studies 
to date have identified robust biomarkers to predict PE and IUGR disorders at early 
gestation.  The main predictor of outcome remains previous pregnancy outcome, which is 
not relevant for nulliparous women (who are in their first pregnancy). Here, we lack any 
predictive diagnostic tools.  Chapter 3 described the derivation of a (SOP) for the analysis 
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of urine samples using an animal model.  This Chapter describes the use of FTIR with our 
SOP to explore the spectral profiles of PE and IUGR vs. uncomplicated pregnancies. 
 
4.2. Chapter aims  
1. To investigate spectral profiles of urine samples collected in a case/control study 
of PE related at 15 and 20 weeks gestational age respectively using FTIR. 
2.  To investigate spectral profile of urine samples collected in a case/control study 
of IUGR cases vs. normal birthweight controls at 15 and 20 weeks of pregnancy 
respectively using FTIR. 
 
4.3. Materials and methods  
4.3.1. Urine sample collection  
240 urine samples (450 μL each.) were obtained from subjects of PE and IUGR 
respectively.  60 samples for each pregnancy condition (PE and IUGR respectively); and 
120 from healthy pregnant women were collected.  All subjects were prospectively 
recruited and their samples collected at 15 and 20 weeks’ gestation pregnancy via the 
SCOPE (Screening for Pregnancy Outcomes) study arm at University College Cork (UCC), 
Republic of Ireland (see section 2.3.5), with approval by the local ethics committee (see 
appendices for local approval letter). 
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4.3.2. Sample preparation 
4.3.2.1. Centrifugal filtrate and protein ultrafiltration protocol 
450 μL from each sample was centrifuged to pellet urinary tract cells (i.e. uroepithelial 
cells) using centrifugation at 3220 g for 10 min, 4o C (Eppendorf, Germany).  Non-pelleted 
matter was decanted into clean labelled eppendorf tubes.  Clarified samples were 
subjected to ultrafiltration (10 kDa MWCO filters, Polyethersulfone (PES), 2 mL) (Sartorius 
AG). Prior to their use, membranes were cleaned by spinning 3 X with 2 mL HPLC grade 
water to remove storage buffer contaminants from PES membranes and resultant 
interference spectra.  Urine samples were then added to membranes and ultrafiltration 
carried out. The retained urine fraction following ultrafiltration was further subjected to 
buffer exchange, spinning (3 X) with 0.5M triethylammonium bicarbonate (TEAB) (Sigma-
Aldrich, UK) at 3220 g, 4° C.  Concentrated retentates (~150 μL) were collected, aliquotted 
and stored at -80° C until FTIR analysis. 
4.3.3.  FTIR experiment setup  
The FTIR optimisation described in Chapter 3 was carried out using ATR-FTIR, due to both 
time constraints and availability of new equipment part way through the project, this 
chapter employs micro-FTIR using reflection rather than ATR. Samples of urine were 
treated exactly as reported in Chapter 3, with volumes of 5 μL being found to give 
reliability for reflection-based spectroscopy analysis.  
Ultrafiltration-treated urine samples were subjected to FTIR analysis. 5 μL of each sample 
was spotted on an aluminium micro-spot slide (ThermoFisher Scientific, Winsford, 
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Cheshire UK) (see Fig 4.1 B). Samples were then analysed using the FTIR (ThermoFisher 
Scientific iN10). This FTIR instrument, housed at Loughborough University, was fitted with 
an imaging infrared microscope with a 10 X objective and computer controlled x-y-z stage 
(Figure. 4.1 A). The instrument was equipped with liquid nitrogen cooled Mercury 
Cadmium Telluride (MCT) detector.  Infrared spectral images were collected in reflection 
mode with 128 scans being averaged at 8 cm-1 resolution, and a physical 400 x 400 μm 
aperture size being used to cover the spatial field of view.  Instrument background 
analysis and subtraction was performed between each sample for calibration using the 
same scan number (128) used for the biological samples.  These background calibration 
spectra were used to minimise the influence of ambient CO2 on observed spectra. 
Prepared urine samples as in (section 4.3.2.1) above were spotted upon 12-position 
aluminium micro spot slides (Figure 4.1 B) and air dried prior FTIR analyses to reduce the 
water contribution in the data collection.  Spectra were collected saved in map files. 
Composite files were split into their individual constituent spectra individual files of each 
sample using Omnic Picta software (version 2.0, ThermoFisher Scientific). 
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Figure 4. 1: FTIR instrument and its sampling platform.  
(A): IR spectra recorded using Nicolet iN10 MX FTIR (ThermoFisher Scientific iN10). (B): 
12-position aluminium micro spot slides used as sampling platform for urine samples. 
 
4.3.4. Spectral transformation 
Spectra are subjected to baseline subtraction using offset correction to remove baseline 
shifts caused by scattering.  To decrease the signal-to-noise impact on spectra, 5-point 
Savitzky-Golay smoothing was used.  Recorded spectra are normalised using vector unit 
normalisation (Brereton, 2009).  Transformation of spectral data was carried out using 
Unscrambler ®X software (version 10.4. Camo, Norway). 
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4.3.5. Data analysis  
Principal Component Analysis (PCA), unsupervised multivariate algorithm typically used to 
identify differences in multivariate data, more detail in chapter 3 (section 3.7.6).  Data 
analysis and plotting were performed using Excel (version 10, Microsoft).  The global 
experimental approach in this chapter is summarised in Figure 4.2. 
 
Figure 4. 2: Summary workflow of methods  
 
 
4.4. Results  
4.4.1. FTIR spectral profile of PE and control at 15 week gestational 
age  
FTIR spectroscopy was performed for urine samples obtained from women who went on 
to develop PE (n=30) and those with uncomplicated pregnancies (control) (n=30) at 15 
Sample 
collection 
•  240  samples: PE (n=30), IUGR (n=30) paired with uncomplicated 
pregnant controls (n= 30) at both 15 and 20 weeks gestational age 
respectively via SCOPE centre (UCC), Republic of Ireland 
Sample 
process 
• Isolate >10kDa protein from acellular supernatant material using 
ultrafiltration centrifuge/ buffer exchange/ retentate concentration    
Spectra 
collection 
• FTIR collected spectra; Spectra transformation (baseline correction, 
smoothing and normalisation)  
Data 
analysis 
• PCA  performed for each cohort (case-control ) for PE and IUGR 
respectively  
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weeks’ gestation.  Figure S1 (see appendix 4) shows general FTIR spectra in PE and control 
at 15 weeks gestation. There is very little visible differences between these spectra over 
FTIR mid-range of 4000-600 cm-1. Identification of emergent spectral differences 
therefore requires mean spectra difference.  Differences in averaged spectral profiles 
between PE (n=30) and non-complicated (n=30) samples is shown in Figure 4.3.  A mean 
spectral profile for PE shows lower intensity absorbance compared with the 
corresponding spectral profile of uncomplicated pregnancies at 15 weeks gestation 
(Figure 4.3).  Peaks ranging from 3500-3100 cm-1 related to amide A, N-H and O-H 
stretching vibration delineate cases vs. controls (Figure 4.3).  Other peaks related to 
protein fingerprint (1800-1000 cm-1) also show variation in intensities between PE and 
control (Figure 4.3).  Amide I and amide II show case/control-related differences (1700-
1450 cm-1), as do amide III at band range 1235-1224 cm-1.  Peaks related to C-H stretching 
bonds (lipid region, 3100-2700 cm-1) are also observed Figure 4.3.  A small peak at 1730 
cm-1 associated with (C=O) stretching bond of ester; bending vibration of (CH2) at peak 
around 1465 cm-1, and stretch band peaks (1100-1050 cm-1), related to both (C–O) and (C-
O–C) of carbohydrates are also observed in Figure 4.3. 
 
Figure 4. 3: Averaged spectral profile (means) for PE and control at 15 week gestational 
age at mid FTIR range. (n = 30) samples 
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Averaged (mean) FTIR spectral profiles for PE (n=30) and control (n=30) at 15 weeks’ gestation.  
FTIR spectra were taken at mid-IR (4000-600) cm-1 region.  Wavenumber is plotted vs. absorbance 
intensity.  Red A (s) =mean of PE (n=30) at 15 week of pregnancy, blue C (c) = mean of control 
(n=30) at 15 week of pregnancy. 
 
The following section describes the spectral profiles of PE and control at 15 weeks of 
pregnancy using PCA description related to protein fingerprint (1800-1000 cm-1) and lipid 
(3100-2700 cm-1) regions respectively. 
 
4.4.2. Spectral profile study of protein fingerprint region for PE and 
control at 15 weeks gestational age  
Data presented in Figure 4.4A show PCA plot for PE and control FTIR data at 15 weeks 
gestation over the protein fingerprint region (1800-1000 cm-1). 99 % of inter-sample 
variation is accounted for by PC1 and 1 % in PC2.  The score plot that in Figure 4.4B shows 
somewhat some clusters related to PE and control respectively at protein fingerprint 
region of 1800-1000 cm-1.  Small outlier group of control subjects are outlier when a 95 % 
confidence interval is applied.  Loading plot (Figure 4.4B) shows different intensity peaks 
related to amide I at range of 1700-1600 cm-1 and amide II at range of ~1665-1530 cm-1.  
Data associated with both PC1 and PC2 of PE and control at 15 week gestational age are 
presented in Figure 4.4B. 
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Figure 4. 4: PCA plot of PE and control during 15 week of gestation at protein region of 
1800-1000 cm-1 
PCA plot shows scores distribution of PC1 and PC2 around normalised scale (A) for PE and control.  
Data were analysed for protein fingerprint area at 1800-1000 cm-1 using confidence interval at 95 
%.  Different absorbance intensities associates with PC1 and PC2 loading spectra (B) corresponds 
to amide I at range 1700-1500 cm-1 , amide II at range 1500-1350 cm-1 , and amide III at range 
~1335-1220 cm-1 related to PE and control are observed.  A: Scores of IR spectral waves, A (s) = PE 
at 15 week, C (c) = non-complicated pregnancies (control) at 15 week, B: Loading score of IR 
vibrational bands at 1800-1000 cm-1 region; PC1 (blue); PC2 (red). 
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4.4.3. Spectral profile study of lipid region for PE and control at 15 
weeks gestational age 
PCA plots for PE and control FTIR data at 15 weeks gestational age, lipid region (3100-
2700 cm-1) (Figure 4.5A) 99 % of population variance is accounted for by PC1 and 1 % by 
PC2.  Some clusters within the data are observed (Figure 4.5A); however there is overlap 
between some cases and some controls.  Figure 4.5A demonstrates the observation of an 
outlier group of control subject samples at a 95 % confidence interval.  Loading plot 
(Figure 4.5B) demonstrated peaks of C-H stretching at asym.(2985-2950) cm-1 ; sym. 
(2885-2865) cm-1 for CH3 group, and at range (2990-2950) cm
-1 and (2850-2780) cm-1 
(asymmetric and symmetric) vibrational bonds respectively for CH2 group are responsible 
for the significant PC2 variation associated with this outlier separation.  This region was 
associated with both PC1 and PC2; intensities related to PE and control at 15 week 
gestational age for lipid region of 3100-2700 cm-1 are observed in Figure 4.5B. 
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Figure 4. 5 : PCA and loadings plot of lipid region of (3100-2700 cm-1) for 15 week 
gestation samples in PE vs. control subjects 
PCA plot displays score distribution of PC1 and PC2 around normalised scale (A) for PE and 
control.  Data were analysed using lipid region at 3100-2700 cm-1 using 95 % confidence interval.  
Different absorbance intensities between PC1 and PC2 loading spectra (B) were observed.  A: 
Scores of IR spectral waves, A (s) = PE at 15 week, C (c) = non-complicated pregnancies (control) at 
15 week, B: Loading score of IR vibrational bands at 3100-2700 cm-1 region; PC1 (blue); PC2 (red). 
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4.4.4. Spectral profile study for PE and control subjects at 20 weeks’ 
gestation  
Mid-IR region FTIR spectral profiles (4000-600cm-1) were collected for samples provided 
at 20 weeks’ gestation from women with PE and non-complicated pregnancies (controls).  
Mean spectral profiles for these groups are plotted in Figure 4.6.  Higher intensity FTIR 
spectral profiles are observed for PE subjects compared with controls (Figure 4.6).  The 
primary observed differences are in peaks in specific ranges; amide A, N-H and O-H 
stretching vibration (3500-3100 cm-1 ), amide I and amide II (1700-1450 cm-1), amide III 
(1235-1224 cm-1),  C-H stretching bonds of lipids (2960–2950 cm-1, CH), 2880–2865 cm-1 
and 2860–2840 cm-1 for (asymmetric and symmetric) vibrational bonds respectively (CH3 
and CH2) all show increased absorbance in cases as compared to controls at this gestation 
(Figure 4.6).  A smaller peak at 1730 cm-1 ((C=O) stretching bond of ester), alongside 
bending vibration of (CH2, ~1465 cm
-1), and carbohydrate-related (C–O) and (C–O–C 
stretch band peaks (1170-1000 cm-1) (Figure 4.6). 
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Figure 4. 6: Averaged mid FTIR spectral profiles for PE and control samples at 20 weeks’ 
gestation 
FTIR spectral profile averages were calculated for PE (n=30) and control (n=30) samples.  Red B (s) 
=mean of PE (n=30) at 20 week of pregnancy, blue D (c) = mean of control (n=30) at 20 week of 
pregnancy. 
 
The following section describes the spectral profiles of PE and control at 20 weeks of 
pregnancy using PCA description related to protein fingerprint of 1800-1000 cm-1 and 
lipid at 3100-2700 cm-1 regions respectively. 
 
4.4.5. Spectral profile study of protein fingerprint region for PE and 
control at 20 weeks gestational age 
PCA plots of protein fingerprint region of 1800-1000 cm-1are presented in Figure 4.7A for 
PE and control samples at 20 weeks of pregnancy at 95 % of observed variation is related 
to PC1 vs 4 % for PC2.  The score plot that presented in Figure 4.7A shows some degree of 
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separation related to PE and control over this protein fingerprint region.  Some data fall 
outside the 95 % confidence interval (outside black line).  The associated loading plot 
(Figure 4.7B) demonstrates differences in the observed intensity of peaks related to 
amide I (1700-1600 cm-1), a band at ~1650 cm-1, and amide II (~1685-1530 cm-1).   
 
Figure 4. 7: PCA plot protein region (1800-1000 cm-1) for PE and control samples at 20 
weeks’ gestation  
PCA plot shows scores distribution of PC1 and PC2 around normalised scale (A) for PE and control.  
Data are presented for protein fingerprint area (1800-1000 cm-1) with a 95% confidence interval. 
Outlier data lie out with the 95% confidence interval. A: Scores of IR spectral waves, B (s) = PE at 
125 
 
20 week, D (c) = non-complicated pregnancies (control) at 20 week, B: Loading score of IR 
vibrational bands at 1800-1000 cm-1 region; PC1 (blue); PC2 (red). 
 
4.4.6. Spectral profile study of lipid region for PE and control at 20 
weeks gestational age 
Data presented in Figure 4.8A as a score plot for PE and control urine samples’ lipid region 
(3100-2700 cm-1) at 20 weeks’ gestation .  The scores plot in Figure 4.8A shows 97 % of 
populations are related to PC1 and 3 % in PC2.  Some clusters differentiating PE and 
controls are observed in this region (Figure 4.8A).  A number of outliers are observed 
which are outside the PCA 95% confidence interval.  The associated loading plot (Figure 
4.8B) shows a number of differential peaks: asymmetric and symmetric CH3 C-H 
stretching (2985-2950 and 2885-2865 cm-1 respectively); and also asymmetric and 
symmetric vibrations CH2 group for CH3 group (2990-2950 and 2850-2780 cm
-1 
respectively).  Peaks with significant contributions to both PC1 and PC2 were observed at 
these wavenumbers showing different intensities related to PE and control at 20 week 
gestation (Figure 4.8B). 
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Figure 4. 8: PCA plot of PE and control during 20 week of gestation at lipid region of 
3100-2700 cm-1 
PCA plot showing score distribution of PC1 and PC2 around normalised scale (A) for PE and 
control at 20 weeks of pregnancy.  Data were analysed using lipid region at 3100-2700 cm-1 using 
confidence interval 95 %.  Outlier data related to PE at 20 week gestational age of PCA scores 
using 95 % confidence interval are observed.  Different absorbance intensities between PC1 and 
PC2 loading spectra (B) were observed related to C-H stretching vibrational bond of asym.(2985-
2950 cm-1) cm-1 ; sym. (2885-2865) cm-1 for CH3 group, and at range (2990-2950) cm
-1 and (2850-
2780) cm-1 (asymmetric and symmetric) vibrational bonds respectively for CH2 group.  A: Scores of 
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IR spectral waves, B (s) = PE at 20 week, D (c) = non-complicated pregnancies (control) at 20 week, 
B: Loading score of IR vibrational bands at 3100-2700 cm-1 region; PC1 (blue); PC2 (red). 
 
4.4.7. FTIR spectral profile of IUGR and control at 15 weeks’ gestation  
Spectral profiling by FTIR was carried out on urine samples collected from subjects with 
IUGR and those with uncomplicated pregnancies (controls) at 15 weeks’ gestation over 
the mid-IR region (4000-600 cm-1).  Figure S2 (see appendix 5) shows overlaid FTIR spectra 
in IUGR and control at 15 weeks gestation. There are few visible differences; indicating 
mean spectral difference analysis is merited to observe emergent differences between 
cases and controls.  Figure 4.9 shows differences between mean spectral profiles for IUGR 
(n=30) and uncomplicated pregnancies (n=30).  Data are presented as absorbance 
intensity vs wavenumber. Mean spectral profile for IUGR shows overall higher intensity 
absorbance compared with that of uncomplicated pregnancy (Figure 4.9).  The principal 
differences are peaks related to amide A, N-H and O-H stretching vibrations (3500-3100 
cm-1, Figure 4.9).  Different intensities in spectral profile between IUGR and control 
related to protein fingerprint are also observed (1800-1000 cm-1), as are amide I and 
amide II (1700-1450 cm-1); amide III (1235-1224 cm-1), C-H stretching (lipid region, 3100-
2700 cm-1).  Smaller peaks at 1730 cm-1 (C=O stretching bond of ester); bending vibration 
of (CH2) at 1465 cm
-1, and carbohydrate-related signals (1100-1050 cm-1, (C–O) and (C–O–
C)) were also observed as differential signals (Figure 4.9). 
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Figure 4. 9: Mean spectral profiles for mid-IR analysis of IUGR and control urine samples 
at 15 weeks’ gestation  
FTIR spectral profile means for IUGR (n=30) and control (n=30) samples were calculated.  
Wavenumber is plotted vs. absorbance intensity.  Red E (s) =mean of IUGR samples (n=30) at 15 
week of pregnancy, blue G (c) = mean of control samples (n=30). 
 
The following sections describe the spectral profiles of IUGR and control at 15 weeks of 
pregnancy using PCA of protein fingerprint (1800-1000 cm-1) and lipid (3100-2700 cm-1) 
regions. 
 
4.4.8. Spectral profile investigation of protein fingerprint region for 
IUGR and control urine samples at 15 weeks’ gestation 
Figure 4.10A shows a score plot for IUGR and control urine sample FTIR at 15 weeks’ 
gestational age at protein fingerprint region (1800-1000 cm-1). The score plot in Figure 
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4.10A shows 92 % of signal variance is related to PC1 and 6 % to PC2.  Some outcome-
related clusters are observed within this region (Figure 4.10A).  A group of observations as 
outliers beyond the 95 % confidence interval were observed for the IUGR subjects.  
Loading plot (Figure 4.10B) attributes the differences in observed intensity to peaks 
related to amide I at (1700-1600 cm-1), amide II (~1665-1530 cm-1), with lower-scale 
differences related to amide III (1229-1220 cm-1).  These changes were across both PC1 
and PC2 (Figure 4.10B). 
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Figure 4. 10: PCA plot of IUGR and control urine samples collected at 15 weeks’ 
gestation for protein region 1800-1000 cm-1 
PCA plot shows score distribution of PC1 and PC2 around normalised scale (A) for IUGR and 
control.  Data were analysed using protein fingerprint area at 1800-1000 cm-1 at confidence 
interval at 95 %.  Outlier data related to IUGR at 15 week gestational age of PCA scores using 95 % 
confidence interval are observed.  Different absorbance intensities associate with PC1 and PC2 
loading spectra (B).  A: Scores of IR spectral waves, E (s) = IUGR at 15 week, G (c) = uncomplicated 
pregnancies (control) at 15 week, B: Loading score of IR vibrational bands at 1800-1000 cm-1 
region; PC1 (blue); PC2 (red). 
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4.4.9. Spectral profile investigation of lipid region for IUGR and 
control urine samples at 15 weeks’ gestation 
Figure 4.11A shows score plot for IUGR and control urine samples at 15 weeks of 
pregnancy over the lipid region (3100-2700 cm-1).  99 % of observed variation is related to 
PC1 and 1 % to PC2.  Some differential clustering of cases and controls is observed (Figure 
4.11A); with a subgroup of outlier observations pertaining to IUGR cases lie out with the 
PCA 95 % confidence interval.  The loading plot associated with this PCA (Figure 4.11B) 
shows that differences are attributable to C-H stretching peaks (CH2 and CH3 (symmetric 
and asymmetric) ~ 2950-2850 cm-1). Intensity differences are observed in both PC1 and 
PC2 (Figure 4.11B). 
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Figure 4. 11: PCA plot of IUGR and control urine samples collected at 15 weeks’ 
gestation over lipid region of 3100-2700 cm-1 
PCA plot shows score distribution of PC1 and PC2 around normalised scale (A) for IUGR and 
control urine at 15 weeks of pregnancy.  Lipid region at 3100-2700 cm-1 plotted, at a 95% 
confidence interval PC1 and PC2 loading spectra (B).  A: Scores of IR spectral waves, E (s) = IUGR 
at 15 week, G (c) = non-complicated pregnancies (control) at 15 week, B: Loading plot of IR 
vibrational bands at 3100-2700 cm-1 region; PC1 (blue); PC2 (red). 
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4.4.10. Spectral profiling of urine samples collected from IUGR and 
control subjects at 20 weeks’ gestation 
FTIR analysis was performed for urine samples obtained from subjects with IUGR and 
uncomplicated pregnancies (controls) at 20 weeks’ gestation.  Limited difference was 
observed in mean spectral profile between IUGR (n=30) and control (n=30) samples over 
the mid-IR range (4000-600 cm-1, Figure 4.12).  Observationally, minor differences are 
present related to amide A, N-H and O-H stretching vibration (3500-3100 cm-1) and C-H 
stretching (2960–2950 cm-1) (Figure 4.12). More evident are protein finger print region 
amide I and amide II variations (1700-1000 cm-1).  Increased variation of intensity is 
observed for (C=O) stretching bond of ester (small peak at 1730 cm-1); bending vibration 
of CH2 (1465 cm
-1), and carbohydrate-related (C–O) and (C–O–C) stretch (1170-1000 cm-
1). 
 
Figure 4. 12: Spectral profile comparison of mean FTIR of IUGR and control samples at 
20 weeks’ gestation 
134 
 
Mean FTIR spectral profiles plotted for IUGR (n=30) and control (n=30) urine samples collected at 
week 20 of pregnancies.  Red F (s) =mean of IUGR (n=30) at 20 week of pregnancy, blue H (c) = 
mean of control (n=30) at 20 week of pregnancy. 
 
The following section describes the spectral profiles of IUGR and control at 20 weeks of 
pregnancy using PCA description divided according to protein fingerprint (1800-1000 cm-
1) and lipid (3100-2700 cm-1) regions respectively. 
 
4.4.11. Spectral profile investigation of protein fingerprint region for 
urine samples taken from IUGR cases and controls at 20 weeks’ 
gestation 
Figure 4.13A is a PCA score plot for IUGR and control samples at 20 weeks of pregnancy 
over the protein fingerprint region of 1800-1000 cm-1.  91% of observed variance was 
accounted for by PC1, and 8% in PC2.  Figure 4.13A shows some overlapping clusters 
related to IUGR and control observations.  A number of case observations are outlier out 
with the 95% confidence interval.  Associated loading plot for this analysis (Figure 4.13B) 
shows a number of variant peaks related to amide I (1700-1600 cm-1), and amide II 
(~1585-1480 cm-1), associated with PC1.  PC2 shows a small shift related to amide I (1670-
1575 cm-1), and amide II (1560-1475 cm-1).  
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Figure 4. 13: PCA plot of IUGR and control urine samples collected at 20 weeks’ 
gestation over protein region, 1800-1000 cm-1 
PCA plot shows score distribution of PC1 and PC2 around normalised scale (A) for IUGR and 
control.  Data were analysed using protein fingerprint area at 1800-1000 cm-1 at a 95% confidence 
interval   A: Scores of IR spectral waves, F (s) = IUGR at 20 week, H (c) = non-complicated 
pregnancies (control) at 20 week, B: Loading score of IR vibrational bands at 1800-1000 cm-1 
region; PC1 (blue); PC2 (red). 
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4.4.12. Spectral profile investigation of lipid region for IUGR and 
control at 20 weeks’ gestation 
Data presented in Figure 4.14A show score plots for IUGR and control urine samples at 20 
week of pregnancy at lipid region of 3100-2700 cm-1.  Score plot (Figure 4.14A) shows 93 
% of variation is related to PC1 and 6 % to PC2.  Data show no clear pattern, with both 
cases and control observations being spread around scale at a 95% confidence interval.  A 
small number of both case and control outlier observations sit out with the PCA 95% 
confidence interval.  Loading plot (Figure 4.14 B) showed differences could be attributed 
to broad peaks of C-H stretching (2950-2850 cm-1), corresponding to CH2 and CH3 
(symmetric and asymmetric).   
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Figure 4. 14: PCA plot of IUGR and control subjects for 20 week’s gestation using lipid 
region of 3100-2700 cm-1 
PCA plot shows score distribution of PC1 and PC2 around normalised scale (A) for IUGR and 
control at 20 weeks of pregnancy.  Data were analysed using lipid region at 3100-2700 cm-1 using 
confidence interval 95 %.   A: Scores of IR spectral waves, F (s) = IUGR at 20 week, H (c) = non-
complicated pregnancies (control) at 20 week, B: Loading score of IR vibrational bands at 3100-
2700 cm-1 region; PC1 (blue); PC2 (red). 
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4.5. Discussion  
This study was performed to identify whether changes in IR spectral profile could be 
observed for PE and IUGR disorders when compared to uncomplicated control 
pregnancies.  The aim of this Chapter was to report the investigation of mid-IR spectral 
differences between urine samples from women clinical presenting with these disorders 
during 15 and 20 weeks of gestational age using FTIR. No clinically useful screening test 
currently exists to predict the progress of PE prior to onset of clinically-observable 
symptoms (Conde-Agudelo et al., 2004).  According to the changes observed 
hypothesised to be within the protein (and lipid) profiles of these diseases; not only might 
these profiles change in regard to the composition of these species, but also due to their 
structural changes, i.e. quaternary and secondary structures of proteins. 
Differences in urine profiles may be indicative of implantation abnormality in PE (Roberts, 
1998, Powell et al., 2018) or IUGR (Conde‐Agudelo et al., 2013, Powell et al., 2018).  These 
differences could manifest as either up or down regulation of profile expression (Takacs 
et al., 2003, Powers et al., 2005).  In order to be of prognostic value, biomarkers need to 
show predictable and robust changes before and during clinical manifestation of PE 
(Hubel, 1999, Krauss et al., 1997, Taylor et al., 1991).   
It has been suggested by others that PE is a disturbance of antioxidant inadequacy 
appearing when the normal antioxidant equilibrium is upset (Stark, 1993).  Oxidative 
damage induced by free radicals or Reactive Oxygen Species (ROS) could cause protein 
modification and lipid peroxidation (Sinclair et al., 1990), and consequently alterations in 
membrane properties and cell damage (Spickett et al., 1998).  When free radicals attack 
polyunsaturated fatty acids or cholesterol in membrane and lipoproteins, they generate 
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high reactive species of lipid peroxidation and lipid hydroperoxides (Sinclair et al., 1990).  
In normal physiological function, lipid hydroperoxides are regulated by enzymes and 
redox-sensitive genes (Marnett, 1992, Sen and Packer, 1996).  Uncontrolled lipid 
peroxidation could be causing cellular dysfunction and damage which associates with 
abnormal placentation such as in PE and IUGR (Hubel, 1999, Hubel et al., 1990, Walsh, 
1998, Maisonneuve et al., 2015).  Therefore, oxidative stress results in such damage, 
which normally prevented by wide-ranging and manifold antioxidant substances.  
Antioxidant also known as defence system that having substances with different 
molecular weight (Sinclair et al., 1990).   
Albumin represents major circulating antioxidant components in plasma, allowing 
exposing to continuous oxidative stress (Soriani et al., 1994).  Albumin has direct 
protective effects vs mortality risk due to the opposite relationship between serum 
albumin level and mortality risk has suggested (Goldwasser and Feldman, 1997, Phillips et 
al., 1989, Halliwell, 1990).  Alterations in the structure of albumin perhaps result in 
impairments of its biological functions (Terawaki et al., 2004).  Modifications of albumin 
functions may occur in many pathological conditions associated with early incidence of 
vascular complications conditions such in case of PE and insulin dependent diabetes 
mellitus patients and IUGR.  
On the basis of the above consideration, we can explain the major alteration in the band 
intensities of protein finger print region of 1800-1000 cm-1 , amide I C=O stretching at 
range ~1750-1560 cm-1, amide II N-H bending at range around 1550-1430 cm-1, and amide 
III (complex vibrations bonds) at range about (1335-1220) cm-1.  The scores of the PCA 
plot showed a degree of data separation between case and control related to PE at 20 
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weeks of pregnancy can be seen in Figure 4.7A.  Similarly, some clusters have been 
observed relating to patients complicated with IUGR during 15 and 20 weeks respectively 
compared to normal pregnancies (Figure 4.10A and 4.13A).  Alterations in secondary 
structure of proteins could be associates with a lack in an antioxidant system. These 
findings agree with a study presented by Raouf and co-workers (2011) who used FTIR 
analysis of serum to study protein structure of PE at different gestational ages (Raouf et 
al., 2011).  
It has been suggested that there is a positive correlation between early pregnancy 
dyslipidemia and PE (Enquobahrie et al., 2004).  Women with a history of PE show a 
significant difference in lipid profile and high susceptibility to lipoprotein oxidation 
compared with uncomplicated pregnancies (Gratacós et al., 2003, Mittal et al., 2017).  
Therefore, disturbance of lipoprotein metabolism could be a characteristic of major 
causes of hypertension and proteinuria in PE (Gratacós et al., 2003).  The correlation 
between women complicated with IUGR and lipid peroxidation results in oxidative stress 
has been reported by a number of studies (Hracsko et al., 2008, Lutnicki et al., 1998, 
Karowicz-Bilińska, 2006, Dikbas et al., 2017). For example, study reported by Fraile and 
colleagues (2003) showed that the ratio between amide II/I was higher in pure albumin 
than with albumin interacting with lipids (Fraile et al., 2003).  They suggested that 
structure of pure albumin has destabilised by lipids, which is now a well-understood and 
accepted mechanism of protein stabilisation (Fraile et al., 2003)  
The current research in this chapter has shown variation in a lipid region of range 
3100-2700 cm-1 in PE at 20 week gestational age (Figure 4.8) and IUGR at 15 week of 
pregnancy (Figure4.11) respectively.  These bands correspond to C-H stretching bonds of 
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lipids components at range 2960–2950 cm-1 (as); CH3, 2880–2865 cm
-1, and at 2860–2840 
cm-1 for (as and s), and bending vibration of CH2 at peak around 1465 cm
-1 of lipid acyl 
group, and ester (C=O) stretching at ~1750-1700 cm-1. Results in this chapter obtained 
from urine samples in complicated pregnancies agreed with a previous report suggesting 
that strongly correlation exists between maternal complications and abnormal lipid 
metabolism of pre-eclamptic patients (Aziz and Mahboob, 2007).   
Other research agreed with our findings (Lorentzen et al., 1994).  Their results revealed 
that the concentration of Free Fatty Acid (FFA), triglycerides (TG), and lipolytic activity 
were significantly increased in pre-eclamptic women at 16-18 weeks of gestational age 
compared to normal pregnancies (Lorentzen et al., 1994).  Elsewhere, studies by Kamath, 
et al, stated that the possible increases of lipid peroxidation of malondialdehyde (MDA) 
and protein oxidation in both maternal and fetal erythrocytes for intrauterine growth 
retardation (Kamath et al., 2006).  Therefore, lipid profile abnormalities could be used as 
discriminatory biomarkers for maternal pathogenic conditions such in the case of PE and 
IUGR (Lorentzen et al., 1994, Alvino et al., 2008). 
4.6. Conclusions 
The results presented in this chapter highlight key spectral differences between controls 
and PE and IUGR clinical urine samples collected at various time points post conception. 
PCA is not completely discriminatory but scores plots for these samples highlight areas of 
difference, particularly in the protein bond regions. This is supported by other evidence 
from literature and aligns with other spectral differences observed in the lipid range and 
with the proteomics data in Chapter 2, where specific proteins were observed to show 
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altered expression patterns in PE and IUGR.  Further study will be required in the future 
for integrative validation in a larger cohort. 
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Chapter 5 
 
5. General discussion, conclusions and 
future work 
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5.1 Aim and direction of work 
The overarching aim of the work presented in this thesis was to investigate the potential 
for urine-based biomarkers for both PE and IUGR studies at early stages of pregnancy. 
Here the results are discussed in context with the current state-of-the-art in proteomic 
biomarker analysis. Using two analytical techniques to independently assess a range of 
clinical samples, liquid chromatography mass spectrometry (LC-MS) and FTIR were used 
to investigate possible biomarkers, with the purpose of leading towards improved 
diagnostics and earlier management of PE and IUGR.  
5.2 FTIR optimisation for urine-based samples  
FTIR interrogation of urine samples was carried out in order to optimise methodology; it 
was important to consider the subsequent clinical use of this FTIR methodology with 
focus on the volumes of samples obtained (Lovergne et al., 2015). Human samples are 
costly, have specific storage and handling requirements and are available in limited 
amounts, therefore rat urine was used as alternative to human samples for optimisation 
experiment work (Chapter 3); this enabled testing of urine volumes needed to produce 
reproducible spectra from as low volumes as possible.  
Previous research has indicated differences in both protein bands (main amide bands 
have focussed on the region (1700-1550 cm-1) and lipid regions (~3100-2700 cm-1) (Raouf 
et al., 2011). Since the thesis hypothesis was focussed on protein/ peptide biomarkers 
being found in urine from patients with PE and IUGR, the amide region was used for 
optimisation of signal clarity. A bands of amide I, II at range (1800-1500 cm-1) were 
assessed by peak area, height peak, and wavenumber of peak maximum to understand 
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both the noise levels in terms of absorbance intensity and band reproducibility of band 
position, (Figure. 3.7 and 3.8). Spectra obtained from urine samples clearly showed amide 
bands with good sample repeat consistency. Peak height showed some degree of 
variance (Figure 3.8) having a mean of 0.175 with standard error of 0.053, which was 
most reliable with volumes of 5 μL. As this is a measure of in essence a single point within 
the spectra the level of noise can be expected. For this reason, the area (integrating 
under the amide profile) was used; this takes into account any variance across the whole 
region of interest and so ~ 60 data points were assessed rather than just 1 at the 
maximum. This is a common route used for the comparison of such spectra (Lovergne et 
al., 2015). In addition to this, optimisation of data processing showed the reduced signal / 
noise, but importantly maintained consistency of data, when spectral smoothing was 
applied. There are always concerns that use of smoothing algorithms introduces spectral 
artefacts (Mukherjee et al., 2014), and for this reason a low level 5 point adjacent 
averaging smoothing function was applied (Baker et al., 2010). 
Using amide I as the main band upon which methods were optimised, this work 
demonstrated a very good signal to noise ratio across the whole mid-IR range from 
samples with volumes as low as 5 μL. Figure (3.8) showed variability of observed signal 
according to volumes of 1, 2, 5 and 10 μL.  However, results indicate a higher sensitivity 
related to most parameters at 5 and 10 μL vs 1 and 2 μL Figure (3.8).  Previous research 
by (Hoşafçı et al., 2007) used 5 μL of sample to investigate FTIR spectral vibration of urine 
and blood samples, other studies also used this volume of biofluid typically blood sample 
for FTIR analysis (Bonnier et al., 2014, Lovergne et al., 2015). Bonnier and co-workers 
(2014) revealed good improvement in FTIR spectra identification after protein fractions 
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using centrifugal filtrate at different molecular weight cut-off using blood sample at 5 μL, 
especially after centrifugal filtrate purification prior sampling. This was a very positive 
outcome since the total volumes expected from human samples (after processing; protein 
fractionation, etc.) and protein fractionation to establish the lowest reliable volumes 
which could be used to assess clinical samples, and which would be the best method to 
possibly identify spectral differences. A simple ultrafiltration protocol, based on molecular 
weight fractionation was used, enabling spectral profile determination of samples with 
improved observation of amide band (Bonnier et al., 2014)  
The outcome of optimisation of FTIR sampling demonstrated lower limits of reliable FTIR 
sampling. The second optimisation experiment was carried out to determine the 
influence of sample preparation procedure on FTIR spectra at different conditions 
including (whole rat urine, >10 kDa ultrafiltration urine sample without buffer exchange 
and >10 kDa after sample buffer exchange). (Bonnier et al., 2014) has used ultrafiltration 
fractions bases on molecular weight cut-off to improve spectral profile outcome of blood 
sample. However, centrifugal filtrate bases on molecular weight cut-off coupled with 
buffer exchange method (Hart et al., 2015, Çorbacı and Uçar, 2018) enabling to introduce 
a simple and robust methodology by removing unwanted molecules (Hall, 2015) that has 
a similar functional group and could be overlapping with the sample of interest.  
Ultrafiltration experiments displayed spectra peaks visibly of retentate of > 10 kDa 
compare with spectra of whole urine sample (Figure 3.9). Protein bands are clearly 
observed after retentate buffer exchange (see Figure.3.9 C) at spectra range 1700-1650 
cm-1 with distinct peak at ~1650 cm-1 (amide I).  A band of amide II observed at 1650-1500 
cm-1, amide III peak at ~1330-1220 cm-1 was also observed (Lacombe et al., 2015).  
147 
 
Similarly, the spectra correspond to amide A and OH bands at 3650-3500 cm-1 and also C-
H stretching band at 3000-2830 cm-1 in IR (Lacombe et al., 2015). Although no attempt 
has been made to quantify the spectral characteristics corresponds to the constituent 
components in the urine, the study rather demonstrates that using such centrifugal 
fractionation procedure there is a passivity for ultimately developing medical diagnostics 
using this methodology.  
In Chapter 4 the SOP that was established in Chapter 3 for urine sample analysis was 
applied to clinical samples. This strategy was used to investigate spectral profile of clinical 
samples in different pregnancy time points using FTIR technique.  The first aim was to 
investigate spectral profile of PE related to case and control during both 15 and 20 weeks 
of gestational age respectively.  The second aim was to investigate spectral profile of 
IUGR related to case and control during both 15 and 20 weeks of pregnancy respectively. 
 
5.3 FTIR spectral profile for PE and IUGR 
Chapter 4 presents the results of FTIR analysis, showing differences in intensity of mean 
spectra between PE (n=30) and controls (n=30) at 15 and 20 weeks gestational age (Figure 
4.3 and 4.6) respectively using mid FTIR range of 4000-600 cm-1.  Same observations 
related to IUGR (n=30) compared with controls (n=30) at 15 and 20 weeks of pregnancy 
respectively were detected (Figure 4.9 and 4.12).  Significant differences in protein finger 
print region of 1800- 1000 cm-1, amide I C=O stretching at range ~1750-1560 cm-1, amide 
II N-H bending at range around 1550-1430 cm-1, and amide III (complex vibrations bonds) 
at range about (1335-1220) cm-1.  The scores of the PCA plot showed a degree of data 
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separation between case and control related to PE at 20 weeks of pregnancy can be seen 
in Figure 4.7A.  Similarly, some clusters have been observed also related to patients 
complicated with IUGR during 15 and 20 weeks respectively compared to normal 
pregnancies (Figure 4.10A and 4.13A).  The alterations in secondary structure of proteins 
could be associated with a lack in an antioxidant system. These findings agree with a 
study presented by Raouf and co-workers (2011) who used FTIR analysis of serum to 
study protein structure of PE at different gestational ages (Raouf et al., 2011).  
A positive correlation between early pregnancy dyslipidemia and PE has been suggested 
(Enquobahrie et al., 2004).  The current study in this chapter has shown variation in a 
range of mid-IR spectral bands mainly corresponds to lipid region at range of 3100-2700 
cm-1 in PE at 20 week gestational age (Figure 4.8) and in IUGR at 15 week of pregnancy 
(Figure4.11) respectively.  These bands correspond to C-H stretching bonds for lipids 
components at range 2960–2950cm-1 (as); CH3, 2880–2865 cm
-1, and at 2860–2840 cm-1 
for (as and s), and bending vibration of CH2 at peak around 1465 cm
-1 of lipid acyl group, 
and to ester (C=O) stretching at ~1750 1700 cm-1. Results in this chapter for complicated 
pregnancies urine agreed with a previous report suggesting that strongly correlation 
exists between maternal complicates conditions and abnormal lipid metabolism of pre-
eclamptic patients (Aziz and Mahboob, 2007). These spectral changes could be due to the 
potential impact of protein oxidant damage and lipid peroxidation caused by oxidative 
stress (Kamath et al., 2006, Maisonneuve et al., 2015, Dickinson et al., 2017).  Similar 
study revealed that women with a history of PE show a significant difference in lipid 
profile and high susceptibility to lipoprotein oxidation compared with uncomplicated 
pregnancies (Gratacós et al., 2003, Mittal et al., 2017). Another study which agreed with 
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our finding was carried out by (Enquobahrie et al., 2004), and found a high correlation 
between early pregnancy dyslipidemia and PE.  Work by Raouf and co-workers (2011) 
investigating FTIR spectral profiles in PE at different time points of pregnancies using 
blood sample shows broad agreement with the present study.  Correlation was observed 
in Rauf’s work between lipoprotein oxidation and maternal implantation abnormality.  
Results in chapter 2 also indicated that urothelial markers were observed as differentially 
expressed proteins, suggesting that the amount of epithelial shedding from different 
individual during micturition (Kumar et al., 2013) may play a role in the biological 
variation observed (see Tables S1-S4 in the appendix 3).   
 
5.4 MS process methodology 
LC-MS is a powerful method for proteomic analysis, especially when combined with 
iTRAQ labelling technique (Long et al., 2018). This method enables concurrent 
identification and quantification of putative proteomic biomarkers; in the case of this 
study, with the aim of early pregnancy prediction of risk of late pregnancy complications 
such as PE or/and in utero growth restriction (IUGR).  The ultrafiltration protocol that was 
used in present study has been used elsewhere (Tirumalai et al., 2003). iTRAQ labelling 
coupled with LC-MS analysis were performed, also used by others in proteomic analyses 
biomarker study in PE using urine sample (Carty et al., 2011).  Data-dependent iTRAQ 
analysis with LC-MS improves throughput by analysing [differently labelled] pooled 
samples simultaneously (Carty et al., 2011).  This reduces the potential impact of inter-
run technical variation.  The application of the iTRAQ methodology to urine samples is 
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dependent on removal of low molecular weight solutes such as sugar, urea, amino acid in 
organic salts which are freely filtered by the kidney into urine (Hall, 2015); these 
components could interfere with labelling and subsequent analysis. Data-dependent 
analysis using the fusion mass spectrometer was performed at present study using a total 
sample loading of ~400 ng.  The MS acquisition program followed the multi-notch MS 3 
method developed previously by (McAlister et al., 2014).  Unique peptides were only 
accepted for quantification when all reporter channels were presents with an average S/N 
> 5. In effect, as there is a low level of contribution of isotopomeric impurities to adjacent 
peaks (i.e. 114 has a low level of contribution to 115 and so on), this means that in 
practice no peaks with significant reporter ion intensity will be missed.  Peptide and 
protein identifies were accepted using 0.01 FDR for strict filtering at a 99 % confidence 
interval. Inter-sample normalisation was performed based on the spiked enolase standard 
(Cutillas, 2010).  
 
5.4.1 Proteomic biomarkers of PE 
PE improves immediately after delivery, but presently no specific intervention, save 
delivery of often premature infants, is available for PE. Prophylactic treatment with low 
dose aspirin has, however, been demonstrated to be of clinical use if administered to 
high-risk patients during early stages of pregnancy (6-16 weeks). (Bujold et al., 2014) This 
strategy reduces overall risk of PE for these individuals.  For primiparous women however 
the risk of PE is unknown, thus such treatment cannot be prospectively given.  Urine is an 
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ideal biofluid sample for clinical investigation of PE and IUGR due to its ease of collection.  
The findings obtained in this thesis can be summarised as the following: 
The results outlined in Chapter 2 focused on the use of LC-MS for the proteomics analysis 
of urine, using iTRAQ methodology. This strategy was implemented for the investigation 
of peptides having a molecular weight fraction >10 kDa.  Samples were analysed at 
different gestational age time points at 15 and 20 weeks for PE and IUGR.  Results 
highlighted 988 unique peptides from a total of 315 proteins in each 8-plex labelling 
sample at 99 % confidence interval with 0.01 false discovery rate cut-off, of which 173 
/826 (protein / peptides) proteins have sufficient reporter ion signal for quantification 
related to PE and IUGR at each week respectively (see Tables S1-S4 in the appendix 3).  
Proteins with < 2 peptides are excluded from identification / quantification analysis, due 
to reduced confidence of protein/peptide identification; these data are routinely 
excluded from ratiometric determinations made by others (Evans et al., 2012).   
Identified proteins were subjected to relative quantification, with differentially-expressed 
proteins being associated with log 2 fold change of abundance ratio (cases: control) during 
15 and 20 weeks of PE and IUGR respectively compared with uncomplicated pregnancies 
(Figures 2.7 - 2.9 for PE; Figures 2.11 - 2.13 for IUGR).  Quantitatively, all data were 
normalised within a known amount of internal standard of enolase which log 2 fold 
change ratio equal to zero (supplementary Tables S1 - S4 in Appendix 3, Figure (2.7 -2.9) 
for PE and in Figure (2.11 - 2.13) for IUGR respectively. 
In PE, dysregulated proteins (n=173) that shown highly significant differences (P < 0.01) in 
protein profile at 95 % confidence interval using one sample Wilcoxon test (Figure 2.7 and 
2.8 at 15 and 20 weeks’ gestation respectively).  Results revealed about 26.7 % (n=46) 
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proteins were upregulated, and 73.3 % (n= 126) proteins were downregulated at 15 
weeks’ gestation in PE cases compared with uncomplicated pregnancies (Table S 1 in 
appendix 3).  At 20 weeks’ gestation in pregnancies complicated by PE, about 60.5 % 
(n=104) proteins were upregulated and 39.5 % (n = 68) proteins were downregulated 
compared with uncomplicated pregnancies (Table S 2).  Quantitative data in Figure 2.9 
showed highly significant differences (P < 0.01) between 15 and 20 weeks of PE related to 
log 2 fold change abundance ratio (case / control) at 95 % confidence interval using Mann-
Whitney test.  In a similar study of urinary proteomic analysis using iTRAQ labelling work 
by (Chen et al., 2011) 113 proteins were identified. These proteins were expressed 
differentially between complicated hypertension (PE and hypertension pregnancies) and 
normal pregnancy.  31/113 of these proteins revealed statistically significant differences 
between these study groups. 
Outlier data in these analysis are represented highly dysregulated proteins (up / down) 
compared with control for PE are showed in Table 2.3 and 2.4.  16 proteins were 
identified at outlier are showed highly dysregulated proteins compared with 
uncomplicated pregnancies using one sample Wilcoxon test are showed at Figure 2.7, of 
which 50 % (n=8) proteins are upregulated and downregulated respectively for PE during 
15 week of pregnancy (Table 2.3).  For 20 week of PE, 7 proteins were upregulated, and 8 
proteins are downregulated were identified in Table 2.4.  However, in present study, the 
putative proteomic biomarkers which showed highly dysregulated profiles compared with 
the control group of uncomplicated pregnancies have found in previous studies, which 
are listed in Table 2.7 (section 2.9).  Three proteins were identified as having very similar 
profile changes at both 15 and 20 weeks in pregnancies subsequently complicated by PE 
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(fibrinogen beta chain, haptoglobin and carboxypeptidase), highlighted in Table 2.3 and 
2.4 and shown in Figure 2.10.   Similar proteins identified in previous studies are 
highlighted in Table 2.7.  
Among putative biomarkers that showing highly dysregulated expression profiles 
associates with complicated pregnancies such as PE compared with uncomplicated 
pregnancies (Table 2.7), for instant, alpha-2-macroglobulin, haptoglobin and roundabout 
were identified.  Alpha-2-macroglobulin showed a log 2 fold change abundances ratio 
change of +3.5 (case: control) at 15 weeks gestation in PE subjects compared with 
uncomplicated pregnancies (control).  Alpha-2-macroglobulin has antiplasmin activity; the 
increased level of protein observed in preeclampsia may explain the intravascular 
coagulation observed in this condition (Horne et al., 1970). Similar findings have been 
previously observed in serum samples (Auer et al, 2010, Blumenstein et al., 2009, D'Silva 
et al., 2018).  Elsewhere, studies of proteomic biomarkers in PE also agreed with this 
finding using urine samples (Chen et al., 2011, Carty et al., 2011). 
Haptoglobin is another biomarker shown as highly dysregulated in protein expression, 
with a log 2 fold change abundances ratio of +2.53 (case: control) for PE cases compared 
with uncomplicated pregnancies (control) at 15 weeks’ gestation.  Many other previous 
studies have reported similar result using different types of samples e.g. urine and / or 
serum to study proteomic biomarkers in PE (Auer et al, 2010, Blumenstein et al., 2009, 
Chen et al., 2011, Carty et al., 2011, D'Silva et al., 2018, Little et al., 2010) (see Table 2.7). 
Roundabout (ROBO4) showed downregulation (-3.19) in protein expression of PE at 15 
weeks gestational age compared with normotensive pregnancies (Table 2.3).  This protein 
has previously been found in developing placenta and embryonic tissues (Park et al., 
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2003), and has been shown to inhibit endothelial cell migration (Park et al., 2003).  
Downregulation in the protein expression could be an indication of impaired fetal 
development observed in later pregnancy.  Similar findings have been previously 
identified in urine (Chen et al., 2011) or in blood and serum (Nagalla et al., 2010, Myers et 
al., 2013) (see Table 2.7).  
 
5.4.2 Proteomic biomarkers of IUGR 
In parallel with the urine sample analysis in PE, samples were evaluated with respect to 
patients suffering from IUGR.  This dataset revealed several interesting potential 
biomarkers. At the 15 week gestation time point, no statistically significant quantitative 
differences were observed in the 173 identified proteins, however 16 outlier observations 
were tentatively assigned as differentially expressed proteins (n=173) were identified as 
43 % (n=74) upregulated, and 98 proteins (57 %) downregulated in Table S3 (Appendix 3).  
These dysregulated proteins showed a median expression fold change value of (-0.077), 
and max.-to-min. values of (2.7-(-1.639)) of 95 % interval using a one sample Wilcoxon 
test (Figure 2.11).  Of the 16 outlier proteins, eight were categorised as highly 
dysregulated (up/ down) compared with uncomplicated pregnancies (Figure 2.11 and 
Table 2.5).   
At 20 weeks’ gestation in participants who went on to develop IUGR, highly statistically 
significant differences were observed (P < 0.01) using one sample Wilcoxon test.  Median 
fold-change ratio at (-0.353) and max. and min. values at (1.549-(-2.44)) were determined 
for the 173 proteins identified (Figure 2.12).  27.9 % (n=48) were upregulated, while 
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around 72.1 % (n=124) were downregulated compared with uncomplicated pregnancies 
(Table S4, Appendix 3).  Additionally, quantitative data (Figure 2.13) showed highly 
significant differences (P < 0.01) between 15 and 20 weeks of IUGR using a Mann-
Whitney test.  Similar work using iTRAQ labelling coupled with MS analysis identified 
proteomic biomarkers in IUGR using serum (Auer et al., 2010). There, 166 proteins were 
identified, of which 31/128 identified proteins/ peptides showed expression changes in 
IUGR (14 up and 17 down-regulated) (Auer et al., 2010). 
A total of 74 peptides were revealed as outlier observations from 16 proteins.  50 % (n = 
8) of these proteins are upregulated and eight downregulated respectively in samples 
taken at 15 weeks’ gestation for of IUGR compared with uncomplicated pregnancies; 
these proteins are shown in Table 2.5.  At 20 weeks’ gestation, 16 / 60 (protein/peptides) 
were observed as being highly dysregulated in IUGR compared to uncomplicated 
pregnancy; 8 proteins are upregulated and 8 are downregulated (Table 2.6).  Similar 
identified proteins were observed in previous studies, summarised Table 2.8, using 
different sample types such as urine (Carty et al., 2011, Chen et al., 2011), serum (Auer et 
al, 2010), plasma (Blumenstein et al., 2009), amniotic fluid (Tsangaris et al., 2006) and 
placental cells (Mandò et al., 2016, Xin et al., 2012). 
Seven of the dysregulated proteins identified as outlier observations showed highly 
similar profiles at both 15 and 20 weeks’ gestation. These were zinc-alpha-2-glycoprotein, 
leucine-rich alpha-2-glycoprotein, alpha-1-acid glycoprotein 1, alpha-1-acid glycoprotein 
2, histone H4, CD44 antigen and lysosome-associated membrane glycoprotein 2, 
highlighted in Table 2.5 and 2.6, and shown in Figure 2.14.  Similar findings have been 
made by various previous studies, again which are highlighted in Table 2.8.  
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Among proteomic biomarkers which have shown dysregulation in their profile associated 
with pregnancies complicated by IUGR which are shown in Table 2.8., for example, Zinc-
alpha-2-glycoprotein, log 2 fold change value has upregulated at (2.707) in Table 2.5.  Zinc-
alpha-2-glycoprotein, a protein play various important functions in the human body, 
including fertilization (Ohkubo et al., 1990) and lipid mobilization (Morse et al., 2017).  
Zinc-alpha-2-glycoprotein stimulates lipid degradation in adipocytes and causes the 
extensive fat losses associated with some advanced cancers (Hirai et al., 1998, Zhang et 
al., 2018); this protein could bind with polyunsaturated fatty acids.  Upregulation of zinc-
alpha-2-glycoprotein may therefore be a key regulator of fetal growth in later pregnancy. 
The protein has been identified by others using serum or urine samples to study 
proteomic biomarkers in complicated pregnancies such as IUGR and PE (Auer et al., 2010, 
Blumenstein et al., 2009)(Chen et al., 2011),(Carty et al., 2011). 
Leucine-rich alpha-2-glycoprotein-1 (Lrg1), another putative IUGR biomarker was 
upregulated (+1.79 Log 2 fold-changes, Table 2.5). Leucine-rich alpha-2-glycoprotein-1 
(Lrg1) is an emerging biomarker for angiogenesis (Lio et al., 2018).  Angiogenesis is the 
process of new blood vessel formation, and is involved in the development and 
progression of several diseases, including cancers, proliferative diabetic retinopathy and 
chronic wound healing (Carmeliet, 2005).  Vascular endothelial growth factors (VEGFs) 
and their receptors play a crucial role in angiogenesis (Carmeliet et al., 1996).  Similar 
finding was detected using serum sample to identify protein leucine‐rich alpha‐2‐
glycoprotein as a putative biomarker of recombinant human growth hormone abuse (Kay 
et al., 2009).  Another study has also identified similar protein using amniotic fluid to 
predict abnormal fetal biomarkers has been previously performed (Tsangaris et al., 2006).  
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The presence of urothelial markers as differentially expressed proteins is an indication 
that the amount of epithelial shedding from different individuals during micturition 
(urination) is playing a role in the observed biological variation; therefore, this influence 
needs to be excluded before further exploitation of these putative biomarkers is possible. 
 
5.5 Conclusions 
This work has presented a proof of concept investigation using a rat urine model for 
optimisation experiment design to measure volume sensitivity and built up a standard 
operating protocol for the further study of clinical samples.  We conclude that spectra 
using 5 μL volume showed appropriate sensitivity for the mid FTIR region. Furthermore, 
the ultrafiltration protocol displayed robust and simple preparation method for protein 
identification at urine sample.  However, FTIR instrumental limitation is that it is 
somewhat slow and presents long sampling times due to drying of samples (required for 
reproducibility). This makes it is poorly-suited to measure larger sample sizes.  Therefore, 
a higher throughput and more rapid spectroscopic instrument would be needed, such as 
FT-IMR to achieve this objective. 
LC-MS coupling with iTRAQ technique introducing high throughput analysis enabling to 
identified and quantified proteomic biomarkers for both PE and IUGR simultaneously. 
This study identified 28 proteomic biomarkers that have showed highly dysregulated 
proteins (up /down) for PE shown in Table 2.7, and 24 possible biomarkers for IUGR 
compared with uncomplicated pregnancies respectively, shown in Table 2.8.  The 
fetoplacental markers of hypoxia and vascular dysfunction into urine via the maternal 
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blood in a manner enabling quantitative detection of their variation is a strong indicator 
that this strategy has merit for determination of potential markers for malfunction of the 
fetoplacental unit. The limitations of this study are, however, clear – we have yet to 
interrogate these markers using quantitative methods in an independent cohort of 
women who have the same conditions, or to investigate putative markers found in 
individual samples in (preferably independent) individuals. Independent confirmation of 
these markers using targeted mass spectrometric assay and/or biochemical assay 
methods such as ELISA is essential before these markers can be taken forward for clinical 
translation. 
 
5.6 Future work 
Mortality and morbidity associated with both maternal hypertension and children born 
following pregnancies complicated by pre-eclampsia and its consequences are a major 
burden (Villar et al., 2001, Van Lerberghe et al., 2005). The World Health Organization 
estimates that around 15 % of maternal deaths are directly associated with preeclampsia 
and eclampsia in low- and middle-income countries (Van Lerberghe et al., 2005), and over 
recent decades the condition remains the major causes of maternal death in the UK 
(Lewis, 2012, Hibbard and Milner, 1994). The Confidential Enquiry into Stillbirths and 
Deaths in Infancy (CESDI) 5th annual report (Sidebotham, 1998) revealed 1 in 6 stillbirths 
and around 1 in 6 neonatal deaths occurred due to gestational problems associated with 
maternal hypertension; gestational hypertension was found to be responsible for ~20% of 
special care costs at neonatal units in the UK (Sidebotham, 1998).  The morbidity burden 
159 
 
of prematurity does not cease at the neonatal stage; children born early as a result of PE 
have increased rates of hypertension, heart disorders, and disability in adulthood (Meyer 
and Zhang, 2007, Barker et al., 1989).  Significant effort has been invested in fetal growth 
restriction studies; however no unifying hypothesis has emerged to explain its occurrence 
(Lin and Santolaya-Forgas, 1998). In addition to adverse health consequences, PE is also 
has economic burden due to the medical services needed to take care of pregnant and 
postnatal women and their babies, who are often born preterm (Obstetricians and 
Gynecologists, 2013, Medicine, 2007). Stevens et al., (2017) documented the short-term 
medical costs associated with PE. State hospital discharge data, birth document data, 
economic insurance claims data, and nationally representative Healthcare Cost and 
Utilization Project (HCUP) data were interrogated to allocate nationally representative 
estimates of the additional cost of care for women with PE and their infants compared to 
women experiencing uncomplicated birth. This cost was estimated at $2.18 billion USD in 
2012, including $1.03 billion in costs of caring for mothers, and $1.15 billion for newborns 
(Stevens et al., 2017).  Elsewhere, study reported by (Fox et al., 2017), estimated the cost 
of PE in a socialised medical system using secondary data from the SCOPE study.  The Irish 
cohort in Cork was recruited between November 2008 and February 2011. Within the 
cohort of 1774 women, 68 developed PE (3.8%); these cases were compared with 171 
randomly-selected controls.  Pregnant women affected by PE had higher service use 
levels (Fox et al., 2017). The average service cost for women complicated by PE was 
€5243 per case vs. ~€2452 per case for women without complications.  The national cost 
of PE is thus estimated as between €6.5 and €9.1 million annually using prevalence rate 5-
7% (Fox et al., 2017). Ongoing effort to establish early pregnancy markers for this 
condition (and to therefore reduce the impact of PE on women and the healthcare sector) 
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is thus a valid direction of future investigation. The following future plans are summarised 
below:  
 The development of targeted assays for pregnancy under particular complications 
can be assisted by the use of detailed urinary protein analysis. The influence of 
biological variability necessitates further study of a larger, independent cohort 
using more targeted methods, such as immunoassay or mass spectrometric 
multiple reaction monitoring.   
 A urinary metabolomics study for PE and IUGR respectively during (15 and 20) 
weeks gestational age at <10 kDa molecular weight cut off using MS and FTIR 
techniques. 
 Genetic study such as DNA and RNA at (15 and 20) weeks of gestational age for 
each PE & IUGR disorders respectively using cells derived from urine samples. 
 Raman spectroscopic analysis for PE and IUGR disorders at (15 and 20) weeks of 
gestational using urine sample at molecular weight higher and lower than 10 kDa 
cut off respectively. 
 NMR spectroscopic study for PE and IUGR during both (15 and 20) weeks of 
gestational age for <10 kDa molecular weight cut off using urine sample.
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The use of multi-omics data as an endpoint, and the novelty of our investigation, gives unique 
challenges in determining sample size. Our previous experiences, and those of the SCOPE 
consortium, therefore inform our sample size and proteome coverage depth respectively. 
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Section C - Ethically sensitive, challenging or issues of risk 
C1 Will the research involve deceased persons, body parts or other human elements 
such as blood, hair or tissue samples (including saliva and waste products)? Yes ☒ No ☐ 
If yes, please discuss this project with Dr Alan Harper, Human Tissue Officer on 01782 674472 / 734654 
or e-mail a.g.s.harper@keele.ac.uk. Please cite the reference number given by Dr Harper for this 
research project below;- 
1706AGSH2016 
If yes, please give details with reference to the Human Tissue Act 2004. 
Urine samples are considered relevant materials under the HTA 2004. 
Appropriate logging of daughter fractions generated from these samples has been discussed in 
detail with the HTA officer, with guidance and a protocol for sample tracking and logging of 
sample processing and disposal being provided. The initial step in the preparation of all 
samples will be centrifugation to pellet and remove uroepithelial material shed from the urinary 
tract – at this point the samples will be rendered effectively acellular, significantly reducing the 
risks associated with their use. Protein extraction procedures will then be undertaken on the 
residual acellular material. 
Human Tissue Act can be accessed via https://www.hta.gov.uk/human-tissue-act-2004 
C2 Outline any potential risks to individuals, participants and members of the research team; the measures 
that will be taken to minimise risk; and the procedures that will be adopted in the event of an adverse 
event. 
Human samples will only be handled in a designated area within appropriately equipped 
laboratories at Keele University, observing or exceeding all biological safety rules in place at the 
time of experimentation. Standard operating protocols will be followed for all laboratory 
procedures. 
The University’s Lone Working Policy can be accessed via http://www.keele.ac.uk/dohs/a2z/loneworking/ 
C3 Will the research be undertaken overseas? 
If yes, have you consulted the foreign and commonwealth office website for 
guidance/travel advice and is it safe to travel there? 
Yes ☐ No ☒ 
Yes ☐ No ☐ 
Have you completed and submitted a risk assessment form? Yes ☐ No ☐ 
Foreign and Commonwealth Office travel advice website: https://www.gov.uk/foreign-travel-advice 
Overseas Travel Policy and risk assessment form (covers both Staff and PGR students) is available from 
http://www.keele.ac.uk/finance/insurance/travelinsurance/travellingoverseas-policyriskassessment/ 
C4 Will the research include children or vulnerable adults such as individuals with a learning 
disability or individuals with cognitive impairment? Yes ☐ No ☒ 
C5 Will participants be deceived in any way about the study? 
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If yes, describe the nature and extent of deception involved, including how and when this deception will 
be revealed and who will administer this feedback (debrief). 
SECTION D - Recruitment & consent process 
D1 Indicate how potential participants will be identified, approached and recruited and outline any 
relationship between the researcher and potential participant. 
This study will utilise material collected by a biobanking study (SCOPE) and as such no patient 
recruitment is necessary. 
Remember to attach copies of posters, advertisements, invitation letters/e-mails to be used as part of the recruitment 
process with version numbers included in the footer. 
D2 Describe the process that will be used to seek and obtain informed consent. 
All samples were obtained within the SCOPE study, with full informed consent to use the samples for 
future research being obtained from participants by the originating investigators at UCC. Ethical approval 
was obtained from the local ethics committee at Cork (ECM5(10)05/02/08); all women provided written 
informed consent, which is retained by the originating investigators. 
Broad ethical approval for commercial and non-commercial research outwith the original aims of SCOPE 
was consented at the time of original recruitment and consenting (see Participant Consent Form, 
attached). Recruitment has now finished, but during recruitment participants were made aware that they 
could withdraw from the study at any point (Patient Information Leaflet p2, Participant Consent Form Q2). 
If you answered yes to C4 (your participants are children or vulnerable adults) explain how you will 
ensure that individuals in these groups are competent to give consent to participate in this study. 
N/A 
Remember to attach your information sheet and consent form with versions numbers & date included in the footer 
Templates available from http://www.keele.ac.uk/researchsupport/researchethics/ 
D3 Will consent be sought to use the data for other research? 
Will consent be sought to contact the individual to participate in future research? 
Yes ☐ 
Yes ☐ 
No ☒ 
No ☒ 
D4 Can participants withdraw from the research? 
If yes, state up to what point participants are able to withdraw from the research 
Yes ☐ No ☒ 
If yes, outline how participants will be informed of their right to withdraw, how they can do this and what 
will happen to their data if they withdraw. 
If no, explain why they cannot withdraw (eg anonymous survey). 
Samples are entirely anonymised, detaching them from any patient-identifiable information, with full 
informed consent having been taken during the sample collection phase of the project. Thus, at the point 
where samples are provided to Keele, re-contact is not possible. All samples are denoted by a unique 
identifier provided within the SCOPE database. 
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SECTION E - Confidentiality and anonymity 
E1 Outline the procedures that will be used to protect, as far as possible, the anonymity of participants 
and/or confidentiality of data during the conduct of the research and in the release of its findings. 
Our SCOPE collaborators (from whom we are purchasing the samples) provide no patient-identifiable 
information within database entries, thus anonymity is ensured. 
SECTION F - Storage, access to, management of, and disposal of data 
F1 Describe the research data that will be stored; where it will be stored and for how long; the measures that 
will be put in place to ensure the security of data; who will have access to the data; long term data 
management plans following completion of the project; and how/when data will be disposed of. 
Spectroscopic data (raw files) and identification (Mascot and Scaffold) data will be stored at Keele 
University on a password protected hard drive, with robust backup facilities via networked storage. No 
patient identifiable data will be available to the research team. Data will be accessible initially to Dr Hart 
and Ms Al-Jasim, with sharing of outcomes with collaborators at Cork, Manchester and Leicester, but will 
be deposited in a public data archive, for example the PRoteomics IDEntifications (PRIDE) Archive 
hosted by EBI, coinciding with publication (in accordance with the guidelines of most scientific journals). 
Data will be retained for a minimum of 5 years following the conclusion of this project. 
SECTION G - Other ethical issues raised by the research 
G1 Are there any other ethical issues that may be raised by the research? 
If yes, please give details. 
Yes ☐ No ☒ 
SECTION H - Other approvals required 
H1 Does the project require researcher(s) to have a Disclosure and Barring Service 
(DBS) check? 
If yes, have you attached a confirmation of satisfactory DBS check memo? 
Yes ☐ 
Yes ☐ 
No ☒ 
No ☐ 
Does the project require National Offender Management Service (NOMS) 
approval? Yes ☐ No ☒ 
Does the project require NHS Research Development (R&D) Approval? Yes ☐ No ☒ 
Does the project require approval from another organisation? Yes ☐ No ☒ 
SECTION I - Checklist 
I1 Please list the documents attached to this application 
DocumentVersion number 
Schematic workflow1.0 
Date 
27/6/16 
SECTION J - Declarations 
J1 Declaration by researcher 
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I confirm that:- 
    The form is accurate to the best of my knowledge 
    I will abide by the University’s ethical requirements 
    I will inform the panel of any changes to the project 
    I am aware of my responsibility to be up to date and comply with the requirements of the law and 
         any relevant professional guidelines 
Researcher name (in capitals) Miss Wafaa Al Jasim 
Researcher signature 
Date 4/8/16 
J2 Declaration by supervisor (PGR applications only) 
I confirm that:- 
    The application has been appropriately peer reviewed 
    I have read the application and am happy for it to proceed for ethical review 
    The application is accurate to the best of my knowledge 
    The project will comply with the University’s ethical requirements 
    The applicant will inform the panel of any changes to the project 
    I am aware of my responsibility to ensure that the applicant is familiar with and complies with the 
         requirements of the law and any relevant professional guidelines 
Supervisor name (in capitals) Dr Sarah Hart 
Supervisor signature 
Date 4/8/16 
J3 Declaration by Faculty Research Office/Research Institute Director, Centre/Theme Head, or Head of 
School (Staff applications only) 
I confirm that:- 
    The application has been appropriately peer reviewed 
    I have read the application and am happy for it to proceed for ethical review 
    The form is accurate to the best of my knowledge 
    The project will comply with the University’s ethical requirements 
    The applicant will inform the panel of any changes to the project 
    I am aware of my responsibility to ensure that the applicant is familiar with and complies with the 
         requirements of the law and any relevant professional guidelines 
Name (in capitals) 
Post 
Signature 
PROF NICHOLAS R FORSYTH 
INSTITUTE DIRECTOR - ISTM 
Date 29/06/16 
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No 
Ref: ERP380 
8th August 2016 
Dr Sarah Hart/Miss Wafaa Al-Jasiim 
ISTM 
Keele University 
Dear Sarah and Wafaa, 
Re: Urinary proteome analysis in Pre-eclamptic and Intrauerine Growth restricted Pregnancies 
Thank you for submitting your revised application for review. I am pleased to inform you that 
your application has been approved by the Ethics Review Panel. The following documents have 
been reviewed and approved by the panel as follows: 
Document(s) 
ERP Application Form 
Schematic Workflow 
Version Number 
1 
1 
Date 
05-10-2016 
05-10-2016 
If the fieldwork goes beyond the date stated in your application, 30th September 2017, or there 
are any other amendments to your study you must submit an ‘application to amend study’ form 
to the ERP administrator at research.erps@keele.ac.uk stating ERP3 in the subject line of the e- 
mail. This form is available via http://www.keele.ac.uk/researchsupport/researchethics/ 
If you have any queries, please do not hesitate to contact me via the ERP administrator on 
research.erps@keele.ac.uk stating ERP3 in the subject line of the e-mail. 
Yours sincerely 
Dr Helen Price 
Vice Chair – Ethical Review Panel 
CC RI Manager 
Directorate of Engagement & Partnerships 
                   T: +44(0)1782 734467 
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6.3 Appendix 3: Dataset of all protein expression data for PE and IUGR with their controls 
Protein expression dataset that shows significant changes compared with control using confidence interval 99 % at FDR< 0.01 for PE and 
IUGR respectively at both 15 and 20 week gestational age are presented in supplementary Tables (S2-S4) respectively as below: 
Table S 1: Dataset of protein expression for PE and control at 15 weeks gestational age 
No. Protein 
FDR 
Confidence
: Combined 
Accession 
No. 
Protein name  # Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of PE at 
15 W 
Abundances 
of reporter 
ion of 
control at 15 
W 
Abundanc
e ratio 
(Case / 
Control) of 
PE at 15 W 
Log 2 
fold 
chang
e 
1 High P01023 Alpha-2-macroglobulin OS=Homo 
sapiens OX=9606 GN=A2M PE=1 SV=3 
2 163.2 234.4 20.7 11.33 3.502 
2 High P02675 Fibrinogen beta chain OS=Homo 
sapiens OX=9606 GN=FGB PE=1 SV=2 
2 55.9 159.4 16.9 9.415 3.235 
3 High Q6GTX8 Leukocyte-associated immunoglobulin-
like receptor 1 OS=Homo sapiens 
OX=9606 GN=LAIR1 PE=1 SV=1 
2 31.4 143.4 15.6 9.223 3.205 
4 High Q8IYS5 Osteoclast-associated immunoglobulin-
like receptor OS=Homo sapiens 
OX=9606 GN=OSCAR PE=1 SV=3 
2 30.5 42.4 5.4 7.89 2.980 
5 High P00738 Haptoglobin OS=Homo sapiens 
OX=9606 GN=HP PE=1 SV=1 
4 45.2 219.5 38 5.78 2.531 
6 High P02788 Lactotransferrin OS=Homo sapiens 
OX=9606 GN=LTF PE=1 SV=6 
3 78.1 273.3 50.6 5.404 2.434 
7 High P06733 Alpha-enolase OS=Homo sapiens 
OX=9606 GN=ENO1 PE=1 SV=2 
4 47.1 98.4 18.4 5.351 2.420 
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8 High P13796 Plastin-2 OS=Homo sapiens OX=9606 
GN=LCP1 PE=1 SV=6 
4 70.2 177.4 37.8 4.692 2.230 
9 High Q02487 Desmocollin-2 OS=Homo sapiens 
OX=9606 GN=DSC2 PE=1 SV=1 
3 99.9 38.7 10.2 3.795 1.924 
10 High P62805 Histone H4 OS=Homo sapiens OX=9606 
GN=HIST1H4A PE=1 SV=2 
3 11.4 156.6 45.8 3.416 1.772 
11 High P08185 Corticosteroid-binding globulin 
OS=Homo sapiens OX=9606 
GN=SERPINA6 PE=1 SV=1 
3 45.1 113 36.1 3.132 1.647 
12 High P60174 Triosephosphate isomerase OS=Homo 
sapiens OX=9606 GN=TPI1 PE=1 SV=3 
2 30.8 76 28.3 2.686 1.425 
13 High P18510 Interleukin-1 receptor antagonist 
protein OS=Homo sapiens OX=9606 
GN=IL1RN PE=1 SV=1 
2 20 37 15.4 2.4 1.263 
14 High P05164 Myeloperoxidase OS=Homo sapiens 
OX=9606 GN=MPO PE=1 SV=1 
3 83.8 110.7 47.2 2.347 1.231 
15 High P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens OX=9606 GN=KRT2 
PE=1 SV=2 
5 65.4 57.7 24.8 2.329 1.220 
16 High P25815 Protein S100-P OS=Homo sapiens 
OX=9606 GN=S100P PE=1 SV=2 
2 10.4 109.3 47.6 2.293 1.197 
17 High Q9ULI3 Protein HEG homolog 1 OS=Homo 
sapiens OX=9606 GN=HEG1 PE=1 SV=3 
3 147.4 44.9 21.9 2.048 1.034 
18 High P00450 Ceruloplasmin OS=Homo sapiens 
OX=9606 GN=CP PE=1 SV=1 
13 122.1 82 40.6 2.022 1.016 
19 High P02787 Serotransferrin OS=Homo sapiens 
OX=9606 GN=TF PE=1 SV=3 
12 77 88.1 45.2 1.952 0.965 
20 High P19652 Alpha-1-acid glycoprotein 2 OS=Homo 
sapiens OX=9606 GN=ORM2 PE=1 SV=2 
2 23.6 47.5 25.2 1.886 0.915 
21 High Q93088 Betaine--homocysteine S-
methyltransferase 1 OS=Homo sapiens 
OX=9606 GN=BHMT PE=1 SV=2 
3 45 57.5 32.8 1.754 0.811 
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22 High P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
OX=9606 GN=ACTB PE=1 SV=1 
6 41.7 80.5 49.6 1.623 0.699 
23 High P01859 Immunoglobulin heavy constant 
gamma 2 OS=Homo sapiens OX=9606 
GN=IGHG2 PE=1 SV=2 
4 35.9 94.7 60.8 1.557 0.639 
24 High P02763 Alpha-1-acid glycoprotein 1 OS=Homo 
sapiens OX=9606 GN=ORM1 PE=1 SV=1 
3 23.5 29.2 19.2 1.526 0.610 
25 High P04075 Fructose-bisphosphate aldolase A 
OS=Homo sapiens OX=9606 GN=ALDOA 
PE=1 SV=2 
2 39.4 80.1 52.7 1.52 0.604 
26 High P29972 Aquaporin-1 OS=Homo sapiens 
OX=9606 GN=AQP1 PE=1 SV=3 
2 28.5 40.4 26.9 1.501 0.586 
27 High P02768 Serum albumin OS=Homo sapiens 
OX=9606 GN=ALB PE=1 SV=2 
19 69.3 91 61.1 1.491 0.576 
28 High P0DOY2 Immunoglobulin lambda constant 2 
OS=Homo sapiens OX=9606 GN=IGLC2 
PE=1 SV=1 
3 11.3 43.2 31.7 1.366 0.450 
29 High P01876 Immunoglobulin heavy constant alpha 
1 OS=Homo sapiens OX=9606 
GN=IGHA1 PE=1 SV=2 
5 37.6 66 49.2 1.342 0.424 
30 High Q14515 SPARC-like protein 1 OS=Homo sapiens 
OX=9606 GN=SPARCL1 PE=1 SV=2 
4 75.2 35.9 27 1.33 0.411 
31 High P11142 Heat shock cognate 71 kDa protein 
OS=Homo sapiens OX=9606 GN=HSPA8 
PE=1 SV=1 
9 70.9 71.5 54.8 1.304 0.383 
32 High P04217 Alpha-1B-glycoprotein OS=Homo 
sapiens OX=9606 GN=A1BG PE=1 SV=4 
3 54.2 62.5 48.7 1.282 0.358 
33 High P01019 Angiotensinogen OS=Homo sapiens 
OX=9606 GN=AGT PE=1 SV=1 
2 53.1 45.9 37.7 1.216 0.282 
34 High P02750 Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens OX=9606 GN=LRG1 
PE=1 SV=2 
5 38.2 31 26 1.193 0.255 
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35 High P06703 Protein S100-A6 OS=Homo sapiens 
OX=9606 GN=S100A6 PE=1 SV=1 
3 10.2 76.1 64.1 1.188 0.249 
36 High P01614 Immunoglobulin kappa variable 2D-40 
OS=Homo sapiens OX=9606 
GN=IGKV2D-40 PE=1 SV=2 
2 13.3 52.8 44.5 1.188 0.249 
37 High P07476 Involucrin OS=Homo sapiens OX=9606 
GN=IVL PE=1 SV=2 
9 68.4 25.9 21.8 1.187 0.247 
38 High P01871 Immunoglobulin heavy constant mu 
OS=Homo sapiens OX=9606 GN=IGHM 
PE=1 SV=4 
2 49.4 48.1 42 1.147 0.198 
39 High P01834 Immunoglobulin kappa constant 
OS=Homo sapiens OX=9606 GN=IGKC 
PE=1 SV=2 
3 11.8 46.6 41.4 1.126 0.171 
40 High P01857 Immunoglobulin heavy constant 
gamma 1 OS=Homo sapiens OX=9606 
GN=IGHG1 PE=1 SV=1 
7 36.1 60.4 54.2 1.115 0.157 
41 High P10599 Thioredoxin OS=Homo sapiens 
OX=9606 GN=TXN PE=1 SV=3 
3 11.7 70.6 63.4 1.115 0.157 
42 High P80188 Neutrophil gelatinase-associated 
lipocalin OS=Homo sapiens OX=9606 
GN=LCN2 PE=1 SV=2 
3 22.6 61.5 55.7 1.104 0.143 
43 High P09211 Glutathione S-transferase P OS=Homo 
sapiens OX=9606 GN=GSTP1 PE=1 SV=2 
2 23.3 33.4 30.4 1.097 0.134 
44 High P12273 Prolactin-inducible protein OS=Homo 
sapiens OX=9606 GN=PIP PE=1 SV=1 
2 16.6 31.1 29.5 1.057 0.080 
45 High P41222 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens OX=9606 GN=PTGDS 
PE=1 SV=1 
3 21 47.2 45.7 1.033 0.047 
46 High Q08345 Epithelial discoidin domain-containing 
receptor 1 OS=Homo sapiens OX=9606 
GN=DDR1 PE=1 SV=1 
4 101.1 64.8 64.8 1.001 0.001 
47 High P00924 Enolase 1 OS=Saccharomyces 14 46.8 100 100 1 0.000 
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cerevisiae (strain ATCC 204508 / S288c) 
GN=ENO1 PE=1 SV=3 
48 High B9A064 Immunoglobulin lambda-like 
polypeptide 5 OS=Homo sapiens 
OX=9606 GN=IGLL5 PE=2 SV=2 
3 23 47.7 47.8 0.999 -0.001 
49 High P31947 14-3-3 protein sigma OS=Homo sapiens 
OX=9606 GN=SFN PE=1 SV=1 
5 27.8 58.4 59.6 0.981 -0.028 
50 High P25311 Zinc-alpha-2-glycoprotein OS=Homo 
sapiens OX=9606 GN=AZGP1 PE=1 SV=2 
13 34.2 22.8 23.7 0.963 -0.054 
51 High Q8NBJ4 Golgi membrane protein 1 OS=Homo 
sapiens OX=9606 GN=GOLM1 PE=1 
SV=1 
7 45.3 34.3 35.7 0.96 -0.059 
52 High Q9Y5Y7 Lymphatic vessel endothelial hyaluronic 
acid receptor 1 OS=Homo sapiens 
OX=9606 GN=LYVE1 PE=1 SV=2 
2 35.2 31.8 34.1 0.932 -0.102 
53 High P02774 Vitamin D-binding protein OS=Homo 
sapiens OX=9606 GN=GC PE=1 SV=1 
5 52.9 55.2 59.4 0.93 -0.105 
54 High Q96NY8 Nectin-4 OS=Homo sapiens OX=9606 
GN=NECTIN4 PE=1 SV=1 
3 55.4 51.7 57.3 0.903 -0.147 
55 High P05060 Secretogranin-1 OS=Homo sapiens 
OX=9606 GN=CHGB PE=1 SV=2 
2 78.2 28.1 31.2 0.902 -0.149 
56 High P01011 Alpha-1-antichymotrypsin OS=Homo 
sapiens OX=9606 GN=SERPINA3 PE=1 
SV=2 
6 47.6 34.2 38.6 0.884 -0.178 
57 High P01009 Alpha-1-antitrypsin OS=Homo sapiens 
OX=9606 GN=SERPINA1 PE=1 SV=3 
14 46.7 35.1 39.8 0.881 -0.183 
58 High P35527 Keratin, type I cytoskeletal 9 OS=Homo 
sapiens OX=9606 GN=KRT9 PE=1 SV=3 
5 62 44.4 51.6 0.86 -0.218 
59 High Q9BY67 Cell adhesion molecule 1 OS=Homo 
sapiens OX=9606 GN=CADM1 PE=1 
SV=2 
3 48.5 35.3 41.2 0.857 -0.223 
60 High P01591 Immunoglobulin J chain OS=Homo 2 18.1 38.4 45 0.854 -0.228 
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sapiens OX=9606 GN=JCHAIN PE=1 
SV=4 
61 High P04083 Annexin A1 OS=Homo sapiens OX=9606 
GN=ANXA1 PE=1 SV=2 
6 38.7 15.4 18 0.852 -0.231 
62 High P13645 Keratin, type I cytoskeletal 10 
OS=Homo sapiens OX=9606 GN=KRT10 
PE=1 SV=6 
14 58.8 57.4 67.6 0.85 -0.234 
63 High P01040 Cystatin-A OS=Homo sapiens OX=9606 
GN=CSTA PE=1 SV=1 
2 11 29.1 34.7 0.84 -0.252 
64 High P10451 Osteopontin OS=Homo sapiens 
OX=9606 GN=SPP1 PE=1 SV=1 
11 35.4 16.4 19.9 0.828 -0.272 
65 High P06702 Protein S100-A9 OS=Homo sapiens 
OX=9606 GN=S100A9 PE=1 SV=1 
7 13.2 44.8 55 0.814 -0.297 
66 High P01877 Immunoglobulin heavy constant alpha 
2 OS=Homo sapiens OX=9606 
GN=IGHA2 PE=1 SV=4 
3 36.6 53.4 66.9 0.799 -0.324 
67 High P06396 Gelsolin OS=Homo sapiens OX=9606 
GN=GSN PE=1 SV=1 
6 85.6 28.6 35.9 0.797 -0.327 
68 High Q6UXB8 Peptidase inhibitor 16 OS=Homo 
sapiens OX=9606 GN=PI16 PE=1 SV=1 
2 49.4 31.8 41.2 0.77 -0.377 
69 High P24855 Deoxyribonuclease-1 OS=Homo sapiens 
OX=9606 GN=DNASE1 PE=1 SV=1 
3 31.4 25.2 32.9 0.768 -0.381 
70 High P05543 Thyroxine-binding globulin OS=Homo 
sapiens OX=9606 GN=SERPINA7 PE=1 
SV=2 
6 46.3 35.3 46.3 0.761 -0.394 
71 High P11021 Endoplasmic reticulum chaperone BiP 
OS=Homo sapiens OX=9606 GN=HSPA5 
PE=1 SV=2 
5 72.3 39.6 52 0.761 -0.394 
72 High P01833 Polymeric immunoglobulin receptor 
OS=Homo sapiens OX=9606 GN=PIGR 
PE=1 SV=4 
7 83.2 34.5 46.2 0.748 -0.419 
73 High P02765 Alpha-2-HS-glycoprotein OS=Homo 3 39.3 34.6 46.3 0.747 -0.421 
196 
 
sapiens OX=9606 GN=AHSG PE=1 SV=1 
74 High P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens OX=9606 GN=KRT1 PE=1 SV=6 
17 66 59.2 79.4 0.746 -0.423 
75 High P50995 Annexin A11 OS=Homo sapiens 
OX=9606 GN=ANXA11 PE=1 SV=1 
3 54.4 41.9 56.6 0.741 -0.432 
76 High Q9UBG3 Cornulin OS=Homo sapiens OX=9606 
GN=CRNN PE=1 SV=1 
4 53.5 23.9 32.4 0.736 -0.442 
77 High P07355 Annexin A2 OS=Homo sapiens OX=9606 
GN=ANXA2 PE=1 SV=2 
8 38.6 30.9 42.8 0.722 -0.470 
78 High P15144 Aminopeptidase N OS=Homo sapiens 
OX=9606 GN=ANPEP PE=1 SV=4 
12 109.5 43.1 60.4 0.713 -0.488 
79 High P05109 Protein S100-A8 OS=Homo sapiens 
OX=9606 GN=S100A8 PE=1 SV=1 
5 10.8 44.2 63.7 0.694 -0.527 
80 High P34059 N-acetylgalactosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GALNS 
PE=1 SV=1 
2 58 22.3 32.4 0.686 -0.544 
81 High P02751 Fibronectin OS=Homo sapiens OX=9606 
GN=FN1 PE=1 SV=4 
11 262.5 41.1 60.2 0.683 -0.550 
82 High P98164 Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
OX=9606 GN=LRP2 PE=1 SV=3 
6 521.6 42.6 62.4 0.683 -0.550 
83 High Q6UVK1 Chondroitin sulfate proteoglycan 4 
OS=Homo sapiens OX=9606 GN=CSPG4 
PE=1 SV=2 
2 250.4 39.3 57.8 0.68 -0.556 
84 High P12830 Cadherin-1 OS=Homo sapiens OX=9606 
GN=CDH1 PE=1 SV=3 
8 97.4 25.1 37 0.679 -0.559 
85 High O60494 Cubilin OS=Homo sapiens OX=9606 
GN=CUBN PE=1 SV=5 
3 398.5 46.6 68.8 0.676 -0.565 
86 High O00187 Mannan-binding lectin serine protease 
2 OS=Homo sapiens OX=9606 
GN=MASP2 PE=1 SV=4 
3 75.7 19.5 29 0.673 -0.571 
87 High P13647 Keratin, type II cytoskeletal 5 OS=Homo 11 62.3 36.4 54.3 0.671 -0.576 
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sapiens OX=9606 GN=KRT5 PE=1 SV=3 
88 High P04746 Pancreatic alpha-amylase OS=Homo 
sapiens OX=9606 GN=AMY2A PE=1 
SV=2 
7 57.7 35.2 52.5 0.671 -0.576 
89 High P50895 Basal cell adhesion molecule OS=Homo 
sapiens OX=9606 GN=BCAM PE=1 SV=2 
3 67.4 16.4 25 0.655 -0.610 
90 High O00391 Sulfhydryl oxidase 1 OS=Homo sapiens 
OX=9606 GN=QSOX1 PE=1 SV=3 
5 82.5 23.1 35.6 0.648 -0.626 
91 High P05090 Apolipoprotein D OS=Homo sapiens 
OX=9606 GN=APOD PE=1 SV=1 
3 21.3 51.3 80.1 0.641 -0.642 
92 High P13473 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
OX=9606 GN=LAMP2 PE=1 SV=2 
2 44.9 28.7 44.9 0.64 -0.644 
93 High P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 OS=Homo 
sapiens OX=9606 GN=GNB1 PE=1 SV=3 
2 37.4 45.3 71.1 0.638 -0.648 
94 High P05154 Plasma serine protease inhibitor 
OS=Homo sapiens OX=9606 
GN=SERPINA5 PE=1 SV=3 
4 45.6 33.5 53.1 0.631 -0.664 
95 High P09603 Macrophage colony-stimulating factor 
1 OS=Homo sapiens OX=9606 GN=CSF1 
PE=1 SV=2 
4 60.1 21.9 35.2 0.622 -0.685 
96 High P15586 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GNS 
PE=1 SV=3 
3 62 39.9 64.4 0.619 -0.692 
97 High P78324 Tyrosine-protein phosphatase non-
receptor type substrate 1 OS=Homo 
sapiens OX=9606 GN=SIRPA PE=1 SV=2 
3 54.9 32.2 52.5 0.613 -0.706 
98 High P08779 Keratin, type I cytoskeletal 16 
OS=Homo sapiens OX=9606 GN=KRT16 
PE=1 SV=4 
6 51.2 23.1 37.8 0.611 -0.711 
99 High Q68CJ9 Cyclic AMP-responsive element-binding 2 49 28.4 46.6 0.608 -0.718 
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protein 3-like protein 3 OS=Homo 
sapiens OX=9606 GN=CREB3L3 PE=1 
SV=2 
100 High P02790 Hemopexin OS=Homo sapiens OX=9606 
GN=HPX PE=1 SV=2 
5 51.6 51.5 85.8 0.6 -0.737 
101 High A8K2U0 Alpha-2-macroglobulin-like protein 1 
OS=Homo sapiens OX=9606 GN=A2ML1 
PE=1 SV=3 
6 161 32.6 54.6 0.597 -0.744 
102 High P06870 Kallikrein-1 OS=Homo sapiens OX=9606 
GN=KLK1 PE=1 SV=2 
3 28.9 37.5 62.9 0.597 -0.744 
103 High P62736 Actin, aortic smooth muscle OS=Homo 
sapiens OX=9606 GN=ACTA2 PE=1 SV=1 
5 42 23.1 38.8 0.595 -0.749 
104 High P26992 Ciliary neurotrophic factor receptor 
subunit alpha OS=Homo sapiens 
OX=9606 GN=CNTFR PE=1 SV=2 
2 40.6 35.4 60.4 0.587 -0.769 
105 High P07339 Cathepsin D OS=Homo sapiens 
OX=9606 GN=CTSD PE=1 SV=1 
6 44.5 41.7 71.9 0.58 -0.786 
106 High Q01459 Di-N-acetylchitobiase OS=Homo 
sapiens OX=9606 GN=CTBS PE=1 SV=1 
2 43.7 23.2 40.3 0.576 -0.796 
107 High P08571 Monocyte differentiation antigen CD14 
OS=Homo sapiens OX=9606 GN=CD14 
PE=1 SV=2 
4 40.1 25.4 44.2 0.574 -0.801 
108 High Q14624 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens OX=9606 
GN=ITIH4 PE=1 SV=4 
4 103.3 22.7 39.6 0.573 -0.803 
109 High P0C0L5 Complement C4-B OS=Homo sapiens 
OX=9606 GN=C4B PE=1 SV=2 
3 192.6 31.4 54.8 0.573 -0.803 
110 High P07911 Uromodulin OS=Homo sapiens 
OX=9606 GN=UMOD PE=1 SV=1 
7 69.7 31.5 56.8 0.555 -0.849 
111 High Q9UQ72 Pregnancy-specific beta-1-glycoprotein 
11 OS=Homo sapiens OX=9606 
GN=PSG11 PE=2 SV=3 
7 37.1 28.3 51.1 0.553 -0.855 
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112 High P10909 Clusterin OS=Homo sapiens OX=9606 
GN=CLU PE=1 SV=1 
4 52.5 34.7 62.7 0.553 -0.855 
113 High P19835 Bile salt-activated lipase OS=Homo 
sapiens OX=9606 GN=CEL PE=1 SV=3 
3 79.3 35.2 63.7 0.553 -0.855 
114 High P05155 Plasma protease C1 inhibitor OS=Homo 
sapiens OX=9606 GN=SERPING1 PE=1 
SV=2 
6 55.1 30.4 55.5 0.547 -0.870 
115 High Q9UBC9 Small proline-rich protein 3 OS=Homo 
sapiens OX=9606 GN=SPRR3 PE=1 SV=2 
5 18.1 27.5 50.3 0.546 -0.873 
116 High Q9NZP8 Complement C1r subcomponent-like 
protein OS=Homo sapiens OX=9606 
GN=C1RL PE=1 SV=2 
3 53.5 30.1 55.7 0.541 -0.886 
117 High P02760 Protein AMBP OS=Homo sapiens 
OX=9606 GN=AMBP PE=1 SV=1 
5 39 28.1 52.5 0.535 -0.902 
118 High P12109 Collagen alpha-1(VI) chain OS=Homo 
sapiens OX=9606 GN=COL6A1 PE=1 
SV=3 
10 108.5 33.8 63.3 0.534 -0.905 
119 High Q13510 Acid ceramidase OS=Homo sapiens 
OX=9606 GN=ASAH1 PE=1 SV=5 
3 44.6 41.2 77.4 0.532 -0.911 
120 High Q08380 Galectin-3-binding protein OS=Homo 
sapiens OX=9606 GN=LGALS3BP PE=1 
SV=1 
10 65.3 30.5 57.9 0.526 -0.927 
121 High P01042 Kininogen-1 OS=Homo sapiens 
OX=9606 GN=KNG1 PE=1 SV=2 
6 71.9 34.8 67.7 0.514 -0.960 
122 High O43451 Maltase-glucoamylase, intestinal 
OS=Homo sapiens OX=9606 
GN=MGAM PE=1 SV=5 
4 209.7 39.1 77.4 0.505 -0.986 
123 High Q8NFZ8 Cell adhesion molecule 4 OS=Homo 
sapiens OX=9606 GN=CADM4 PE=1 
SV=1 
2 42.8 36.8 72.9 0.504 -0.989 
124 High Q9BRK3 Matrix remodeling-associated protein 8 
OS=Homo sapiens OX=9606 
4 49.1 26.6 52.9 0.503 -0.991 
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GN=MXRA8 PE=1 SV=1 
125 High P09668 Pro-cathepsin H OS=Homo sapiens 
OX=9606 GN=CTSH PE=1 SV=4 
2 37.4 25.9 51.5 0.502 -0.994 
126 High P04259 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens OX=9606 GN=KRT6B 
PE=1 SV=5 
20 60 24.7 51 0.484 -1.047 
127 High P11464 Pregnancy-specific beta-1-glycoprotein 
1 OS=Homo sapiens OX=9606 GN=PSG1 
PE=1 SV=1 
4 47.2 29.3 60.8 0.482 -1.053 
128 High P39059 Collagen alpha-1(XV) chain OS=Homo 
sapiens OX=9606 GN=COL15A1 PE=1 
SV=2 
2 141.6 44.7 94.2 0.475 -1.074 
129 High Q16270 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens OX=9606 
GN=IGFBP7 PE=1 SV=1 
3 29.1 23 48.6 0.473 -1.080 
130 High P15289 Arylsulfatase A OS=Homo sapiens 
OX=9606 GN=ARSA PE=1 SV=3 
6 53.6 27.8 59 0.471 -1.086 
131 High P19440 Glutathione hydrolase 1 proenzyme 
OS=Homo sapiens OX=9606 GN=GGT1 
PE=1 SV=2 
2 61.4 20.5 43.6 0.471 -1.086 
132 High P31944 Caspase-14 OS=Homo sapiens OX=9606 
GN=CASP14 PE=1 SV=2 
2 27.7 19.9 42.7 0.465 -1.105 
133 High P43121 Cell surface glycoprotein MUC18 
OS=Homo sapiens OX=9606 GN=MCAM 
PE=1 SV=2 
3 71.6 28.2 60.9 0.462 -1.114 
134 High P30086 Phosphatidylethanolamine-binding 
protein 1 OS=Homo sapiens OX=9606 
GN=PEBP1 PE=1 SV=3 
3 21 31.7 68.9 0.461 -1.117 
135 High P16070 CD44 antigen OS=Homo sapiens 
OX=9606 GN=CD44 PE=1 SV=3 
3 81.5 43.9 95.9 0.458 -1.127 
136 High Q12907 Vesicular integral-membrane protein 
VIP36 OS=Homo sapiens OX=9606 
3 40.2 20.1 43.9 0.458 -1.127 
201 
 
GN=LMAN2 PE=1 SV=1 
137 High Q8TDQ0 Hepatitis A virus cellular receptor 2 
OS=Homo sapiens OX=9606 
GN=HAVCR2 PE=1 SV=3 
2 33.4 26.2 57.9 0.453 -1.142 
138 High P14384 Carboxypeptidase M OS=Homo sapiens 
OX=9606 GN=CPM PE=1 SV=2 
2 50.5 28.9 65.3 0.443 -1.175 
139 High P19013 Keratin, type II cytoskeletal 4 OS=Homo 
sapiens OX=9606 GN=KRT4 PE=1 SV=4 
12 57.3 22.7 52.9 0.43 -1.218 
140 High P29508 Serpin B3 OS=Homo sapiens OX=9606 
GN=SERPINB3 PE=1 SV=2 
6 44.5 18 42.6 0.421 -1.248 
141 High P15941 Mucin-1 OS=Homo sapiens OX=9606 
GN=MUC1 PE=1 SV=3 
3 122 31.1 74 0.42 -1.252 
142 High Q92820 Gamma-glutamyl hydrolase OS=Homo 
sapiens OX=9606 GN=GGH PE=1 SV=2 
3 35.9 29.9 73.5 0.407 -1.297 
143 High P55290 Cadherin-13 OS=Homo sapiens 
OX=9606 GN=CDH13 PE=1 SV=1 
3 78.2 25.5 63.2 0.404 -1.308 
144 High Q7KYR7 Butyrophilin subfamily 2 member A1 
OS=Homo sapiens OX=9606 
GN=BTN2A1 PE=1 SV=3 
3 59.6 29.5 74 0.399 -1.326 
145 High Q9NQ84 G-protein coupled receptor family C 
group 5 member C OS=Homo sapiens 
OX=9606 GN=GPRC5C PE=1 SV=2 
2 48.2 25.7 64.9 0.396 -1.336 
146 High Q16651 Prostasin OS=Homo sapiens OX=9606 
GN=PRSS8 PE=1 SV=1 
2 36.4 18.7 47.7 0.392 -1.351 
147 High P01008 Antithrombin-III OS=Homo sapiens 
OX=9606 GN=SERPINC1 PE=1 SV=1 
4 52.6 22.7 58.1 0.391 -1.355 
148 High P63104 14-3-3 protein zeta/delta OS=Homo 
sapiens OX=9606 GN=YWHAZ PE=1 
SV=1 
5 27.7 39.8 102.8 0.388 -1.366 
149 High P13646 Keratin, type I cytoskeletal 13 
OS=Homo sapiens OX=9606 GN=KRT13 
PE=1 SV=4 
18 49.6 19.4 50.3 0.386 -1.373 
202 
 
150 High P01133 Pro-epidermal growth factor OS=Homo 
sapiens OX=9606 GN=EGF PE=1 SV=2 
11 133.9 24.3 63.2 0.385 -1.377 
151 High P27482 Calmodulin-like protein 3 OS=Homo 
sapiens OX=9606 GN=CALML3 PE=1 
SV=2 
4 16.9 16.8 43.8 0.383 -1.385 
152 High P98160 Basement membrane-specific heparan 
sulfate proteoglycan core protein 
OS=Homo sapiens OX=9606 GN=HSPG2 
PE=1 SV=4 
12 468.5 29.9 79.5 0.376 -1.411 
153 High P62979 Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens OX=9606 
GN=RPS27A PE=1 SV=2 
3 18 24.3 65 0.373 -1.423 
154 High Q99988 Growth/differentiation factor 15 
OS=Homo sapiens OX=9606 GN=GDF15 
PE=1 SV=3 
3 34.1 26.8 72.5 0.37 -1.434 
155 High P10153 Non-secretory ribonuclease OS=Homo 
sapiens OX=9606 GN=RNASE2 PE=1 
SV=2 
2 18.3 28.6 77.3 0.37 -1.434 
156 High P08637 Low affinity immunoglobulin gamma Fc 
region receptor III-A OS=Homo sapiens 
OX=9606 GN=FCGR3A PE=1 SV=2 
2 29.1 12.4 34 0.364 -1.458 
157 High P54802 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens OX=9606 
GN=NAGLU PE=1 SV=2 
5 82.2 22.1 63.5 0.348 -1.523 
158 High P05937 Calbindin OS=Homo sapiens OX=9606 
GN=CALB1 PE=1 SV=2 
3 30 25.3 72.8 0.347 -1.527 
159 High O75882 Attractin OS=Homo sapiens OX=9606 
GN=ATRN PE=1 SV=2 
4 158.4 20.7 61.2 0.338 -1.565 
160 High O94919 Endonuclease domain-containing 1 
protein OS=Homo sapiens OX=9606 
GN=ENDOD1 PE=1 SV=2 
3 55 19.1 57.6 0.332 -1.591 
161 High P02538 Keratin, type II cytoskeletal 6A 19 60 14.8 49.7 0.297 -1.751 
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OS=Homo sapiens OX=9606 GN=KRT6A 
PE=1 SV=3 
162 High P01861 Immunoglobulin heavy constant 
gamma 4 OS=Homo sapiens OX=9606 
GN=IGHG4 PE=1 SV=1 
3 35.9 25 85.1 0.293 -1.771 
163 High P05062 Fructose-bisphosphate aldolase B 
OS=Homo sapiens OX=9606 GN=ALDOB 
PE=1 SV=2 
2 39.4 25.7 89.4 0.287 -1.801 
164 High Q03154 Aminoacylase-1 OS=Homo sapiens 
OX=9606 GN=ACY1 PE=1 SV=1 
2 45.9 21.1 76.3 0.277 -1.852 
165 High Q6EMK4 Vasorin OS=Homo sapiens OX=9606 
GN=VASN PE=1 SV=1 
5 71.7 19.5 70.6 0.276 -1.857 
166 High Q06830 Peroxiredoxin-1 OS=Homo sapiens 
OX=9606 GN=PRDX1 PE=1 SV=1 
2 22.1 19 69.2 0.274 -1.868 
167 High P10253 Lysosomal alpha-glucosidase OS=Homo 
sapiens OX=9606 GN=GAA PE=1 SV=4 
4 105.3 14.5 60.5 0.24 -2.059 
168 High Q9Y646 Carboxypeptidase Q OS=Homo sapiens 
OX=9606 GN=CPQ PE=1 SV=1 
2 51.9 16.4 79 0.208 -2.265 
169 High Q9P121 Neurotrimin OS=Homo sapiens 
OX=9606 GN=NTM PE=1 SV=1 
2 37.9 13.5 72.9 0.184 -2.442 
170 High P07195 L-lactate dehydrogenase B chain 
OS=Homo sapiens OX=9606 GN=LDHB 
PE=1 SV=2 
2 36.6 13 79.8 0.163 -2.617 
171 High Q8WZ75 Roundabout homolog 4 OS=Homo 
sapiens OX=9606 GN=ROBO4 PE=1 
SV=1 
2 107.4 7.8 71.6 0.109 -3.198 
172 High Q9HCU0 Endosialin OS=Homo sapiens OX=9606 
GN=CD248 PE=1 SV=1 
2 80.8 3.3 38 0.086 -3.540 
173 High Q07075 Glutamyl aminopeptidase OS=Homo 
sapiens OX=9606 GN=ENPEP PE=1 SV=3 
3 109.2 1.7 28.2 0.059 -4.083 
Data identified at confidence interval (CI): 99 %, FDR < 0.01; Peptides no. ≥ 2. 
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Table S 2: Dataset of protein expression for PE and control at 20 weeks gestation 
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
 Protein name  # Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of PE at 
20 W 
Abundances 
of reporter 
ion of 
control at 
20 W 
Abundance 
ratio (Case 
/ Control) 
of PE at 20 
W 
Log 2 
fold 
change  
1 High P02675 Fibrinogen beta chain OS=Homo 
sapiens OX=9606 GN=FGB PE=1 SV=2 
2 55.9 167.3 22.2 7.526 2.912 
2 High P00738 Haptoglobin OS=Homo sapiens 
OX=9606 GN=HP PE=1 SV=1 
4 45.2 183.4 48 3.823 1.935 
3 High P02787 Serotransferrin OS=Homo sapiens 
OX=9606 GN=TF PE=1 SV=3 
12 77 179.2 61.4 2.919 1.545 
4 High P01861 Immunoglobulin heavy constant 
gamma 4 OS=Homo sapiens OX=9606 
GN=IGHG4 PE=1 SV=1 
3 35.9 201.1 75.1 2.677 1.421 
5 High P01877 Immunoglobulin heavy constant alpha 
2 OS=Homo sapiens OX=9606 
GN=IGHA2 PE=1 SV=4 
3 36.6 203 78.6 2.582 1.368 
6 High P00450 Ceruloplasmin OS=Homo sapiens 
OX=9606 GN=CP PE=1 SV=1 
13 122.1 227.8 88.8 2.564 1.358 
7 High P01859 Immunoglobulin heavy constant 
gamma 2 OS=Homo sapiens OX=9606 
GN=IGHG2 PE=1 SV=2 
4 35.9 179.4 71.7 2.502 1.323 
8 High P13796 Plastin-2 OS=Homo sapiens OX=9606 
GN=LCP1 PE=1 SV=6 
4 70.2 105.6 45.6 2.316 1.212 
9 High P04217 Alpha-1B-glycoprotein OS=Homo 
sapiens OX=9606 GN=A1BG PE=1 SV=4 
3 54.2 223 96.3 2.316 1.212 
10 High P01023 Alpha-2-macroglobulin OS=Homo 
sapiens OX=9606 GN=A2M PE=1 SV=3 
2 163.2 128.1 55.4 2.312 1.209 
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11 High P01009 Alpha-1-antitrypsin OS=Homo sapiens 
OX=9606 GN=SERPINA1 PE=1 SV=3 
14 46.7 213 95 2.242 1.165 
12 High P11021 Endoplasmic reticulum chaperone BiP 
OS=Homo sapiens OX=9606 GN=HSPA5 
PE=1 SV=2 
5 72.3 115.5 54.5 2.119 1.083 
13 High Q6GTX8 Leukocyte-associated immunoglobulin-
like receptor 1 OS=Homo sapiens 
OX=9606 GN=LAIR1 PE=1 SV=1 
2 31.4 158 77.9 2.029 1.021 
14 High P02768 Serum albumin OS=Homo sapiens 
OX=9606 GN=ALB PE=1 SV=2 
19 69.3 154.6 76.4 2.025 1.018 
15 High P02750 Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens OX=9606 GN=LRG1 
PE=1 SV=2 
5 38.2 165 81.5 2.024 1.017 
16 High Q93088 Betaine--homocysteine S-
methyltransferase 1 OS=Homo sapiens 
OX=9606 GN=BHMT PE=1 SV=2 
3 45 159.1 79.5 2.002 1.001 
17 High P18510 Interleukin-1 receptor antagonist 
protein OS=Homo sapiens OX=9606 
GN=IL1RN PE=1 SV=1 
2 20 171.5 85.8 1.998 0.999 
18 High P01614 Immunoglobulin kappa variable 2D-40 
OS=Homo sapiens OX=9606 
GN=IGKV2D-40 PE=1 SV=2 
2 13.3 154.7 80.1 1.932 0.950 
19 High P04746 Pancreatic alpha-amylase OS=Homo 
sapiens OX=9606 GN=AMY2A PE=1 
SV=2 
7 57.7 175.7 93.5 1.88 0.911 
20 High P07476 Involucrin OS=Homo sapiens OX=9606 
GN=IVL PE=1 SV=2 
9 68.4 203.7 110 1.851 0.888 
21 High P0DOY2 Immunoglobulin lambda constant 2 
OS=Homo sapiens OX=9606 GN=IGLC2 
PE=1 SV=1 
3 11.3 167 90.7 1.841 0.880 
22 High P41222 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens OX=9606 GN=PTGDS 
3 21 190.8 105 1.817 0.862 
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PE=1 SV=1 
23 High P01876 Immunoglobulin heavy constant alpha 
1 OS=Homo sapiens OX=9606 
GN=IGHA1 PE=1 SV=2 
5 37.6 160.3 90.3 1.774 0.827 
24 High P04083 Annexin A1 OS=Homo sapiens OX=9606 
GN=ANXA1 PE=1 SV=2 
6 38.7 259.2 146.8 1.765 0.820 
25 High P08185 Corticosteroid-binding globulin 
OS=Homo sapiens OX=9606 
GN=SERPINA6 PE=1 SV=1 
3 45.1 171.9 100.2 1.715 0.778 
26 High Q02487 Desmocollin-2 OS=Homo sapiens 
OX=9606 GN=DSC2 PE=1 SV=1 
3 99.9 188.4 114 1.653 0.725 
27 High P01871 Immunoglobulin heavy constant mu 
OS=Homo sapiens OX=9606 GN=IGHM 
PE=1 SV=4 
2 49.4 206.5 126.9 1.628 0.703 
28 High P05060 Secretogranin-1 OS=Homo sapiens 
OX=9606 GN=CHGB PE=1 SV=2 
2 78.2 168.4 103.9 1.62 0.696 
29 High P01011 Alpha-1-antichymotrypsin OS=Homo 
sapiens OX=9606 GN=SERPINA3 PE=1 
SV=2 
6 47.6 178 110.1 1.617 0.693 
30 High P25815 Protein S100-P OS=Homo sapiens 
OX=9606 GN=S100P PE=1 SV=2 
2 10.4 110.6 68.5 1.613 0.690 
31 High P01019 Angiotensinogen OS=Homo sapiens 
OX=9606 GN=AGT PE=1 SV=1 
2 53.1 145.2 95.3 1.523 0.607 
32 High P01591 Immunoglobulin J chain OS=Homo 
sapiens OX=9606 GN=JCHAIN PE=1 
SV=4 
2 18.1 157.7 104.4 1.51 0.595 
33 High P06733 Alpha-enolase OS=Homo sapiens 
OX=9606 GN=ENO1 PE=1 SV=2 
4 47.1 141.1 93.8 1.505 0.590 
34 High P11142 Heat shock cognate 71 kDa protein 
OS=Homo sapiens OX=9606 GN=HSPA8 
PE=1 SV=1 
9 70.9 138.1 92.1 1.5 0.585 
35 High P29508 Serpin B3 OS=Homo sapiens OX=9606 6 44.5 153.3 103.3 1.483 0.569 
207 
 
GN=SERPINB3 PE=1 SV=2 
36 High Q9HCU0 Endosialin OS=Homo sapiens OX=9606 
GN=CD248 PE=1 SV=1 
2 80.8 221.1 150.3 1.471 0.557 
37 High B9A064 Immunoglobulin lambda-like 
polypeptide 5 OS=Homo sapiens 
OX=9606 GN=IGLL5 PE=2 SV=2 
3 23 152.2 105.2 1.446 0.532 
38 High P15144 Aminopeptidase N OS=Homo sapiens 
OX=9606 GN=ANPEP PE=1 SV=4 
12 109.5 150.6 104.9 1.436 0.522 
39 High P25311 Zinc-alpha-2-glycoprotein OS=Homo 
sapiens OX=9606 GN=AZGP1 PE=1 SV=2 
13 34.2 123.9 86.8 1.428 0.514 
40 High P50995 Annexin A11 OS=Homo sapiens 
OX=9606 GN=ANXA11 PE=1 SV=1 
3 54.4 112 78.7 1.423 0.509 
41 High Q96NY8 Nectin-4 OS=Homo sapiens OX=9606 
GN=NECTIN4 PE=1 SV=1 
3 55.4 139.2 98 1.421 0.507 
42 High Q13510 Acid ceramidase OS=Homo sapiens 
OX=9606 GN=ASAH1 PE=1 SV=5 
3 44.6 152.9 108.2 1.414 0.500 
43 High P04075 Fructose-bisphosphate aldolase A 
OS=Homo sapiens OX=9606 GN=ALDOA 
PE=1 SV=2 
2 39.4 107.1 76.1 1.406 0.492 
44 High P10599 Thioredoxin OS=Homo sapiens 
OX=9606 GN=TXN PE=1 SV=3 
3 11.7 138.9 99.7 1.393 0.478 
45 High P05090 Apolipoprotein D OS=Homo sapiens 
OX=9606 GN=APOD PE=1 SV=1 
3 21.3 143.8 103.3 1.392 0.477 
46 High P01834 Immunoglobulin kappa constant 
OS=Homo sapiens OX=9606 GN=IGKC 
PE=1 SV=2 
3 11.8 147.7 107 1.381 0.466 
47 High P06703 Protein S100-A6 OS=Homo sapiens 
OX=9606 GN=S100A6 PE=1 SV=1 
3 10.2 119.2 86.4 1.379 0.464 
48 High O00187 Mannan-binding lectin serine protease 
2 OS=Homo sapiens OX=9606 
GN=MASP2 PE=1 SV=4 
3 75.7 183.8 133.3 1.378 0.463 
49 High P01833 Polymeric immunoglobulin receptor 7 83.2 146.3 109.9 1.331 0.413 
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OS=Homo sapiens OX=9606 GN=PIGR 
PE=1 SV=4 
50 High P05937 Calbindin OS=Homo sapiens OX=9606 
GN=CALB1 PE=1 SV=2 
3 30 116.2 87.9 1.323 0.404 
51 High P01857 Immunoglobulin heavy constant 
gamma 1 OS=Homo sapiens OX=9606 
GN=IGHG1 PE=1 SV=1 
7 36.1 124.1 94.2 1.317 0.397 
52 High P05543 Thyroxine-binding globulin OS=Homo 
sapiens OX=9606 GN=SERPINA7 PE=1 
SV=2 
6 46.3 159 121.5 1.309 0.388 
53 High Q07075 Glutamyl aminopeptidase OS=Homo 
sapiens OX=9606 GN=ENPEP PE=1 SV=3 
3 109.2 195.5 150.5 1.299 0.377 
54 High P07339 Cathepsin D OS=Homo sapiens 
OX=9606 GN=CTSD PE=1 SV=1 
6 44.5 126.9 100.4 1.264 0.338 
55 High P11464 Pregnancy-specific beta-1-glycoprotein 
1 OS=Homo sapiens OX=9606 GN=PSG1 
PE=1 SV=1 
4 47.2 162.3 130 1.249 0.321 
56 High Q7KYR7 Butyrophilin subfamily 2 member A1 
OS=Homo sapiens OX=9606 
GN=BTN2A1 PE=1 SV=3 
3 59.6 125.3 100.4 1.248 0.320 
57 High Q6EMK4 Vasorin OS=Homo sapiens OX=9606 
GN=VASN PE=1 SV=1 
5 71.7 125.6 101.2 1.241 0.312 
58 High P05155 Plasma protease C1 inhibitor OS=Homo 
sapiens OX=9606 GN=SERPING1 PE=1 
SV=2 
6 55.1 143.2 115.5 1.24 0.310 
59 High P10153 Non-secretory ribonuclease OS=Homo 
sapiens OX=9606 GN=RNASE2 PE=1 
SV=2 
2 18.3 113.4 91.4 1.24 0.310 
60 High Q8TDQ0 Hepatitis A virus cellular receptor 2 
OS=Homo sapiens OX=9606 
GN=HAVCR2 PE=1 SV=3 
2 33.4 128.7 104.2 1.235 0.305 
61 High Q9UQ72 Pregnancy-specific beta-1-glycoprotein 7 37.1 162.2 133 1.219 0.286 
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11 OS=Homo sapiens OX=9606 
GN=PSG11 PE=2 SV=3 
62 High Q9Y5Y7 Lymphatic vessel endothelial 
hyaluronic acid receptor 1 OS=Homo 
sapiens OX=9606 GN=LYVE1 PE=1 SV=2 
2 35.2 173.5 142.5 1.218 0.285 
63 High P19652 Alpha-1-acid glycoprotein 2 OS=Homo 
sapiens OX=9606 GN=ORM2 PE=1 SV=2 
2 23.6 142.9 117.4 1.217 0.283 
64 High Q08345 Epithelial discoidin domain-containing 
receptor 1 OS=Homo sapiens OX=9606 
GN=DDR1 PE=1 SV=1 
4 101.1 115.5 95.1 1.215 0.281 
65 High P35527 Keratin, type I cytoskeletal 9 OS=Homo 
sapiens OX=9606 GN=KRT9 PE=1 SV=3 
5 62 116.5 96.7 1.205 0.269 
66 High P02760 Protein AMBP OS=Homo sapiens 
OX=9606 GN=AMBP PE=1 SV=1 
5 39 146.2 121.7 1.201 0.264 
67 High O43451 Maltase-glucoamylase, intestinal 
OS=Homo sapiens OX=9606 
GN=MGAM PE=1 SV=5 
4 209.7 110.3 91.9 1.199 0.262 
68 High Q9UBC9 Small proline-rich protein 3 OS=Homo 
sapiens OX=9606 GN=SPRR3 PE=1 SV=2 
5 18.1 129.4 108 1.198 0.261 
69 High P98164 Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
OX=9606 GN=LRP2 PE=1 SV=3 
6 521.6 131.4 110.2 1.193 0.255 
70 High Q8NBJ4 Golgi membrane protein 1 OS=Homo 
sapiens OX=9606 GN=GOLM1 PE=1 
SV=1 
7 45.3 130.9 110.5 1.184 0.244 
71 High P02774 Vitamin D-binding protein OS=Homo 
sapiens OX=9606 GN=GC PE=1 SV=1 
5 52.9 120.9 102.6 1.178 0.236 
72 High P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
OX=9606 GN=ACTB PE=1 SV=1 
6 41.7 119.1 101.8 1.17 0.227 
73 High P55290 Cadherin-13 OS=Homo sapiens 
OX=9606 GN=CDH13 PE=1 SV=1 
3 78.2 147.3 126.3 1.166 0.222 
74 High Q9NZP8 Complement C1r subcomponent-like 3 53.5 115.9 99.7 1.162 0.217 
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protein OS=Homo sapiens OX=9606 
GN=C1RL PE=1 SV=2 
75 High P02763 Alpha-1-acid glycoprotein 1 OS=Homo 
sapiens OX=9606 GN=ORM1 PE=1 SV=1 
3 23.5 135.4 117.3 1.154 0.207 
76 High Q99988 Growth/differentiation factor 15 
OS=Homo sapiens OX=9606 GN=GDF15 
PE=1 SV=3 
3 34.1 98.5 85.5 1.153 0.205 
77 High A8K2U0 Alpha-2-macroglobulin-like protein 1 
OS=Homo sapiens OX=9606 GN=A2ML1 
PE=1 SV=3 
6 161 132.8 116 1.145 0.195 
78 High P02538 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens OX=9606 GN=KRT6A 
PE=1 SV=3 
19 60 97.4 85.4 1.139 0.188 
79 High P10909 Clusterin OS=Homo sapiens OX=9606 
GN=CLU PE=1 SV=1 
4 52.5 118.7 104.7 1.134 0.181 
80 High Q14515 SPARC-like protein 1 OS=Homo sapiens 
OX=9606 GN=SPARCL1 PE=1 SV=2 
4 75.2 134.4 118.8 1.132 0.179 
81 High Q03154 Aminoacylase-1 OS=Homo sapiens 
OX=9606 GN=ACY1 PE=1 SV=1 
2 45.9 120.8 106.8 1.131 0.178 
82 High Q6UXB8 Peptidase inhibitor 16 OS=Homo 
sapiens OX=9606 GN=PI16 PE=1 SV=1 
2 49.4 143.5 127.4 1.126 0.171 
83 High Q12907 Vesicular integral-membrane protein 
VIP36 OS=Homo sapiens OX=9606 
GN=LMAN2 PE=1 SV=1 
3 40.2 144.8 128.7 1.124 0.169 
84 High P24855 Deoxyribonuclease-1 OS=Homo sapiens 
OX=9606 GN=DNASE1 PE=1 SV=1 
3 31.4 116.4 105.2 1.107 0.147 
85 High P01040 Cystatin-A OS=Homo sapiens OX=9606 
GN=CSTA PE=1 SV=1 
2 11 130 118.3 1.099 0.136 
86 High P02788 Lactotransferrin OS=Homo sapiens 
OX=9606 GN=LTF PE=1 SV=6 
3 78.1 66.6 62.4 1.067 0.094 
87 High P08779 Keratin, type I cytoskeletal 16 
OS=Homo sapiens OX=9606 GN=KRT16 
6 51.2 120 112.8 1.064 0.089 
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PE=1 SV=4 
88 High P19440 Glutathione hydrolase 1 proenzyme 
OS=Homo sapiens OX=9606 GN=GGT1 
PE=1 SV=2 
2 61.4 130.6 122.7 1.064 0.089 
89 High P09603 Macrophage colony-stimulating factor 
1 OS=Homo sapiens OX=9606 GN=CSF1 
PE=1 SV=2 
4 60.1 127.2 119.9 1.061 0.085 
90 High P12109 Collagen alpha-1(VI) chain OS=Homo 
sapiens OX=9606 GN=COL6A1 PE=1 
SV=3 
10 108.5 124.2 117.2 1.06 0.084 
91 High P08571 Monocyte differentiation antigen CD14 
OS=Homo sapiens OX=9606 GN=CD14 
PE=1 SV=2 
4 40.1 145.7 137.6 1.059 0.083 
92 High P09668 Pro-cathepsin H OS=Homo sapiens 
OX=9606 GN=CTSH PE=1 SV=4 
2 37.4 132.1 124.7 1.059 0.083 
93 High Q9ULI3 Protein HEG homolog 1 OS=Homo 
sapiens OX=9606 GN=HEG1 PE=1 SV=3 
3 147.4 142.6 135.5 1.053 0.075 
94 High P54802 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens OX=9606 
GN=NAGLU PE=1 SV=2 
5 82.2 144.4 137.6 1.049 0.069 
95 High Q6UVK1 Chondroitin sulfate proteoglycan 4 
OS=Homo sapiens OX=9606 GN=CSPG4 
PE=1 SV=2 
2 250.4 130.5 124.9 1.045 0.064 
96 High O94919 Endonuclease domain-containing 1 
protein OS=Homo sapiens OX=9606 
GN=ENDOD1 PE=1 SV=2 
3 55 125.1 120 1.043 0.061 
97 High P14384 Carboxypeptidase M OS=Homo sapiens 
OX=9606 GN=CPM PE=1 SV=2 
2 50.5 102 97.9 1.042 0.059 
98 High Q16651 Prostasin OS=Homo sapiens OX=9606 
GN=PRSS8 PE=1 SV=1 
2 36.4 116.9 112.7 1.037 0.052 
99 High P60174 Triosephosphate isomerase OS=Homo 
sapiens OX=9606 GN=TPI1 PE=1 SV=3 
2 30.8 121.7 119 1.023 0.033 
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100 High Q9BY67 Cell adhesion molecule 1 OS=Homo 
sapiens OX=9606 GN=CADM1 PE=1 
SV=2 
3 48.5 130.1 128.5 1.013 0.019 
101 High Q9UBG3 Cornulin OS=Homo sapiens OX=9606 
GN=CRNN PE=1 SV=1 
4 53.5 120.5 119.7 1.007 0.010 
102 High P01008 Antithrombin-III OS=Homo sapiens 
OX=9606 GN=SERPINC1 PE=1 SV=1 
4 52.6 114.9 114.1 1.007 0.010 
103 High P34059 N-acetylgalactosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GALNS 
PE=1 SV=1 
2 58 118.4 117.7 1.006 0.009 
104 High P06396 Gelsolin OS=Homo sapiens OX=9606 
GN=GSN PE=1 SV=1 
6 85.6 153.9 153.5 1.003 0.004 
105 High P00924 Enolase 1 OS=Saccharomyces 
cerevisiae (strain ATCC 204508 / S288c) 
GN=ENO1 PE=1 SV=3 
14 46.8 100 100 1 0.000 
106 High P39059 Collagen alpha-1(XV) chain OS=Homo 
sapiens OX=9606 GN=COL15A1 PE=1 
SV=2 
2 141.6 112.8 114.2 0.988 -0.017 
107 High P01042 Kininogen-1 OS=Homo sapiens 
OX=9606 GN=KNG1 PE=1 SV=2 
6 71.9 108.9 111.2 0.98 -0.029 
108 High P05164 Myeloperoxidase OS=Homo sapiens 
OX=9606 GN=MPO PE=1 SV=1 
3 83.8 94.6 96.7 0.978 -0.032 
109 High Q8IYS5 Osteoclast-associated immunoglobulin-
like receptor OS=Homo sapiens 
OX=9606 GN=OSCAR PE=1 SV=3 
2 30.5 110.3 114.5 0.963 -0.054 
110 High P04259 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens OX=9606 GN=KRT6B 
PE=1 SV=5 
20 60 100 104.1 0.96 -0.059 
111 High O00391 Sulfhydryl oxidase 1 OS=Homo sapiens 
OX=9606 GN=QSOX1 PE=1 SV=3 
5 82.5 119.1 124.9 0.954 -0.068 
112 High Q68CJ9 Cyclic AMP-responsive element-binding 
protein 3-like protein 3 OS=Homo 
2 49 114.2 120.4 0.949 -0.076 
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sapiens OX=9606 GN=CREB3L3 PE=1 
SV=2 
113 High P02751 Fibronectin OS=Homo sapiens OX=9606 
GN=FN1 PE=1 SV=4 
11 262.5 112.3 119.5 0.94 -0.089 
114 High Q06830 Peroxiredoxin-1 OS=Homo sapiens 
OX=9606 GN=PRDX1 PE=1 SV=1 
2 22.1 117.6 125.4 0.938 -0.092 
115 High P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 OS=Homo 
sapiens OX=9606 GN=GNB1 PE=1 SV=3 
2 37.4 109.2 116.7 0.936 -0.095 
116 High P12830 Cadherin-1 OS=Homo sapiens OX=9606 
GN=CDH1 PE=1 SV=3 
8 97.4 135.5 144.9 0.935 -0.097 
117 High P02765 Alpha-2-HS-glycoprotein OS=Homo 
sapiens OX=9606 GN=AHSG PE=1 SV=1 
3 39.3 161.4 173 0.933 -0.100 
118 High P43121 Cell surface glycoprotein MUC18 
OS=Homo sapiens OX=9606 GN=MCAM 
PE=1 SV=2 
3 71.6 109.5 119.1 0.919 -0.122 
119 High P15289 Arylsulfatase A OS=Homo sapiens 
OX=9606 GN=ARSA PE=1 SV=3 
6 53.6 118.2 128.9 0.917 -0.125 
120 High P10451 Osteopontin OS=Homo sapiens 
OX=9606 GN=SPP1 PE=1 SV=1 
11 35.4 150.8 165 0.914 -0.130 
121 High P98160 Basement membrane-specific heparan 
sulfate proteoglycan core protein 
OS=Homo sapiens OX=9606 GN=HSPG2 
PE=1 SV=4 
12 468.5 114.2 126 0.907 -0.141 
122 High P19835 Bile salt-activated lipase OS=Homo 
sapiens OX=9606 GN=CEL PE=1 SV=3 
3 79.3 97.7 108.8 0.899 -0.154 
123 High P15586 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GNS 
PE=1 SV=3 
3 62 123.6 137.4 0.899 -0.154 
124 High Q9P121 Neurotrimin OS=Homo sapiens 
OX=9606 GN=NTM PE=1 SV=1 
2 37.9 94.6 106.3 0.89 -0.168 
125 High P78324 Tyrosine-protein phosphatase non- 3 54.9 112.5 126.5 0.889 -0.170 
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receptor type substrate 1 OS=Homo 
sapiens OX=9606 GN=SIRPA PE=1 SV=2 
126 High P06870 Kallikrein-1 OS=Homo sapiens OX=9606 
GN=KLK1 PE=1 SV=2 
3 28.9 89.7 101.3 0.886 -0.175 
127 High P15941 Mucin-1 OS=Homo sapiens OX=9606 
GN=MUC1 PE=1 SV=3 
3 122 122.7 139.1 0.882 -0.181 
128 High P80188 Neutrophil gelatinase-associated 
lipocalin OS=Homo sapiens OX=9606 
GN=LCN2 PE=1 SV=2 
3 22.6 95.7 110.1 0.869 -0.203 
129 High P06702 Protein S100-A9 OS=Homo sapiens 
OX=9606 GN=S100A9 PE=1 SV=1 
7 13.2 109.6 126.3 0.868 -0.204 
130 High Q8NFZ8 Cell adhesion molecule 4 OS=Homo 
sapiens OX=9606 GN=CADM4 PE=1 
SV=1 
2 42.8 89.1 104.2 0.855 -0.226 
131 High P05154 Plasma serine protease inhibitor 
OS=Homo sapiens OX=9606 
GN=SERPINA5 PE=1 SV=3 
4 45.6 125.5 146.9 0.854 -0.228 
132 High P05109 Protein S100-A8 OS=Homo sapiens 
OX=9606 GN=S100A8 PE=1 SV=1 
5 10.8 96.2 113.6 0.846 -0.241 
133 High P16070 CD44 antigen OS=Homo sapiens 
OX=9606 GN=CD44 PE=1 SV=3 
3 81.5 123.4 146.9 0.84 -0.252 
134 High P31944 Caspase-14 OS=Homo sapiens OX=9606 
GN=CASP14 PE=1 SV=2 
2 27.7 111.2 132.6 0.838 -0.255 
135 High O60494 Cubilin OS=Homo sapiens OX=9606 
GN=CUBN PE=1 SV=5 
3 398.5 105.4 126.1 0.836 -0.258 
136 High Q08380 Galectin-3-binding protein OS=Homo 
sapiens OX=9606 GN=LGALS3BP PE=1 
SV=1 
10 65.3 112.8 135.4 0.833 -0.264 
137 High Q16270 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens OX=9606 
GN=IGFBP7 PE=1 SV=1 
3 29.1 109.4 131.8 0.83 -0.269 
138 High P31947 14-3-3 protein sigma OS=Homo sapiens 5 27.8 113.9 138.5 0.823 -0.281 
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OX=9606 GN=SFN PE=1 SV=1 
139 High Q8WZ75 Roundabout homolog 4 OS=Homo 
sapiens OX=9606 GN=ROBO4 PE=1 
SV=1 
2 107.4 110.5 136.1 0.812 -0.300 
140 High P01133 Pro-epidermal growth factor OS=Homo 
sapiens OX=9606 GN=EGF PE=1 SV=2 
11 133.9 98.9 122.4 0.808 -0.308 
141 High P10253 Lysosomal alpha-glucosidase OS=Homo 
sapiens OX=9606 GN=GAA PE=1 SV=4 
4 105.3 99.8 124.2 0.804 -0.315 
142 High Q9BRK3 Matrix remodeling-associated protein 8 
OS=Homo sapiens OX=9606 
GN=MXRA8 PE=1 SV=1 
4 49.1 97.5 122.1 0.798 -0.326 
143 High P26992 Ciliary neurotrophic factor receptor 
subunit alpha OS=Homo sapiens 
OX=9606 GN=CNTFR PE=1 SV=2 
2 40.6 93.7 117.4 0.798 -0.326 
144 High P50895 Basal cell adhesion molecule OS=Homo 
sapiens OX=9606 GN=BCAM PE=1 SV=2 
3 67.4 115.1 145.7 0.79 -0.340 
145 High P13646 Keratin, type I cytoskeletal 13 
OS=Homo sapiens OX=9606 GN=KRT13 
PE=1 SV=4 
18 49.6 85.6 108.6 0.789 -0.342 
146 High O75882 Attractin OS=Homo sapiens OX=9606 
GN=ATRN PE=1 SV=2 
4 158.4 106.9 136 0.786 -0.347 
147 High P07195 L-lactate dehydrogenase B chain 
OS=Homo sapiens OX=9606 GN=LDHB 
PE=1 SV=2 
2 36.6 110.7 141.1 0.784 -0.351 
148 High P13647 Keratin, type II cytoskeletal 5 OS=Homo 
sapiens OX=9606 GN=KRT5 PE=1 SV=3 
11 62.3 87.7 112.8 0.777 -0.364 
149 High P62736 Actin, aortic smooth muscle OS=Homo 
sapiens OX=9606 GN=ACTA2 PE=1 SV=1 
5 42 114.8 148.9 0.771 -0.375 
150 High P02790 Hemopexin OS=Homo sapiens 
OX=9606 GN=HPX PE=1 SV=2 
5 51.6 90.3 117.2 0.77 -0.377 
151 High Q14624 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens OX=9606 
4 103.3 129 167.6 0.77 -0.377 
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GN=ITIH4 PE=1 SV=4 
152 High Q9NQ84 G-protein coupled receptor family C 
group 5 member C OS=Homo sapiens 
OX=9606 GN=GPRC5C PE=1 SV=2 
2 48.2 83.3 108.2 0.77 -0.377 
153 High P29972 Aquaporin-1 OS=Homo sapiens 
OX=9606 GN=AQP1 PE=1 SV=3 
2 28.5 107.9 141.3 0.763 -0.390 
154 High P27482 Calmodulin-like protein 3 OS=Homo 
sapiens OX=9606 GN=CALML3 PE=1 
SV=2 
4 16.9 107.1 141.6 0.756 -0.404 
155 High P62805 Histone H4 OS=Homo sapiens OX=9606 
GN=HIST1H4A PE=1 SV=2 
3 11.4 81.8 110.4 0.741 -0.432 
156 High P62979 Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens OX=9606 
GN=RPS27A PE=1 SV=2 
3 18 103.3 139.8 0.739 -0.436 
157 High P0C0L5 Complement C4-B OS=Homo sapiens 
OX=9606 GN=C4B PE=1 SV=2 
3 192.6 106.8 144.4 0.739 -0.436 
158 High P12273 Prolactin-inducible protein OS=Homo 
sapiens OX=9606 GN=PIP PE=1 SV=1 
2 16.6 119.3 163.2 0.731 -0.452 
159 High P13473 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
OX=9606 GN=LAMP2 PE=1 SV=2 
2 44.9 62.9 86.1 0.73 -0.454 
160 High P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens OX=9606 GN=KRT2 
PE=1 SV=2 
5 65.4 64.9 96.5 0.672 -0.573 
161 High Q92820 Gamma-glutamyl hydrolase OS=Homo 
sapiens OX=9606 GN=GGH PE=1 SV=2 
3 35.9 115 171.1 0.672 -0.573 
162 High Q01459 Di-N-acetylchitobiase OS=Homo 
sapiens OX=9606 GN=CTBS PE=1 SV=1 
2 43.7 107.7 164.5 0.655 -0.610 
163 High P13645 Keratin, type I cytoskeletal 10 
OS=Homo sapiens OX=9606 GN=KRT10 
PE=1 SV=6 
14 58.8 57.4 88.8 0.646 -0.630 
164 High P30086 Phosphatidylethanolamine-binding 3 21 68.1 109.5 0.622 -0.685 
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protein 1 OS=Homo sapiens OX=9606 
GN=PEBP1 PE=1 SV=3 
165 High P08637 Low affinity immunoglobulin gamma Fc 
region receptor III-A OS=Homo sapiens 
OX=9606 GN=FCGR3A PE=1 SV=2 
2 29.1 81.3 136.7 0.595 -0.749 
166 High P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens OX=9606 GN=KRT1 PE=1 SV=6 
17 66 56 95.3 0.588 -0.766 
167 High P19013 Keratin, type II cytoskeletal 4 OS=Homo 
sapiens OX=9606 GN=KRT4 PE=1 SV=4 
12 57.3 59.2 108.7 0.545 -0.876 
168 High Q9Y646 Carboxypeptidase Q OS=Homo sapiens 
OX=9606 GN=CPQ PE=1 SV=1 
2 51.9 84.6 162.8 0.52 -0.943 
169 High P07911 Uromodulin OS=Homo sapiens 
OX=9606 GN=UMOD PE=1 SV=1 
7 69.7 94.1 186.4 0.505 -0.986 
170 High P05062 Fructose-bisphosphate aldolase B 
OS=Homo sapiens OX=9606 GN=ALDOB 
PE=1 SV=2 
2 39.4 57.7 116.4 0.496 -1.012 
171 High P09211 Glutathione S-transferase P OS=Homo 
sapiens OX=9606 GN=GSTP1 PE=1 SV=2 
2 23.3 54 124.9 0.433 -1.208 
172 High P07355 Annexin A2 OS=Homo sapiens OX=9606 
GN=ANXA2 PE=1 SV=2 
8 38.6 78.5 184 0.427 -1.228 
173 High P63104 14-3-3 protein zeta/delta OS=Homo 
sapiens OX=9606 GN=YWHAZ PE=1 
SV=1 
5 27.7 37.6 116.9 0.321 -1.639 
Data identified at confidence interval (CI): 99 %, FDR < 0.01; Peptides no. ≥ 2. 
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Table S 3: Dataset of protein expression for IUGR and control at 15 weeks of pregnancy 
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
 Protein name  # Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of IUGR 
at 15 W 
Abundances 
of reporter 
ion of 
control at 
15 W 
Abundance 
ratio (Case 
/ Control) 
of IUGR at 
15 W 
Log 2 
fold 
change  
1 High P25311 Zinc-alpha-2-glycoprotein OS=Homo 
sapiens OX=9606 GN=AZGP1 PE=1 SV=2 
13 34.2 271.3 41.6 6.528 2.707 
2 High P02750 Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens OX=9606 GN=LRG1 
PE=1 SV=2 
5 38.2 195.9 56.7 3.458 1.790 
3 High P02763 Alpha-1-acid glycoprotein 1 OS=Homo 
sapiens OX=9606 GN=ORM1 PE=1 SV=1 
3 23.5 236.2 68.6 3.442 1.783 
4 High P19652 Alpha-1-acid glycoprotein 2 OS=Homo 
sapiens OX=9606 GN=ORM2 PE=1 SV=2 
2 23.6 193.5 78.5 2.464 1.301 
5 High P02765 Alpha-2-HS-glycoprotein OS=Homo 
sapiens OX=9606 GN=AHSG PE=1 SV=1 
3 39.3 142.1 62.9 2.26 1.176 
6 High P04217 Alpha-1B-glycoprotein OS=Homo 
sapiens OX=9606 GN=A1BG PE=1 SV=4 
3 54.2 146.8 69.5 2.112 1.079 
7 High P01009 Alpha-1-antitrypsin OS=Homo sapiens 
OX=9606 GN=SERPINA1 PE=1 SV=3 
14 46.7 181.5 91.8 1.978 0.984 
8 High P62805 Histone H4 OS=Homo sapiens OX=9606 
GN=HIST1H4A PE=1 SV=2 
3 11.4 149 79.4 1.876 0.908 
9 High P35527 Keratin, type I cytoskeletal 9 OS=Homo 
sapiens OX=9606 GN=KRT9 PE=1 SV=3 
5 62 153.2 81.7 1.875 0.907 
10 High P30086 Phosphatidylethanolamine-binding 
protein 1 OS=Homo sapiens OX=9606 
GN=PEBP1 PE=1 SV=3 
3 21 190.9 109 1.751 0.808 
11 High O00187 Mannan-binding lectin serine protease 
2 OS=Homo sapiens OX=9606 
GN=MASP2 PE=1 SV=4 
3 75.7 155.6 89.4 1.741 0.800 
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12 High P02788 Lactotransferrin OS=Homo sapiens 
OX=9606 GN=LTF PE=1 SV=6 
3 78.1 102.7 59.4 1.729 0.790 
13 High P02787 Serotransferrin OS=Homo sapiens 
OX=9606 GN=TF PE=1 SV=3 
12 77 153.9 89.8 1.715 0.778 
14 High P0DOY2 Immunoglobulin lambda constant 2 
OS=Homo sapiens OX=9606 GN=IGLC2 
PE=1 SV=1 
3 11.3 161.9 96.6 1.676 0.745 
15 High P07476 Involucrin OS=Homo sapiens OX=9606 
GN=IVL PE=1 SV=2 
9 68.4 176.3 105.7 1.669 0.739 
16 High Q93088 Betaine--homocysteine S-
methyltransferase 1 OS=Homo sapiens 
OX=9606 GN=BHMT PE=1 SV=2 
3 45 167.5 102.3 1.637 0.711 
17 High P01019 Angiotensinogen OS=Homo sapiens 
OX=9606 GN=AGT PE=1 SV=1 
2 53.1 141.5 87.1 1.625 0.700 
18 High P13647 Keratin, type II cytoskeletal 5 OS=Homo 
sapiens OX=9606 GN=KRT5 PE=1 SV=3 
11 62.3 196.4 124.7 1.574 0.654 
19 High P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens OX=9606 GN=KRT1 PE=1 SV=6 
17 66 182 117.5 1.549 0.631 
20 High P41222 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens OX=9606 GN=PTGDS 
PE=1 SV=1 
3 21 143.5 93.4 1.536 0.619 
21 High P02538 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens OX=9606 GN=KRT6A 
PE=1 SV=3 
19 60 222.3 145.7 1.526 0.610 
22 High P01008 Antithrombin-III OS=Homo sapiens 
OX=9606 GN=SERPINC1 PE=1 SV=1 
4 52.6 178.1 117.1 1.52 0.604 
23 High Q9Y5Y7 Lymphatic vessel endothelial hyaluronic 
acid receptor 1 OS=Homo sapiens 
OX=9606 GN=LYVE1 PE=1 SV=2 
2 35.2 143.8 94.7 1.519 0.603 
24 High P19013 Keratin, type II cytoskeletal 4 OS=Homo 
sapiens OX=9606 GN=KRT4 PE=1 SV=4 
12 57.3 237.6 158.8 1.496 0.581 
25 High P01011 Alpha-1-antichymotrypsin OS=Homo 6 47.6 148.6 100.1 1.484 0.569 
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sapiens OX=9606 GN=SERPINA3 PE=1 
SV=2 
26 High P04259 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens OX=9606 GN=KRT6B 
PE=1 SV=5 
20 60 196.3 132.4 1.483 0.569 
27 High P08185 Corticosteroid-binding globulin 
OS=Homo sapiens OX=9606 
GN=SERPINA6 PE=1 SV=1 
3 45.1 126.8 85.9 1.475 0.561 
28 High P08571 Monocyte differentiation antigen CD14 
OS=Homo sapiens OX=9606 GN=CD14 
PE=1 SV=2 
4 40.1 157 106.7 1.472 0.558 
29 High P06396 Gelsolin OS=Homo sapiens OX=9606 
GN=GSN PE=1 SV=1 
6 85.6 147.7 101.1 1.461 0.547 
30 High P13646 Keratin, type I cytoskeletal 13 
OS=Homo sapiens OX=9606 GN=KRT13 
PE=1 SV=4 
18 49.6 214.6 147.2 1.459 0.545 
31 High P01871 Immunoglobulin heavy constant mu 
OS=Homo sapiens OX=9606 GN=IGHM 
PE=1 SV=4 
2 49.4 130.4 93 1.401 0.486 
32 High P04075 Fructose-bisphosphate aldolase A 
OS=Homo sapiens OX=9606 GN=ALDOA 
PE=1 SV=2 
2 39.4 148.1 106.3 1.393 0.478 
33 High Q03154 Aminoacylase-1 OS=Homo sapiens 
OX=9606 GN=ACY1 PE=1 SV=1 
2 45.9 171.1 125.4 1.364 0.448 
34 High Q6UXB8 Peptidase inhibitor 16 OS=Homo 
sapiens OX=9606 GN=PI16 PE=1 SV=1 
2 49.4 142.6 106.8 1.335 0.417 
35 High P01614 Immunoglobulin kappa variable 2D-40 
OS=Homo sapiens OX=9606 
GN=IGKV2D-40 PE=1 SV=2 
2 13.3 136.6 102.8 1.329 0.410 
36 High Q02487 Desmocollin-2 OS=Homo sapiens 
OX=9606 GN=DSC2 PE=1 SV=1 
3 99.9 140 109.2 1.282 0.358 
37 High P12830 Cadherin-1 OS=Homo sapiens OX=9606 8 97.4 140 110.1 1.271 0.346 
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GN=CDH1 PE=1 SV=3 
38 High P05543 Thyroxine-binding globulin OS=Homo 
sapiens OX=9606 GN=SERPINA7 PE=1 
SV=2 
6 46.3 140 110.6 1.266 0.340 
39 High Q6EMK4 Vasorin OS=Homo sapiens OX=9606 
GN=VASN PE=1 SV=1 
5 71.7 159 127 1.252 0.324 
40 High Q9UBG3 Cornulin OS=Homo sapiens OX=9606 
GN=CRNN PE=1 SV=1 
4 53.5 166.4 133.1 1.25 0.322 
41 High P00450 Ceruloplasmin OS=Homo sapiens 
OX=9606 GN=CP PE=1 SV=1 
13 122.1 112 89.8 1.247 0.318 
42 High P15586 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GNS 
PE=1 SV=3 
3 62 134.1 108 1.241 0.312 
43 High P02760 Protein AMBP OS=Homo sapiens 
OX=9606 GN=AMBP PE=1 SV=1 
5 39 136.7 110.6 1.237 0.307 
44 High P05937 Calbindin OS=Homo sapiens OX=9606 
GN=CALB1 PE=1 SV=2 
3 30 186 152.3 1.221 0.288 
45 High Q92820 Gamma-glutamyl hydrolase OS=Homo 
sapiens OX=9606 GN=GGH PE=1 SV=2 
3 35.9 133.8 109.8 1.219 0.286 
46 High Q13510 Acid ceramidase OS=Homo sapiens 
OX=9606 GN=ASAH1 PE=1 SV=5 
3 44.6 134 110.5 1.213 0.279 
47 High Q9UBC9 Small proline-rich protein 3 OS=Homo 
sapiens OX=9606 GN=SPRR3 PE=1 SV=2 
5 18.1 162.5 134.3 1.21 0.275 
48 High B9A064 Immunoglobulin lambda-like 
polypeptide 5 OS=Homo sapiens 
OX=9606 GN=IGLL5 PE=2 SV=2 
3 23 136.4 113.8 1.199 0.262 
49 High P02675 Fibrinogen beta chain OS=Homo 
sapiens OX=9606 GN=FGB PE=1 SV=2 
2 55.9 136.6 113.9 1.199 0.262 
50 High Q12907 Vesicular integral-membrane protein 
VIP36 OS=Homo sapiens OX=9606 
GN=LMAN2 PE=1 SV=1 
3 40.2 128.3 108.5 1.183 0.242 
51 High P34059 N-acetylgalactosamine-6-sulfatase 2 58 146.8 124.8 1.176 0.234 
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OS=Homo sapiens OX=9606 GN=GALNS 
PE=1 SV=1 
52 High P06702 Protein S100-A9 OS=Homo sapiens 
OX=9606 GN=S100A9 PE=1 SV=1 
7 13.2 147 125.6 1.171 0.228 
53 High P01834 Immunoglobulin kappa constant 
OS=Homo sapiens OX=9606 GN=IGKC 
PE=1 SV=2 
3 11.8 138.4 119.5 1.158 0.212 
54 High O94919 Endonuclease domain-containing 1 
protein OS=Homo sapiens OX=9606 
GN=ENDOD1 PE=1 SV=2 
3 55 122.1 106.7 1.145 0.195 
55 High P29508 Serpin B3 OS=Homo sapiens OX=9606 
GN=SERPINB3 PE=1 SV=2 
6 44.5 166.2 147 1.13 0.176 
56 High P01859 Immunoglobulin heavy constant 
gamma 2 OS=Homo sapiens OX=9606 
GN=IGHG2 PE=1 SV=2 
4 35.9 104.4 93.2 1.119 0.162 
57 High P39059 Collagen alpha-1(XV) chain OS=Homo 
sapiens OX=9606 GN=COL15A1 PE=1 
SV=2 
2 141.6 137.7 123.7 1.113 0.154 
58 High P43121 Cell surface glycoprotein MUC18 
OS=Homo sapiens OX=9606 GN=MCAM 
PE=1 SV=2 
3 71.6 135.4 123.4 1.098 0.135 
59 High P05109 Protein S100-A8 OS=Homo sapiens 
OX=9606 GN=S100A8 PE=1 SV=1 
5 10.8 141.8 131.2 1.081 0.112 
60 High P09211 Glutathione S-transferase P OS=Homo 
sapiens OX=9606 GN=GSTP1 PE=1 SV=2 
2 23.3 137.3 127.1 1.08 0.111 
61 High P05090 Apolipoprotein D OS=Homo sapiens 
OX=9606 GN=APOD PE=1 SV=1 
3 21.3 134.6 125.8 1.07 0.098 
62 High P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
OX=9606 GN=ACTB PE=1 SV=1 
6 41.7 119 112.5 1.058 0.081 
63 High P10451 Osteopontin OS=Homo sapiens 
OX=9606 GN=SPP1 PE=1 SV=1 
11 35.4 132.4 125.2 1.057 0.080 
64 High P15289 Arylsulfatase A OS=Homo sapiens 6 53.6 129.8 123 1.055 0.077 
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OX=9606 GN=ARSA PE=1 SV=3 
65 High P02751 Fibronectin OS=Homo sapiens OX=9606 
GN=FN1 PE=1 SV=4 
11 262.5 139.8 132.9 1.052 0.073 
66 High P10599 Thioredoxin OS=Homo sapiens 
OX=9606 GN=TXN PE=1 SV=3 
3 11.7 135.9 129.6 1.048 0.068 
67 High P11142 Heat shock cognate 71 kDa protein 
OS=Homo sapiens OX=9606 GN=HSPA8 
PE=1 SV=1 
9 70.9 122.2 117.2 1.043 0.061 
68 High P05155 Plasma protease C1 inhibitor OS=Homo 
sapiens OX=9606 GN=SERPING1 PE=1 
SV=2 
6 55.1 147.6 141.6 1.042 0.059 
69 High Q8NFZ8 Cell adhesion molecule 4 OS=Homo 
sapiens OX=9606 GN=CADM4 PE=1 
SV=1 
2 42.8 165.1 158.6 1.041 0.058 
70 High P0C0L5 Complement C4-B OS=Homo sapiens 
OX=9606 GN=C4B PE=1 SV=2 
3 192.6 135.9 130.9 1.039 0.055 
71 High P01040 Cystatin-A OS=Homo sapiens OX=9606 
GN=CSTA PE=1 SV=1 
2 11 155.6 151.4 1.027 0.038 
72 High Q14624 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens OX=9606 
GN=ITIH4 PE=1 SV=4 
4 103.3 140.3 137.3 1.022 0.031 
73 High P06733 Alpha-enolase OS=Homo sapiens 
OX=9606 GN=ENO1 PE=1 SV=2 
4 47.1 119.1 117.3 1.015 0.021 
74 High P19835 Bile salt-activated lipase OS=Homo 
sapiens OX=9606 GN=CEL PE=1 SV=3 
3 79.3 174 173.4 1.003 0.004 
75 High P00924 Enolase 1 OS=Saccharomyces cerevisiae 
(strain ATCC 204508 / S288c) GN=ENO1 
PE=1 SV=3 
14 46.8 100 100 1 0.000 
76 High P15144 Aminopeptidase N OS=Homo sapiens 
OX=9606 GN=ANPEP PE=1 SV=4 
12 109.5 121.1 123.2 0.983 -0.025 
77 High Q16270 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens OX=9606 
3 29.1 160.9 163.6 0.983 -0.025 
224 
 
GN=IGFBP7 PE=1 SV=1 
78 High Q9NZP8 Complement C1r subcomponent-like 
protein OS=Homo sapiens OX=9606 
GN=C1RL PE=1 SV=2 
3 53.5 140.8 143.5 0.981 -0.028 
79 High Q9BRK3 Matrix remodeling-associated protein 8 
OS=Homo sapiens OX=9606 
GN=MXRA8 PE=1 SV=1 
4 49.1 141.1 144.2 0.978 -0.032 
80 High P12109 Collagen alpha-1(VI) chain OS=Homo 
sapiens OX=9606 GN=COL6A1 PE=1 
SV=3 
10 108.5 142.7 146.1 0.977 -0.034 
81 High P09668 Pro-cathepsin H OS=Homo sapiens 
OX=9606 GN=CTSH PE=1 SV=4 
2 37.4 124.8 127.9 0.976 -0.035 
82 High Q8WZ75 Roundabout homolog 4 OS=Homo 
sapiens OX=9606 GN=ROBO4 PE=1 
SV=1 
2 107.4 133.3 137.3 0.971 -0.042 
83 High P78324 Tyrosine-protein phosphatase non-
receptor type substrate 1 OS=Homo 
sapiens OX=9606 GN=SIRPA PE=1 SV=2 
3 54.9 126.1 130.6 0.965 -0.051 
84 High A8K2U0 Alpha-2-macroglobulin-like protein 1 
OS=Homo sapiens OX=9606 GN=A2ML1 
PE=1 SV=3 
6 161 130.5 135.5 0.963 -0.054 
85 High P05154 Plasma serine protease inhibitor 
OS=Homo sapiens OX=9606 
GN=SERPINA5 PE=1 SV=3 
4 45.6 138.2 144.4 0.957 -0.063 
86 High P05062 Fructose-bisphosphate aldolase B 
OS=Homo sapiens OX=9606 GN=ALDOB 
PE=1 SV=2 
2 39.4 132.6 138.6 0.956 -0.065 
87 High P55290 Cadherin-13 OS=Homo sapiens 
OX=9606 GN=CDH13 PE=1 SV=1 
3 78.2 121.8 128.5 0.948 -0.077 
88 High Q7KYR7 Butyrophilin subfamily 2 member A1 
OS=Homo sapiens OX=9606 
GN=BTN2A1 PE=1 SV=3 
3 59.6 130.9 139.9 0.936 -0.095 
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89 High P05060 Secretogranin-1 OS=Homo sapiens 
OX=9606 GN=CHGB PE=1 SV=2 
2 78.2 130.2 139.2 0.935 -0.097 
90 High P62736 Actin, aortic smooth muscle OS=Homo 
sapiens OX=9606 GN=ACTA2 PE=1 SV=1 
5 42 101.6 108.8 0.934 -0.099 
91 High P62979 Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens OX=9606 
GN=RPS27A PE=1 SV=2 
3 18 137.4 147.1 0.934 -0.099 
92 High P07195 L-lactate dehydrogenase B chain 
OS=Homo sapiens OX=9606 GN=LDHB 
PE=1 SV=2 
2 36.6 124 132.8 0.933 -0.100 
93 High P01857 Immunoglobulin heavy constant 
gamma 1 OS=Homo sapiens OX=9606 
GN=IGHG1 PE=1 SV=1 
7 36.1 128.8 138.4 0.931 -0.103 
94 High Q9BY67 Cell adhesion molecule 1 OS=Homo 
sapiens OX=9606 GN=CADM1 PE=1 
SV=2 
3 48.5 138.9 150.4 0.924 -0.114 
95 High P50995 Annexin A11 OS=Homo sapiens 
OX=9606 GN=ANXA11 PE=1 SV=1 
3 54.4 137.6 150.1 0.917 -0.125 
96 High P31947 14-3-3 protein sigma OS=Homo sapiens 
OX=9606 GN=SFN PE=1 SV=1 
5 27.8 107.2 117.4 0.913 -0.131 
97 High Q6UVK1 Chondroitin sulfate proteoglycan 4 
OS=Homo sapiens OX=9606 GN=CSPG4 
PE=1 SV=2 
2 250.4 124.5 138 0.902 -0.149 
98 High P19440 Glutathione hydrolase 1 proenzyme 
OS=Homo sapiens OX=9606 GN=GGT1 
PE=1 SV=2 
2 61.4 134.1 148.6 0.902 -0.149 
99 High P60174 Triosephosphate isomerase OS=Homo 
sapiens OX=9606 GN=TPI1 PE=1 SV=3 
2 30.8 140.9 156.8 0.899 -0.154 
100 High Q96NY8 Nectin-4 OS=Homo sapiens OX=9606 
GN=NECTIN4 PE=1 SV=1 
3 55.4 127.9 142.5 0.898 -0.155 
101 High Q16651 Prostasin OS=Homo sapiens OX=9606 
GN=PRSS8 PE=1 SV=1 
2 36.4 134.5 150.7 0.893 -0.163 
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102 High O00391 Sulfhydryl oxidase 1 OS=Homo sapiens 
OX=9606 GN=QSOX1 PE=1 SV=3 
5 82.5 145.8 163.7 0.891 -0.167 
103 High P01023 Alpha-2-macroglobulin OS=Homo 
sapiens OX=9606 GN=A2M PE=1 SV=3 
2 163.2 88.7 99.6 0.89 -0.168 
104 High P02768 Serum albumin OS=Homo sapiens 
OX=9606 GN=ALB PE=1 SV=2 
19 69.3 117.1 132 0.887 -0.173 
105 High P02790 Hemopexin OS=Homo sapiens OX=9606 
GN=HPX PE=1 SV=2 
5 51.6 116.8 131.8 0.886 -0.175 
106 High Q14515 SPARC-like protein 1 OS=Homo sapiens 
OX=9606 GN=SPARCL1 PE=1 SV=2 
4 75.2 119.2 134.8 0.884 -0.178 
107 High P26992 Ciliary neurotrophic factor receptor 
subunit alpha OS=Homo sapiens 
OX=9606 GN=CNTFR PE=1 SV=2 
2 40.6 136 154.3 0.881 -0.183 
108 High P14384 Carboxypeptidase M OS=Homo sapiens 
OX=9606 GN=CPM PE=1 SV=2 
2 50.5 143.4 163.3 0.878 -0.188 
109 High P24855 Deoxyribonuclease-1 OS=Homo sapiens 
OX=9606 GN=DNASE1 PE=1 SV=1 
3 31.4 154 175.8 0.876 -0.191 
110 High Q8NBJ4 Golgi membrane protein 1 OS=Homo 
sapiens OX=9606 GN=GOLM1 PE=1 
SV=1 
7 45.3 140.8 160.8 0.875 -0.193 
111 High Q06830 Peroxiredoxin-1 OS=Homo sapiens 
OX=9606 GN=PRDX1 PE=1 SV=1 
2 22.1 111.3 127.6 0.872 -0.198 
112 High P54802 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens OX=9606 GN=NAGLU 
PE=1 SV=2 
5 82.2 107.5 124.4 0.864 -0.211 
113 High Q08380 Galectin-3-binding protein OS=Homo 
sapiens OX=9606 GN=LGALS3BP PE=1 
SV=1 
10 65.3 118.5 137.3 0.863 -0.213 
114 High Q07075 Glutamyl aminopeptidase OS=Homo 
sapiens OX=9606 GN=ENPEP PE=1 SV=3 
3 109.2 106.6 123.6 0.863 -0.213 
115 High Q8TDQ0 Hepatitis A virus cellular receptor 2 
OS=Homo sapiens OX=9606 
2 33.4 127.3 148.1 0.86 -0.218 
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GN=HAVCR2 PE=1 SV=3 
116 High P10909 Clusterin OS=Homo sapiens OX=9606 
GN=CLU PE=1 SV=1 
4 52.5 135.6 158.2 0.857 -0.223 
117 High P25815 Protein S100-P OS=Homo sapiens 
OX=9606 GN=S100P PE=1 SV=2 
2 10.4 106.8 125.1 0.853 -0.229 
118 High Q9HCU0 Endosialin OS=Homo sapiens OX=9606 
GN=CD248 PE=1 SV=1 
2 80.8 127.9 149.9 0.853 -0.229 
119 High Q9P121 Neurotrimin OS=Homo sapiens 
OX=9606 GN=NTM PE=1 SV=1 
2 37.9 144.9 170.2 0.851 -0.233 
120 High P07339 Cathepsin D OS=Homo sapiens 
OX=9606 GN=CTSD PE=1 SV=1 
6 44.5 116.6 137.4 0.849 -0.236 
121 High P08779 Keratin, type I cytoskeletal 16 
OS=Homo sapiens OX=9606 GN=KRT16 
PE=1 SV=4 
6 51.2 139 164.6 0.844 -0.245 
122 High P01042 Kininogen-1 OS=Homo sapiens 
OX=9606 GN=KNG1 PE=1 SV=2 
6 71.9 125 149.2 0.838 -0.255 
123 High P63104 14-3-3 protein zeta/delta OS=Homo 
sapiens OX=9606 GN=YWHAZ PE=1 
SV=1 
5 27.7 101.8 122.5 0.832 -0.265 
124 High P10153 Non-secretory ribonuclease OS=Homo 
sapiens OX=9606 GN=RNASE2 PE=1 
SV=2 
2 18.3 133.5 161.6 0.826 -0.276 
125 High Q08345 Epithelial discoidin domain-containing 
receptor 1 OS=Homo sapiens OX=9606 
GN=DDR1 PE=1 SV=1 
4 101.1 107.9 131.5 0.82 -0.286 
126 High P98164 Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
OX=9606 GN=LRP2 PE=1 SV=3 
6 521.6 118.1 144.5 0.818 -0.290 
127 High P01133 Pro-epidermal growth factor OS=Homo 
sapiens OX=9606 GN=EGF PE=1 SV=2 
11 133.9 135.4 166.4 0.814 -0.297 
128 High P05164 Myeloperoxidase OS=Homo sapiens 
OX=9606 GN=MPO PE=1 SV=1 
3 83.8 103.6 128.2 0.808 -0.308 
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129 High Q99988 Growth/differentiation factor 15 
OS=Homo sapiens OX=9606 GN=GDF15 
PE=1 SV=3 
3 34.1 119.9 149.5 0.802 -0.318 
130 High Q9ULI3 Protein HEG homolog 1 OS=Homo 
sapiens OX=9606 GN=HEG1 PE=1 SV=3 
3 147.4 120.7 151.7 0.795 -0.331 
131 High Q8IYS5 Osteoclast-associated immunoglobulin-
like receptor OS=Homo sapiens 
OX=9606 GN=OSCAR PE=1 SV=3 
2 30.5 129.9 164.2 0.791 -0.338 
132 High P98160 Basement membrane-specific heparan 
sulfate proteoglycan core protein 
OS=Homo sapiens OX=9606 GN=HSPG2 
PE=1 SV=4 
12 468.5 106.1 134.6 0.788 -0.344 
133 High O75882 Attractin OS=Homo sapiens OX=9606 
GN=ATRN PE=1 SV=2 
4 158.4 118.9 152.5 0.779 -0.360 
134 High Q68CJ9 Cyclic AMP-responsive element-binding 
protein 3-like protein 3 OS=Homo 
sapiens OX=9606 GN=CREB3L3 PE=1 
SV=2 
2 49 116.7 149.8 0.779 -0.360 
135 High P07355 Annexin A2 OS=Homo sapiens OX=9606 
GN=ANXA2 PE=1 SV=2 
8 38.6 114.3 148.2 0.772 -0.373 
136 High P01876 Immunoglobulin heavy constant alpha 
1 OS=Homo sapiens OX=9606 
GN=IGHA1 PE=1 SV=2 
5 37.6 110.5 143.8 0.768 -0.381 
137 High P06870 Kallikrein-1 OS=Homo sapiens OX=9606 
GN=KLK1 PE=1 SV=2 
3 28.9 138.9 181.2 0.767 -0.383 
138 High P09603 Macrophage colony-stimulating factor 
1 OS=Homo sapiens OX=9606 GN=CSF1 
PE=1 SV=2 
4 60.1 122.1 159.8 0.764 -0.388 
139 High Q9UQ72 Pregnancy-specific beta-1-glycoprotein 
11 OS=Homo sapiens OX=9606 
GN=PSG11 PE=2 SV=3 
7 37.1 87.1 115 0.757 -0.402 
140 High P01833 Polymeric immunoglobulin receptor 7 83.2 112.9 149.5 0.755 -0.405 
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OS=Homo sapiens OX=9606 GN=PIGR 
PE=1 SV=4 
141 High P02774 Vitamin D-binding protein OS=Homo 
sapiens OX=9606 GN=GC PE=1 SV=1 
5 52.9 117 157.5 0.743 -0.429 
142 High Q9Y646 Carboxypeptidase Q OS=Homo sapiens 
OX=9606 GN=CPQ PE=1 SV=1 
2 51.9 113 153.7 0.735 -0.444 
143 High P15941 Mucin-1 OS=Homo sapiens OX=9606 
GN=MUC1 PE=1 SV=3 
3 122 118.7 162.9 0.729 -0.456 
144 High P10253 Lysosomal alpha-glucosidase OS=Homo 
sapiens OX=9606 GN=GAA PE=1 SV=4 
4 105.3 125.6 173.8 0.723 -0.468 
145 High P04746 Pancreatic alpha-amylase OS=Homo 
sapiens OX=9606 GN=AMY2A PE=1 
SV=2 
7 57.7 109.9 152.3 0.722 -0.470 
146 High P27482 Calmodulin-like protein 3 OS=Homo 
sapiens OX=9606 GN=CALML3 PE=1 
SV=2 
4 16.9 128.9 179.1 0.72 -0.474 
147 High Q6GTX8 Leukocyte-associated immunoglobulin-
like receptor 1 OS=Homo sapiens 
OX=9606 GN=LAIR1 PE=1 SV=1 
2 31.4 121.2 168.4 0.72 -0.474 
148 High P04083 Annexin A1 OS=Homo sapiens OX=9606 
GN=ANXA1 PE=1 SV=2 
6 38.7 76.9 107 0.719 -0.476 
149 High P06703 Protein S100-A6 OS=Homo sapiens 
OX=9606 GN=S100A6 PE=1 SV=1 
3 10.2 96.1 134 0.717 -0.480 
150 High O60494 Cubilin OS=Homo sapiens OX=9606 
GN=CUBN PE=1 SV=5 
3 398.5 99.2 142.7 0.695 -0.525 
151 High Q01459 Di-N-acetylchitobiase OS=Homo 
sapiens OX=9606 GN=CTBS PE=1 SV=1 
2 43.7 89.5 129.1 0.694 -0.527 
152 High P01861 Immunoglobulin heavy constant 
gamma 4 OS=Homo sapiens OX=9606 
GN=IGHG4 PE=1 SV=1 
3 35.9 109.4 158.3 0.691 -0.533 
153 High P29972 Aquaporin-1 OS=Homo sapiens 
OX=9606 GN=AQP1 PE=1 SV=3 
2 28.5 96.7 140.7 0.687 -0.542 
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154 High O43451 Maltase-glucoamylase, intestinal 
OS=Homo sapiens OX=9606 GN=MGAM 
PE=1 SV=5 
4 209.7 108.6 159.3 0.681 -0.554 
155 High Q9NQ84 G-protein coupled receptor family C 
group 5 member C OS=Homo sapiens 
OX=9606 GN=GPRC5C PE=1 SV=2 
2 48.2 124.4 183.3 0.679 -0.559 
156 High P80188 Neutrophil gelatinase-associated 
lipocalin OS=Homo sapiens OX=9606 
GN=LCN2 PE=1 SV=2 
3 22.6 98.5 145.5 0.677 -0.563 
157 High P12273 Prolactin-inducible protein OS=Homo 
sapiens OX=9606 GN=PIP PE=1 SV=1 
2 16.6 118.8 179.4 0.662 -0.595 
158 High P11021 Endoplasmic reticulum chaperone BiP 
OS=Homo sapiens OX=9606 GN=HSPA5 
PE=1 SV=2 
5 72.3 117.9 178.8 0.659 -0.602 
159 High P00738 Haptoglobin OS=Homo sapiens 
OX=9606 GN=HP PE=1 SV=1 
4 45.2 80.7 122.7 0.658 -0.604 
160 High P18510 Interleukin-1 receptor antagonist 
protein OS=Homo sapiens OX=9606 
GN=IL1RN PE=1 SV=1 
2 20 101.3 153.8 0.658 -0.604 
161 High P11464 Pregnancy-specific beta-1-glycoprotein 
1 OS=Homo sapiens OX=9606 GN=PSG1 
PE=1 SV=1 
4 47.2 81.2 125.2 0.649 -0.624 
162 High P13645 Keratin, type I cytoskeletal 10 
OS=Homo sapiens OX=9606 GN=KRT10 
PE=1 SV=6 
14 58.8 134.4 207.8 0.647 -0.628 
163 High P01591 Immunoglobulin J chain OS=Homo 
sapiens OX=9606 GN=JCHAIN PE=1 
SV=4 
2 18.1 91 149.7 0.608 -0.718 
164 High P50895 Basal cell adhesion molecule OS=Homo 
sapiens OX=9606 GN=BCAM PE=1 SV=2 
3 67.4 106.7 185.7 0.575 -0.798 
165 High P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 OS=Homo 
2 37.4 97.5 172.8 0.564 -0.826 
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sapiens OX=9606 GN=GNB1 PE=1 SV=3 
166 High P07911 Uromodulin OS=Homo sapiens 
OX=9606 GN=UMOD PE=1 SV=1 
7 69.7 82.1 148.7 0.552 -0.857 
167 High P16070 CD44 antigen OS=Homo sapiens 
OX=9606 GN=CD44 PE=1 SV=3 
3 81.5 78.6 146.8 0.535 -0.902 
168 High P01877 Immunoglobulin heavy constant alpha 
2 OS=Homo sapiens OX=9606 
GN=IGHA2 PE=1 SV=4 
3 36.6 82.3 155.3 0.53 -0.916 
169 High P08637 Low affinity immunoglobulin gamma Fc 
region receptor III-A OS=Homo sapiens 
OX=9606 GN=FCGR3A PE=1 SV=2 
2 29.1 110.9 232.1 0.478 -1.065 
170 High P13473 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
OX=9606 GN=LAMP2 PE=1 SV=2 
2 44.9 98.8 210.1 0.47 -1.089 
171 High P31944 Caspase-14 OS=Homo sapiens OX=9606 
GN=CASP14 PE=1 SV=2 
2 27.7 85 189.9 0.448 -1.158 
172 High P13796 Plastin-2 OS=Homo sapiens OX=9606 
GN=LCP1 PE=1 SV=6 
4 70.2 52.4 161.2 0.325 -1.621 
173 High P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens OX=9606 GN=KRT2 
PE=1 SV=2 
5 65.4 89.2 277.4 0.321 -1.639 
Data identified at confidence interval (CI): 99 %, FDR < 0.01; Peptides no. ≥ 2. 
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Table S 4: Dataset of protein expression for IUGR and control at 20 weeks of gestation 
No. Protein FDR 
Confidence: 
Combined 
Accession 
No. 
 Protein name  # Unique 
Peptides 
MW 
[kDa] 
Abundances 
of reporter 
ion of IUGR 
at 20 W 
Abundances 
of reporter 
ion of control 
at 20 W 
Abundance 
ratio (Case / 
Control) of 
IUGR at 20 
W 
Log 2 
fold 
change  
1 High P25311 Zinc-alpha-2-glycoprotein OS=Homo 
sapiens OX=9606 GN=AZGP1 PE=1 
SV=2 
13 34.2 171.4 58.6 2.927 1.549 
2 High P02675 Fibrinogen beta chain OS=Homo 
sapiens OX=9606 GN=FGB PE=1 SV=2 
2 55.9 133.2 50.5 2.638 1.399 
3 High P02750 Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens OX=9606 GN=LRG1 
PE=1 SV=2 
5 38.2 173.2 70.8 2.445 1.290 
4 High P02763 Alpha-1-acid glycoprotein 1 OS=Homo 
sapiens OX=9606 GN=ORM1 PE=1 
SV=1 
3 23.5 131.4 62.7 2.097 1.068 
5 High P19652 Alpha-1-acid glycoprotein 2 OS=Homo 
sapiens OX=9606 GN=ORM2 PE=1 
SV=2 
2 23.6 127.6 67.3 1.895 0.922 
6 High P16070 CD44 antigen OS=Homo sapiens 
OX=9606 GN=CD44 PE=1 SV=3 
3 81.5 104.1 60.3 1.727 0.788 
7 High Q9Y5Y7 Lymphatic vessel endothelial 
hyaluronic acid receptor 1 OS=Homo 
sapiens OX=9606 GN=LYVE1 PE=1 
SV=2 
2 35.2 110.5 69.2 1.598 0.676 
8 High Q01459 Di-N-acetylchitobiase OS=Homo 
sapiens OX=9606 GN=CTBS PE=1 SV=1 
2 43.7 149.5 96.3 1.552 0.634 
9 High P01008 Antithrombin-III OS=Homo sapiens 
OX=9606 GN=SERPINC1 PE=1 SV=1 
4 52.6 118.3 76.8 1.541 0.624 
10 High P01019 Angiotensinogen OS=Homo sapiens 2 53.1 148.4 98.9 1.501 0.586 
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OX=9606 GN=AGT PE=1 SV=1 
11 High A8K2U0 Alpha-2-macroglobulin-like protein 1 
OS=Homo sapiens OX=9606 
GN=A2ML1 PE=1 SV=3 
6 161 116.8 81.2 1.439 0.525 
12 High P12273 Prolactin-inducible protein OS=Homo 
sapiens OX=9606 GN=PIP PE=1 SV=1 
2 16.6 93 65.7 1.415 0.501 
13 High P63104 14-3-3 protein zeta/delta OS=Homo 
sapiens OX=9606 GN=YWHAZ PE=1 
SV=1 
5 27.7 162.3 116.3 1.396 0.481 
14 High Q9UBG3 Cornulin OS=Homo sapiens OX=9606 
GN=CRNN PE=1 SV=1 
4 53.5 116.2 87.8 1.323 0.404 
15 High Q6UXB8 Peptidase inhibitor 16 OS=Homo 
sapiens OX=9606 GN=PI16 PE=1 SV=1 
2 49.4 116.6 90 1.296 0.374 
16 High P02787 Serotransferrin OS=Homo sapiens 
OX=9606 GN=TF PE=1 SV=3 
12 77 102.4 80 1.28 0.356 
17 High P04217 Alpha-1B-glycoprotein OS=Homo 
sapiens OX=9606 GN=A1BG PE=1 
SV=4 
3 54.2 85.3 67.8 1.257 0.330 
18 High P18510 Interleukin-1 receptor antagonist 
protein OS=Homo sapiens OX=9606 
GN=IL1RN PE=1 SV=1 
2 20 130.9 104.2 1.256 0.329 
19 High P29508 Serpin B3 OS=Homo sapiens OX=9606 
GN=SERPINB3 PE=1 SV=2 
6 44.5 92.4 77.3 1.196 0.258 
20 High Q9UBC9 Small proline-rich protein 3 OS=Homo 
sapiens OX=9606 GN=SPRR3 PE=1 
SV=2 
5 18.1 102.1 85.9 1.188 0.249 
21 High Q14515 SPARC-like protein 1 OS=Homo 
sapiens OX=9606 GN=SPARCL1 PE=1 
SV=2 
4 75.2 124.7 105.2 1.185 0.245 
22 High P07355 Annexin A2 OS=Homo sapiens 
OX=9606 GN=ANXA2 PE=1 SV=2 
8 38.6 108.9 92.3 1.179 0.238 
23 High P13796 Plastin-2 OS=Homo sapiens OX=9606 4 70.2 118.9 101.2 1.174 0.231 
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GN=LCP1 PE=1 SV=6 
24 High P02765 Alpha-2-HS-glycoprotein OS=Homo 
sapiens OX=9606 GN=AHSG PE=1 
SV=1 
3 39.3 97 82.8 1.171 0.228 
25 High P06702 Protein S100-A9 OS=Homo sapiens 
OX=9606 GN=S100A9 PE=1 SV=1 
7 13.2 102.9 88.8 1.158 0.212 
26 High P08185 Corticosteroid-binding globulin 
OS=Homo sapiens OX=9606 
GN=SERPINA6 PE=1 SV=1 
3 45.1 89.1 77.1 1.155 0.208 
27 High P02760 Protein AMBP OS=Homo sapiens 
OX=9606 GN=AMBP PE=1 SV=1 
5 39 109.3 94.8 1.153 0.205 
28 High P27482 Calmodulin-like protein 3 OS=Homo 
sapiens OX=9606 GN=CALML3 PE=1 
SV=2 
4 16.9 97.7 85.1 1.148 0.199 
29 High Q8NFZ8 Cell adhesion molecule 4 OS=Homo 
sapiens OX=9606 GN=CADM4 PE=1 
SV=1 
2 42.8 91.3 82 1.113 0.154 
30 High B9A064 Immunoglobulin lambda-like 
polypeptide 5 OS=Homo sapiens 
OX=9606 GN=IGLL5 PE=2 SV=2 
3 23 103.4 93.6 1.105 0.144 
31 High P10599 Thioredoxin OS=Homo sapiens 
OX=9606 GN=TXN PE=1 SV=3 
3 11.7 84.6 77.3 1.094 0.130 
32 High P01040 Cystatin-A OS=Homo sapiens 
OX=9606 GN=CSTA PE=1 SV=1 
2 11 94.4 86.5 1.091 0.126 
33 High O00187 Mannan-binding lectin serine 
protease 2 OS=Homo sapiens 
OX=9606 GN=MASP2 PE=1 SV=4 
3 75.7 98.5 90.8 1.085 0.118 
34 High Q6GTX8 Leukocyte-associated 
immunoglobulin-like receptor 1 
OS=Homo sapiens OX=9606 GN=LAIR1 
PE=1 SV=1 
2 31.4 60.1 55.5 1.081 0.112 
35 High P01614 Immunoglobulin kappa variable 2D-40 2 13.3 118 110.5 1.068 0.095 
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OS=Homo sapiens OX=9606 
GN=IGKV2D-40 PE=1 SV=2 
36 High P0DOY2 Immunoglobulin lambda constant 2 
OS=Homo sapiens OX=9606 GN=IGLC2 
PE=1 SV=1 
3 11.3 107.4 101.5 1.059 0.083 
37 High P08571 Monocyte differentiation antigen 
CD14 OS=Homo sapiens OX=9606 
GN=CD14 PE=1 SV=2 
4 40.1 93.8 89.6 1.047 0.066 
38 High P55290 Cadherin-13 OS=Homo sapiens 
OX=9606 GN=CDH13 PE=1 SV=1 
3 78.2 95.9 91.6 1.047 0.066 
39 High P07476 Involucrin OS=Homo sapiens OX=9606 
GN=IVL PE=1 SV=2 
9 68.4 80.1 76.5 1.046 0.065 
40 High P02768 Serum albumin OS=Homo sapiens 
OX=9606 GN=ALB PE=1 SV=2 
19 69.3 85.7 82.1 1.044 0.062 
41 High O94919 Endonuclease domain-containing 1 
protein OS=Homo sapiens OX=9606 
GN=ENDOD1 PE=1 SV=2 
3 55 127.4 122 1.044 0.062 
42 High P05543 Thyroxine-binding globulin OS=Homo 
sapiens OX=9606 GN=SERPINA7 PE=1 
SV=2 
6 46.3 95.4 91.8 1.039 0.055 
43 High P01834 Immunoglobulin kappa constant 
OS=Homo sapiens OX=9606 GN=IGKC 
PE=1 SV=2 
3 11.8 101 98.4 1.027 0.038 
44 High P07911 Uromodulin OS=Homo sapiens 
OX=9606 GN=UMOD PE=1 SV=1 
7 69.7 101.4 98.9 1.025 0.036 
45 High P01011 Alpha-1-antichymotrypsin OS=Homo 
sapiens OX=9606 GN=SERPINA3 PE=1 
SV=2 
6 47.6 96.2 94.2 1.022 0.031 
46 High P98160 Basement membrane-specific 
heparan sulfate proteoglycan core 
protein OS=Homo sapiens OX=9606 
GN=HSPG2 PE=1 SV=4 
12 468.5 105.8 103.9 1.018 0.026 
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47 High P02790 Hemopexin OS=Homo sapiens 
OX=9606 GN=HPX PE=1 SV=2 
5 51.6 104.2 102.4 1.017 0.024 
48 High P05109 Protein S100-A8 OS=Homo sapiens 
OX=9606 GN=S100A8 PE=1 SV=1 
5 10.8 104.8 104.6 1.002 0.003 
49 High P00924 Enolase 1 OS=Saccharomyces 
cerevisiae (strain ATCC 204508 / 
S288c) GN=ENO1 PE=1 SV=3 
14 46.8 100 100 1 0.000 
50 High Q93088 Betaine--homocysteine S-
methyltransferase 1 OS=Homo 
sapiens OX=9606 GN=BHMT PE=1 
SV=2 
3 45 100.5 100.7 0.998 -0.003 
51 High P06396 Gelsolin OS=Homo sapiens OX=9606 
GN=GSN PE=1 SV=1 
6 85.6 89.3 90 0.991 -0.013 
52 High P01861 Immunoglobulin heavy constant 
gamma 4 OS=Homo sapiens OX=9606 
GN=IGHG4 PE=1 SV=1 
3 35.9 72.3 73.6 0.983 -0.025 
53 High Q9HCU0 Endosialin OS=Homo sapiens OX=9606 
GN=CD248 PE=1 SV=1 
2 80.8 53.9 55.5 0.97 -0.044 
54 High P39059 Collagen alpha-1(XV) chain OS=Homo 
sapiens OX=9606 GN=COL15A1 PE=1 
SV=2 
2 141.6 84.1 88.5 0.95 -0.074 
55 High P50995 Annexin A11 OS=Homo sapiens 
OX=9606 GN=ANXA11 PE=1 SV=1 
3 54.4 108.4 114.7 0.945 -0.082 
56 High P01009 Alpha-1-antitrypsin OS=Homo sapiens 
OX=9606 GN=SERPINA1 PE=1 SV=3 
14 46.7 69.5 74.4 0.934 -0.099 
57 High P09211 Glutathione S-transferase P OS=Homo 
sapiens OX=9606 GN=GSTP1 PE=1 
SV=2 
2 23.3 141 151.8 0.929 -0.106 
58 High P01871 Immunoglobulin heavy constant mu 
OS=Homo sapiens OX=9606 GN=IGHM 
PE=1 SV=4 
2 49.4 73.6 79.5 0.927 -0.109 
59 High P05155 Plasma protease C1 inhibitor 6 55.1 79.6 86.7 0.918 -0.123 
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OS=Homo sapiens OX=9606 
GN=SERPING1 PE=1 SV=2 
60 High O43451 Maltase-glucoamylase, intestinal 
OS=Homo sapiens OX=9606 
GN=MGAM PE=1 SV=5 
4 209.7 101.7 111.6 0.911 -0.134 
61 High P00450 Ceruloplasmin OS=Homo sapiens 
OX=9606 GN=CP PE=1 SV=1 
13 122.1 75.4 83.5 0.903 -0.147 
62 High P05090 Apolipoprotein D OS=Homo sapiens 
OX=9606 GN=APOD PE=1 SV=1 
3 21.3 76.2 84.9 0.897 -0.157 
63 High P24855 Deoxyribonuclease-1 OS=Homo 
sapiens OX=9606 GN=DNASE1 PE=1 
SV=1 
3 31.4 89.8 100.7 0.892 -0.165 
64 High P06703 Protein S100-A6 OS=Homo sapiens 
OX=9606 GN=S100A6 PE=1 SV=1 
3 10.2 104.9 119 0.882 -0.181 
65 High P02774 Vitamin D-binding protein OS=Homo 
sapiens OX=9606 GN=GC PE=1 SV=1 
5 52.9 87.1 100.4 0.868 -0.204 
66 High P98164 Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
OX=9606 GN=LRP2 PE=1 SV=3 
6 521.6 88.4 102.5 0.862 -0.214 
67 High Q02487 Desmocollin-2 OS=Homo sapiens 
OX=9606 GN=DSC2 PE=1 SV=1 
3 99.9 92.4 107.3 0.861 -0.216 
68 High P01857 Immunoglobulin heavy constant 
gamma 1 OS=Homo sapiens OX=9606 
GN=IGHG1 PE=1 SV=1 
7 36.1 92.2 107.7 0.856 -0.224 
69 High Q13510 Acid ceramidase OS=Homo sapiens 
OX=9606 GN=ASAH1 PE=1 SV=5 
3 44.6 81 94.9 0.854 -0.228 
70 High P80188 Neutrophil gelatinase-associated 
lipocalin OS=Homo sapiens OX=9606 
GN=LCN2 PE=1 SV=2 
3 22.6 106.7 126.3 0.845 -0.243 
71 High P15941 Mucin-1 OS=Homo sapiens OX=9606 
GN=MUC1 PE=1 SV=3 
3 122 69.3 82.3 0.841 -0.250 
72 High P07339 Cathepsin D OS=Homo sapiens 6 44.5 93.4 111.7 0.836 -0.258 
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OX=9606 GN=CTSD PE=1 SV=1 
73 High Q92820 Gamma-glutamyl hydrolase OS=Homo 
sapiens OX=9606 GN=GGH PE=1 SV=2 
3 35.9 76 90.9 0.836 -0.258 
74 High Q9Y646 Carboxypeptidase Q OS=Homo 
sapiens OX=9606 GN=CPQ PE=1 SV=1 
2 51.9 86.2 104.3 0.826 -0.276 
75 High P01833 Polymeric immunoglobulin receptor 
OS=Homo sapiens OX=9606 GN=PIGR 
PE=1 SV=4 
7 83.2 90.6 110 0.824 -0.279 
76 High Q14624 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens OX=9606 
GN=ITIH4 PE=1 SV=4 
4 103.3 73.9 89.8 0.823 -0.281 
77 High P14384 Carboxypeptidase M OS=Homo 
sapiens OX=9606 GN=CPM PE=1 SV=2 
2 50.5 89.8 109.6 0.819 -0.288 
78 High P41222 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens OX=9606 
GN=PTGDS PE=1 SV=1 
3 21 78.5 95.9 0.818 -0.290 
79 High Q9ULI3 Protein HEG homolog 1 OS=Homo 
sapiens OX=9606 GN=HEG1 PE=1 
SV=3 
3 147.4 82.2 100.6 0.818 -0.290 
80 High P02751 Fibronectin OS=Homo sapiens 
OX=9606 GN=FN1 PE=1 SV=4 
11 262.5 87 107.3 0.811 -0.302 
81 High P12830 Cadherin-1 OS=Homo sapiens 
OX=9606 GN=CDH1 PE=1 SV=3 
8 97.4 92.4 114.9 0.804 -0.315 
82 High Q8TDQ0 Hepatitis A virus cellular receptor 2 
OS=Homo sapiens OX=9606 
GN=HAVCR2 PE=1 SV=3 
2 33.4 92.5 115 0.804 -0.315 
83 High P0C0L5 Complement C4-B OS=Homo sapiens 
OX=9606 GN=C4B PE=1 SV=2 
3 192.6 87.1 108.7 0.801 -0.320 
84 High P00738 Haptoglobin OS=Homo sapiens 
OX=9606 GN=HP PE=1 SV=1 
4 45.2 47.8 60 0.796 -0.329 
85 High P09668 Pro-cathepsin H OS=Homo sapiens 
OX=9606 GN=CTSH PE=1 SV=4 
2 37.4 94.4 118.7 0.795 -0.331 
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86 High P06733 Alpha-enolase OS=Homo sapiens 
OX=9606 GN=ENO1 PE=1 SV=2 
4 47.1 93.8 118.2 0.794 -0.333 
87 High Q9NZP8 Complement C1r subcomponent-like 
protein OS=Homo sapiens OX=9606 
GN=C1RL PE=1 SV=2 
3 53.5 94.1 120.2 0.783 -0.353 
88 High P12109 Collagen alpha-1(VI) chain OS=Homo 
sapiens OX=9606 GN=COL6A1 PE=1 
SV=3 
10 108.5 75.7 96.9 0.782 -0.355 
89 High P43121 Cell surface glycoprotein MUC18 
OS=Homo sapiens OX=9606 
GN=MCAM PE=1 SV=2 
3 71.6 98.1 125.5 0.782 -0.355 
90 High Q8NBJ4 Golgi membrane protein 1 OS=Homo 
sapiens OX=9606 GN=GOLM1 PE=1 
SV=1 
7 45.3 81.4 105.7 0.77 -0.377 
91 High P05164 Myeloperoxidase OS=Homo sapiens 
OX=9606 GN=MPO PE=1 SV=1 
3 83.8 95.3 123.8 0.77 -0.377 
92 High Q9BY67 Cell adhesion molecule 1 OS=Homo 
sapiens OX=9606 GN=CADM1 PE=1 
SV=2 
3 48.5 76.3 99.4 0.768 -0.381 
93 High P13645 Keratin, type I cytoskeletal 10 
OS=Homo sapiens OX=9606 
GN=KRT10 PE=1 SV=6 
14 58.8 80.9 105.7 0.766 -0.385 
94 High P01023 Alpha-2-macroglobulin OS=Homo 
sapiens OX=9606 GN=A2M PE=1 SV=3 
2 163.2 75.1 98 0.766 -0.385 
95 High P11464 Pregnancy-specific beta-1-
glycoprotein 1 OS=Homo sapiens 
OX=9606 GN=PSG1 PE=1 SV=1 
4 47.2 91.6 119.7 0.765 -0.386 
96 High P25815 Protein S100-P OS=Homo sapiens 
OX=9606 GN=S100P PE=1 SV=2 
2 10.4 100.2 131.9 0.76 -0.396 
97 High O75882 Attractin OS=Homo sapiens OX=9606 
GN=ATRN PE=1 SV=2 
4 158.4 87.6 116.3 0.754 -0.407 
98 High P04075 Fructose-bisphosphate aldolase A 2 39.4 98.6 131 0.752 -0.411 
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OS=Homo sapiens OX=9606 
GN=ALDOA PE=1 SV=2 
99 High P15144 Aminopeptidase N OS=Homo sapiens 
OX=9606 GN=ANPEP PE=1 SV=4 
12 109.5 84.5 112.4 0.751 -0.413 
100 High P31944 Caspase-14 OS=Homo sapiens 
OX=9606 GN=CASP14 PE=1 SV=2 
2 27.7 93.7 125.2 0.748 -0.419 
101 High P31947 14-3-3 protein sigma OS=Homo 
sapiens OX=9606 GN=SFN PE=1 SV=1 
5 27.8 87.2 117.8 0.74 -0.434 
102 High P78324 Tyrosine-protein phosphatase non-
receptor type substrate 1 OS=Homo 
sapiens OX=9606 GN=SIRPA PE=1 
SV=2 
3 54.9 93.3 126.2 0.74 -0.434 
103 High P04746 Pancreatic alpha-amylase OS=Homo 
sapiens OX=9606 GN=AMY2A PE=1 
SV=2 
7 57.7 76.7 104.3 0.736 -0.442 
104 High P05060 Secretogranin-1 OS=Homo sapiens 
OX=9606 GN=CHGB PE=1 SV=2 
2 78.2 84.3 114.6 0.736 -0.442 
105 High P11142 Heat shock cognate 71 kDa protein 
OS=Homo sapiens OX=9606 
GN=HSPA8 PE=1 SV=1 
9 70.9 86.4 117.7 0.734 -0.446 
106 High P09603 Macrophage colony-stimulating factor 
1 OS=Homo sapiens OX=9606 
GN=CSF1 PE=1 SV=2 
4 60.1 90.3 123.6 0.731 -0.452 
107 High P01859 Immunoglobulin heavy constant 
gamma 2 OS=Homo sapiens OX=9606 
GN=IGHG2 PE=1 SV=2 
4 35.9 82.6 113.2 0.729 -0.456 
108 High P08637 Low affinity immunoglobulin gamma 
Fc region receptor III-A OS=Homo 
sapiens OX=9606 GN=FCGR3A PE=1 
SV=2 
2 29.1 81.1 111.4 0.728 -0.458 
109 High P62979 Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens OX=9606 
3 18 76.9 106.1 0.725 -0.464 
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GN=RPS27A PE=1 SV=2 
110 High Q8WZ75 Roundabout homolog 4 OS=Homo 
sapiens OX=9606 GN=ROBO4 PE=1 
SV=1 
2 107.4 85.4 118 0.724 -0.466 
111 High Q16651 Prostasin OS=Homo sapiens OX=9606 
GN=PRSS8 PE=1 SV=1 
2 36.4 91.6 127.2 0.72 -0.474 
112 High P19440 Glutathione hydrolase 1 proenzyme 
OS=Homo sapiens OX=9606 GN=GGT1 
PE=1 SV=2 
2 61.4 83.6 116.4 0.718 -0.478 
113 High P04264 Keratin, type II cytoskeletal 1 
OS=Homo sapiens OX=9606 GN=KRT1 
PE=1 SV=6 
17 66 87.8 122.8 0.715 -0.484 
114 High P10451 Osteopontin OS=Homo sapiens 
OX=9606 GN=SPP1 PE=1 SV=1 
11 35.4 79.2 111.1 0.713 -0.488 
115 High Q6UVK1 Chondroitin sulfate proteoglycan 4 
OS=Homo sapiens OX=9606 
GN=CSPG4 PE=1 SV=2 
2 250.4 76.9 108 0.712 -0.490 
116 High Q06830 Peroxiredoxin-1 OS=Homo sapiens 
OX=9606 GN=PRDX1 PE=1 SV=1 
2 22.1 95.6 134.3 0.712 -0.490 
117 High P26992 Ciliary neurotrophic factor receptor 
subunit alpha OS=Homo sapiens 
OX=9606 GN=CNTFR PE=1 SV=2 
2 40.6 84.3 118.5 0.711 -0.492 
118 High P06870 Kallikrein-1 OS=Homo sapiens 
OX=9606 GN=KLK1 PE=1 SV=2 
3 28.9 77.7 110.7 0.702 -0.510 
119 High P50895 Basal cell adhesion molecule 
OS=Homo sapiens OX=9606 
GN=BCAM PE=1 SV=2 
3 67.4 84.4 121.1 0.697 -0.521 
120 High P05154 Plasma serine protease inhibitor 
OS=Homo sapiens OX=9606 
GN=SERPINA5 PE=1 SV=3 
4 45.6 65 93.5 0.695 -0.525 
121 High Q16270 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens OX=9606 
3 29.1 65.7 97 0.678 -0.561 
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GN=IGFBP7 PE=1 SV=1 
122 High Q8IYS5 Osteoclast-associated 
immunoglobulin-like receptor 
OS=Homo sapiens OX=9606 
GN=OSCAR PE=1 SV=3 
2 30.5 93.9 139.4 0.674 -0.569 
123 High Q9BRK3 Matrix remodeling-associated protein 
8 OS=Homo sapiens OX=9606 
GN=MXRA8 PE=1 SV=1 
4 49.1 86.8 129 0.673 -0.571 
124 High P10153 Non-secretory ribonuclease OS=Homo 
sapiens OX=9606 GN=RNASE2 PE=1 
SV=2 
2 18.3 77.9 116.3 0.67 -0.578 
125 High Q9NQ84 G-protein coupled receptor family C 
group 5 member C OS=Homo sapiens 
OX=9606 GN=GPRC5C PE=1 SV=2 
2 48.2 84.3 125.9 0.67 -0.578 
126 High P04083 Annexin A1 OS=Homo sapiens 
OX=9606 GN=ANXA1 PE=1 SV=2 
6 38.7 69.9 106.8 0.654 -0.613 
127 High Q96NY8 Nectin-4 OS=Homo sapiens OX=9606 
GN=NECTIN4 PE=1 SV=1 
3 55.4 72 111.4 0.647 -0.628 
128 High P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
OS=Homo sapiens OX=9606 GN=GNB1 
PE=1 SV=3 
2 37.4 73.6 113.9 0.646 -0.630 
129 High P35527 Keratin, type I cytoskeletal 9 
OS=Homo sapiens OX=9606 GN=KRT9 
PE=1 SV=3 
5 62 100.3 155.7 0.644 -0.635 
130 High P07195 L-lactate dehydrogenase B chain 
OS=Homo sapiens OX=9606 GN=LDHB 
PE=1 SV=2 
2 36.6 77.3 121.3 0.637 -0.651 
131 High P15586 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens OX=9606 GN=GNS 
PE=1 SV=3 
3 62 74.3 118.3 0.628 -0.671 
132 High P01042 Kininogen-1 OS=Homo sapiens 6 71.9 78.3 124.9 0.626 -0.676 
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OX=9606 GN=KNG1 PE=1 SV=2 
133 High P01876 Immunoglobulin heavy constant alpha 
1 OS=Homo sapiens OX=9606 
GN=IGHA1 PE=1 SV=2 
5 37.6 69.2 110.7 0.625 -0.678 
134 High P54802 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens OX=9606 
GN=NAGLU PE=1 SV=2 
5 82.2 77.1 123.4 0.625 -0.678 
135 High P19835 Bile salt-activated lipase OS=Homo 
sapiens OX=9606 GN=CEL PE=1 SV=3 
3 79.3 56.5 90.7 0.623 -0.683 
136 High Q12907 Vesicular integral-membrane protein 
VIP36 OS=Homo sapiens OX=9606 
GN=LMAN2 PE=1 SV=1 
3 40.2 86.5 139.2 0.622 -0.685 
137 High P60709 Actin, cytoplasmic 1 OS=Homo 
sapiens OX=9606 GN=ACTB PE=1 SV=1 
6 41.7 83.1 134.5 0.618 -0.694 
138 High Q08380 Galectin-3-binding protein OS=Homo 
sapiens OX=9606 GN=LGALS3BP PE=1 
SV=1 
10 65.3 79 128.6 0.614 -0.704 
139 High P01877 Immunoglobulin heavy constant alpha 
2 OS=Homo sapiens OX=9606 
GN=IGHA2 PE=1 SV=4 
3 36.6 60.7 99.9 0.608 -0.718 
140 High Q68CJ9 Cyclic AMP-responsive element-
binding protein 3-like protein 3 
OS=Homo sapiens OX=9606 
GN=CREB3L3 PE=1 SV=2 
2 49 84.3 139.6 0.604 -0.727 
141 High Q7KYR7 Butyrophilin subfamily 2 member A1 
OS=Homo sapiens OX=9606 
GN=BTN2A1 PE=1 SV=3 
3 59.6 75 124.9 0.601 -0.735 
142 High P01591 Immunoglobulin J chain OS=Homo 
sapiens OX=9606 GN=JCHAIN PE=1 
SV=4 
2 18.1 80.2 133.6 0.601 -0.735 
143 High P35908 Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens OX=9606 
5 65.4 69.9 119.7 0.584 -0.776 
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GN=KRT2 PE=1 SV=2 
144 High P05062 Fructose-bisphosphate aldolase B 
OS=Homo sapiens OX=9606 
GN=ALDOB PE=1 SV=2 
2 39.4 88 151.5 0.581 -0.783 
145 High P01133 Pro-epidermal growth factor 
OS=Homo sapiens OX=9606 GN=EGF 
PE=1 SV=2 
11 133.9 69.2 120.1 0.576 -0.796 
146 High Q03154 Aminoacylase-1 OS=Homo sapiens 
OX=9606 GN=ACY1 PE=1 SV=1 
2 45.9 64.8 113.6 0.571 -0.808 
147 High Q9UQ72 Pregnancy-specific beta-1-
glycoprotein 11 OS=Homo sapiens 
OX=9606 GN=PSG11 PE=2 SV=3 
7 37.1 80.9 142.4 0.568 -0.816 
148 High P05937 Calbindin OS=Homo sapiens OX=9606 
GN=CALB1 PE=1 SV=2 
3 30 57.8 101.7 0.568 -0.816 
149 High O60494 Cubilin OS=Homo sapiens OX=9606 
GN=CUBN PE=1 SV=5 
3 398.5 76.4 134.8 0.567 -0.819 
150 High P19013 Keratin, type II cytoskeletal 4 
OS=Homo sapiens OX=9606 GN=KRT4 
PE=1 SV=4 
12 57.3 57.6 102.4 0.563 -0.829 
151 High O00391 Sulfhydryl oxidase 1 OS=Homo 
sapiens OX=9606 GN=QSOX1 PE=1 
SV=3 
5 82.5 66.8 121 0.552 -0.857 
152 High P10909 Clusterin OS=Homo sapiens OX=9606 
GN=CLU PE=1 SV=1 
4 52.5 65.3 120 0.544 -0.878 
153 High Q07075 Glutamyl aminopeptidase OS=Homo 
sapiens OX=9606 GN=ENPEP PE=1 
SV=3 
3 109.2 67 126.9 0.528 -0.921 
154 High Q08345 Epithelial discoidin domain-containing 
receptor 1 OS=Homo sapiens 
OX=9606 GN=DDR1 PE=1 SV=1 
4 101.1 75.2 145.2 0.518 -0.949 
155 High Q9P121 Neurotrimin OS=Homo sapiens 
OX=9606 GN=NTM PE=1 SV=1 
2 37.9 67.1 130.6 0.513 -0.963 
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156 High Q6EMK4 Vasorin OS=Homo sapiens OX=9606 
GN=VASN PE=1 SV=1 
5 71.7 66.1 131.1 0.504 -0.989 
157 High P15289 Arylsulfatase A OS=Homo sapiens 
OX=9606 GN=ARSA PE=1 SV=3 
6 53.6 71.3 141.9 0.502 -0.994 
158 High P13647 Keratin, type II cytoskeletal 5 
OS=Homo sapiens OX=9606 GN=KRT5 
PE=1 SV=3 
11 62.3 60.8 126.9 0.479 -1.062 
159 High P10253 Lysosomal alpha-glucosidase 
OS=Homo sapiens OX=9606 GN=GAA 
PE=1 SV=4 
4 105.3 62.3 139.3 0.447 -1.162 
160 High P29972 Aquaporin-1 OS=Homo sapiens 
OX=9606 GN=AQP1 PE=1 SV=3 
2 28.5 74.8 171.4 0.436 -1.198 
161 High P13646 Keratin, type I cytoskeletal 13 
OS=Homo sapiens OX=9606 
GN=KRT13 PE=1 SV=4 
18 49.6 52 122.3 0.425 -1.234 
162 High Q99988 Growth/differentiation factor 15 
OS=Homo sapiens OX=9606 
GN=GDF15 PE=1 SV=3 
3 34.1 73.6 173.7 0.424 -1.238 
163 High P30086 Phosphatidylethanolamine-binding 
protein 1 OS=Homo sapiens OX=9606 
GN=PEBP1 PE=1 SV=3 
3 21 66 156 0.423 -1.241 
164 High P02538 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens OX=9606 
GN=KRT6A PE=1 SV=3 
19 60 52.2 132.5 0.394 -1.344 
165 High P04259 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens OX=9606 
GN=KRT6B PE=1 SV=5 
20 60 51.6 139.8 0.369 -1.438 
166 High P34059 N-acetylgalactosamine-6-sulfatase 
OS=Homo sapiens OX=9606 
GN=GALNS PE=1 SV=1 
2 58 62.4 175.3 0.356 -1.490 
167 High P60174 Triosephosphate isomerase OS=Homo 
sapiens OX=9606 GN=TPI1 PE=1 SV=3 
2 30.8 39.3 118 0.333 -1.586 
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168 High P62736 Actin, aortic smooth muscle OS=Homo 
sapiens OX=9606 GN=ACTA2 PE=1 
SV=1 
5 42 65.4 198.7 0.329 -1.604 
169 High P11021 Endoplasmic reticulum chaperone BiP 
OS=Homo sapiens OX=9606 
GN=HSPA5 PE=1 SV=2 
5 72.3 59.4 182.3 0.326 -1.617 
170 High P62805 Histone H4 OS=Homo sapiens 
OX=9606 GN=HIST1H4A PE=1 SV=2 
3 11.4 42.8 134.2 0.319 -1.648 
171 High P08779 Keratin, type I cytoskeletal 16 
OS=Homo sapiens OX=9606 
GN=KRT16 PE=1 SV=4 
6 51.2 44.8 157.9 0.284 -1.816 
172 High P13473 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
OX=9606 GN=LAMP2 PE=1 SV=2 
2 44.9 50.5 218 0.232 -2.108 
173 High P02788 Lactotransferrin OS=Homo sapiens 
OX=9606 GN=LTF PE=1 SV=6 
3 78.1 28.7 156.2 0.184 -2.442 
Data identified at confidence interval (CI): 99 %, FDR < 0.01; Peptides no. ≥ 2. 
 
247 
 
6.4 Appendix 4: Overlay of all FTIR spectra for PE and control at 
15 week of pregnancy 
 
Figure S 1: Overlay of FTIR Spectra for PE and control at 15 week of gestational age at 
wavenumber range (4000-600) cm-1   
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6.5 Appendix 5: Overlay of all FTIR spectra for IUGR and control 
at 15 week gestational age 
 
Figure S 2: Overlay of FTIR Spectra for IUGR and control urine samples at 15 weeks’ 
gestation, 4000-600 cm-1   
 
 
